[
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ It stabilizes the T state, decreasing oxygen affinity.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ troponin I</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Increase in K m</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ glucose-6-phosphate</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② ATP</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Estrogen receptor</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ antimycin A</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ epinephrine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ AMP → dAMP</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ DNA ligase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Defect in mismatch repair of damaged DNA.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ actinomycin D</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② mRNA</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Tyrosine → Phenylalanine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ adenosine deaminase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ pyridoxal phosphate</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① Gout</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Muscle cell</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Complementary DNA strand</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Rickettsia typhi</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Neisseria gonorrhoeae</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Fosfomycin</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Arbekacin</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Azithromycin</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① linezolid</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Inhibition of neuraminidase function of influenza viruses A and B.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Eosinophils</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ It has variable regions and constant regions.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① B cells</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ interleukin-2 (IL-2)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② interferon-β (IFN-β)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Inactivated killed vaccine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Mycoplasma pneumoniae</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Streptococcus pyogenes</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ varicella-zoster virus</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Type C</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Treponema pallidum</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Borrelia burgdorferi</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① β-arrestin</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ The analgesic effect of morphine is synergistically enhanced.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Affinity</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Mydriasis (pupil dilation) due to contraction of the radial muscle of the iris.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Olanzapine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② carbidopa</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Naloxone</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② formoterol</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① abciximab</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ minoxidil</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Spironolactone</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② colchicine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ omeprazole</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② finasteride</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② liraglutide</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Inhibition of DNA gyrase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ erlotinib</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Cholinesterase inhibition</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Nicotinic receptor – pyridostigmine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 80%\n\nExplanation:\n\nSensitivity is the proportion of truly diseased individuals (patients) who test positive (i.e., the number of patients with a positive test result divided by the total number of patients). In this case, 90 out of 100 patients tested positive, so the sensitivity is 90/100 = 0.9 or 80%. Therefore, the correct answer is ④ 80%.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ ClO- has greater disinfecting power, while HClO has greater residual effect.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Radon (Rn)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ glucose-6-phosphate dehydrogenase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① benzene</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Low expression of P-glycoprotein.\n\nExplanation:\nParaquat is a herbicide that has been shown to have selective toxicity to the lungs. This selective toxicity is thought to be due to the low expression of P-glycoprotein (P-gp) in alveolar epithelial cells. P-gp is a transmembrane efflux pump that plays a critical role in protecting the body from xenobiotics and endogenous toxins. The low expression of P-gp in alveolar epithelial cells makes them more susceptible to the toxic effects of paraquat, leading to cell damage and death.\n\nThe other options are not correct because:\n\n① Selective expression of CYP2D6: While CYP2D6 is involved in the metabolism of paraquat, its selective expression in the lungs is not the primary reason for the herbicide's selective toxicity.\n\n③ High activity of Na+,K+-ATPase: Na+,K+-ATPase is an enzyme that maintains the electrochemical gradient across cell membranes. While it is present in alveolar epithelial cells, its high activity is not responsible for the selective toxicity of paraquat.\n\n④ High activity of glutathione peroxidase: Glutathione peroxidase is an enzyme that protects cells from oxidative damage. While it is present in alveolar epithelial cells, its high activity is not the primary reason for the selective toxicity of paraquat.\n\n⑤ Specific distribution of polyamine transporter: Polyamine transporters are involved in the transport of polyamines, which are important for cell proliferation and differentiation. While polyamine transporters are present in alveolar epithelial cells, their specific distribution is not responsible for the selective toxicity of paraquat.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Mercury (Hg)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Lead (Pb)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① atropine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② cystathionine β-synthase</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Citrus fruits, spinach</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Copper (Cu)</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① CYP3A4 inhibition</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ putrescine</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Enterohemorrhagic E. coli</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Vibrio vulnificus</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Sodium sulfite</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 100</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 4×10^-6</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Reactive oxygen species</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Mast cells</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Acute graft-versus-host disease</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Loss of delayed-type hypersensitivity.\n\nExplanation:\n\nThe patient's negative result in the tuberculin skin test despite having tuberculosis is likely due to the loss of delayed-type hypersensitivity. Delayed-type hypersensitivity is a cell-mediated immune response that occurs 24-48 hours after exposure to an antigen. In HIV-infected individuals, the immune system's ability to mount a delayed-type hypersensitivity response is impaired, which can lead to false-negative results in tuberculin skin tests. This is because the skin test relies on the body's ability to mount a cell-mediated immune response to the tuberculin antigen.\n\nThe other options are not correct explanations for the negative result in the tuberculin skin test:\n\n① Immune tolerance refers to the body's ability to recognize and ignore harmless antigens. This is not relevant to the patient's negative result in the tuberculin skin test.\n\n③ Loss of antibody-dependent cell-mediated cytotoxicity refers to the inability of antibodies to activate killer cells to destroy infected cells. This is not directly related to the patient's negative result in the tuberculin skin test.\n\n④ Arthus reaction refers to a type of hypersensitivity reaction that occurs immediately after exposure to an antigen. This is not relevant to the patient's negative result in the tuberculin skin test, which is a delayed-type hypersensitivity reaction.\n\n⑤ Epitope spreading refers to the process by which the immune system recognizes and responds to multiple epitopes on a single antigen. This is not relevant to the patient's negative result in the tuberculin skin test.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Foam cell</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Phagocytosis by macrophages that have leaked outside the blood vessels.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Hypertension</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Arterial thromboembolism</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Atelectasis</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Decreased alpha-1 antitrypsin activity</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② KRAS</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Acute pancreatitis</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ p53</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Endometritis</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Increased secretion of adrenocorticotropic hormone.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Accumulation of insoluble prions in neurons.</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Basement membrane proliferation</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increase of sorbitol in the lens</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Esophageal varix</s>"
    },
    {
        "year": 2019,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Hepatic encephalopathy</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② hydrogen bond</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2\n\nExplanation:\n\nWhen two liquids, water and n-butyl alcohol, which have partial miscibility, exist as a single completely miscible phase, they form a binary mixture. In this case, the number of degrees of freedom (F) is equal to the number of components - 1.\n\nSince there are two components (water and n-butyl alcohol), the number of degrees of freedom is 2 - 1 = 1.\n\nTherefore, the correct answer is ③ 2.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 63%</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hydrophobic bond</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Maintaining high viscosity after injection.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Specific conductivity</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 279</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ pH 5.0</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Precipitation</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Equilibrium state</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Osmotic pressure</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 100 days</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Q10 (Q10 value)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ The solid surface is negatively charged.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hydrophilic-lipophilic balance.\n\nExplanation:\nSimethicone is a surfactant that works by reducing the surface tension of gas bubbles in the intestines, allowing them to coalesce and be eliminated more easily. The hydrophilic-lipophilic balance (HLB) of a drug is a measure of its balance between hydrophilic (water-loving) and lipophilic (oil-loving) properties. A drug with a similar HLB value to simethicone would be able to interact with both water and lipids in the intestinal environment, allowing it to effectively remove gas bubbles and relieve bloating.\n\nPorosity (①) refers to the ability of a material to allow fluids to pass through it. While this property may be relevant for some drug delivery systems, it is not directly related to the function of simethicone.\n\nPermeability coefficient (②) refers to the rate at which a solute passes through a membrane. This property is important for drugs that need to cross membranes to reach their target site of action, but it is not directly related to the function of simethicone.\n\nDiffusion coefficient (③) refers to the rate at which a solute diffuses through a medium. This property is important for drugs that need to diffuse through tissues to reach their target site of action, but it is not directly related to the function of simethicone.\n\nSpreading coefficient (④) refers to the ability of a drug to spread evenly across a surface. While this property may be relevant for some topical drugs, it is not directly related to the function of simethicone.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Decrease in solvent polarity.\n\nExplanation: Ethanol is a non-polar solvent that can dissolve phenobarbital, a slightly polar compound. The addition of ethanol to water decreases the polarity of the solvent, allowing phenobarbital to dissolve more easily. This is because the non-polar nature of ethanol interacts favorably with the non-polar parts of phenobarbital, increasing its solubility. Therefore, option ③ Decrease in solvent polarity is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 0.760</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ simvastatin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ quinoline</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ ethionamide</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Ac2O/NaOAc</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ paroxetine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ methylphenidate</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ fluconazole</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① aripiprazole</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ diazepam</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ -COOH</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① baclofen</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ C</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 10^-13×0.83^-1</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 9/11</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 10 | 9.4+log 1.5</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Prevention of coprecipitation.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Calcium pantothenate</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NaOCH3 – Dimethylformamide</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Molecules have vibrational and rotational transitions in addition to electronic transitions.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The length of the measurement cell is 100 mm.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Electron Capture Detector (ECD)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Mass spectrometry detector</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Standard addition method</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ It separates neutral substances based on differences in hydrophobicity.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Correlation coefficient</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Q test</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 1750~1600</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 10</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Lactose</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Fluidized bed granulation method</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Sublingual tablet</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Capping occurs.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Absorption ointment</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ ethylene oxide</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Sodium carboxymethylcellulose</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Granules – Increase in drug dissolution rate</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Humectant – Propylene glycol</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Polyethylene glycol</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Sonophoresis</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 60\n\nExplanation:\nThe oral absorption rate (F) of a drug can be calculated using the equation:\nF = (Amount excreted in urine / Total dose administered) x 100\n\nIn this case, the amount excreted in urine is 80 mg, and the total dose administered is 200 mg.\n\nF = (80 / 200) x 100 = 60%\n\nTherefore, the oral absorption rate of this drug is 60%. The correct answer is ③ 60.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Bentonite</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Drugs absorbed in the lower rectum can bypass the first-pass effect of the liver.</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ morphine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① artemisinin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ reserpine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Platycodon Root</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Illicium verum</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ tanshinone I</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Liriopis seu Ophiopogonis Tuber</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ponciri Fructus Immaturus</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Vincae Herba</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① bufotenine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Hyperici Herba</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ (+)-matrine</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Kidney (腎)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Poria cocos (茯苓)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Gobon-hwanjeong-hwan (固本還睛丸)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Sosiho-tang (小柴胡湯)</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ puerarin</s>"
    },
    {
        "year": 2019,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ D-glucuronic acid</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Nifedipine</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Ezetimibe.\n\nThe likely causative drug for the arrhythmia in this case is Ezetimibe, which is known to cause QT interval prolongation and arrhythmias, especially in patients with pre-existing cardiovascular disease. The other medications, including Enalapril, Furosemide, Rosuvastatin, and Vitamin B complex, are less likely to cause arrhythmias.\n\nTherefore, the answer is ③ Ezetimibe.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Atorvastatin.\n\nRationale:\n\nThe patient has stable angina, diabetes, and hypertension. The current medications include aspirin, ramipril, metoprolol, metformin, and nitroglycerin sublingual tablet.\n\nAtorvastatin, a statin, would be an appropriate addition to the patient's medication regimen. It would help to reduce the patient's LDL-C level, which is currently 158 mg/dL, and would also have a beneficial effect on the patient's cardiovascular risk profile.\n\nApixaban, an oral anticoagulant, may be considered for the patient's stable angina, but it is not the most appropriate choice based on the patient's current medication regimen and clinical test results.\n\nDoxazosin, a selective alpha-1 blocker, may be considered for the patient's hypertension, but it is not the most appropriate choice based on the patient's current medication regimen and clinical test results.\n\nEzetimibe, a cholesterol absorption inhibitor, may be considered for the patient's high LDL-C level, but it is not the most appropriate choice based on the patient's current medication regimen and clinical test results.\n\nSpironolactone, a potassium-sparing diuretic, may be considered for the patient's hypertension, but it is not the most appropriate choice based on the patient's current medication regimen and clinical test results.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Serum creatinine.\n\nFondaparinux is a synthetic pentasaccharide that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It works by inhibiting the activity of thrombin, a clotting factor that is involved in the coagulation cascade.\n\nDuring the treatment of myocardial infarction (heart attack) with fondaparinux, it is important to monitor the patient's serum creatinine levels. This is because fondaparinux can cause changes in renal function, particularly in patients with pre-existing renal impairment. Elevated serum creatinine levels can indicate that the patient's kidneys are not functioning properly, which can lead to accumulation of the drug and increase the risk of bleeding complications.\n\nThe other options are not directly related to the use of fondaparinux in the treatment of myocardial infarction:\n\n① Uric acid: Elevated uric acid levels can indicate hyperuricemia, which is a common side effect of fondaparinux therapy. However, it is not a direct indicator of renal function.\n\n② Bilirubin: Bilirubin is a metabolite of red blood cells that is excreted by the liver. It is not directly related to the use of fondaparinux in the treatment of myocardial infarction.\n\n③ Triglycerides: Triglycerides are a type of lipid that can be elevated in patients with cardiovascular disease. However, they are not directly related to the use of fondaparinux in the treatment of myocardial infarction.\n\n④ Glycated hemoglobin: Glycated hemoglobin is a measure of average blood glucose levels over the past 2-3 months. It is not directly related to the use of fondaparinux in the treatment of myocardial infarction.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Rivaroxaban</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Rifampicin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Apixaban.\n\nExplanation:\n\nThe patient has a history of hypertension and atrial fibrillation, which are both risk factors for stroke. The patient's age and creatinine clearance (CrCl) of 72 mL/min also increase the risk of stroke. The patient is currently taking amlodipine and hydrochlorothiazide, which are medications for hypertension and fluid retention, but they do not have any direct effect on stroke prevention.\n\nApixaban is an oral anticoagulant that is recommended for stroke prevention in patients with non-valvular atrial fibrillation, such as this patient. It works by inhibiting the production of thrombin, which is a key enzyme in the coagulation cascade that leads to the formation of blood clots.\n\nAspirin is an antiplatelet agent that can also be used for stroke prevention, but it may not be as effective as apixaban in this patient population. Ticagrelor is another antiplatelet agent that may be used in this patient population, but it has a shorter duration of action compared to apixaban. Argatroban is an anticoagulant that is used in patients with heparin-induced thrombocytopenia, but it is not commonly used for stroke prevention. Aspirin plus cilostazol is a combination therapy that may be used in some patients, but it may not be the most appropriate choice for this patient based on their medical history and current medications.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Pravastatin 20 mg</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Creatine kinase.\n\nRationale: The patient's symptoms of weakness in the legs and muscle pain suggest a possible adverse drug reaction, specifically myalgia and myasthenia. Creatine kinase (CK) is an enzyme that is released into the bloodstream when muscle tissue is damaged, and its levels can be elevated in muscle disorders or muscle damage caused by certain medications, such as statins. Measuring CK levels can help diagnose muscle damage or myopathy, which is a potential side effect of atorvastatin. Therefore, option ⑤ Creatine kinase is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Warfarin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Maintain the current dose.\n\nRationale: The patient's INR of 5.5 indicates that the warfarin therapy is effective in preventing blood clots. Since there are no bleeding symptoms, it is appropriate to maintain the current dose of warfarin. Administering vitamin K intravenously or discontinuing warfarin and administering vitamin K orally or fresh frozen plasma may reverse the anticoagulation effect of warfarin and increase the risk of blood clots. Therefore, option ② is the best answer.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Labetalol (injection)\n\nRationale:\n\nLabetalol is a beta-blocker that can be used to control blood pressure in patients with hypertension, angina, or heart failure. It has a rapid onset of action and can be administered intravenously, which makes it an appropriate choice for thrombolytic therapy in acute ischemic stroke.\n\nDoxazosin, amlodipine, and carvedilol are all oral medications that may take longer to take effect, and may not be suitable for acute management of hypertension in this scenario. Nitroprusside is a vasodilator that can lower blood pressure rapidly, but it may not be suitable for thrombolytic therapy due to its potential to decrease blood pressure too much, which could worsen the stroke.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Edoxaban.\n\nRationale: Edoxaban is an oral anticoagulant that is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis and pulmonary embolism. In this case, the patient has a history of hypertension and diabetes mellitus, which are risk factors for stroke. The patient has also recently missed 3 days of medication, which may have increased the risk of stroke. Edoxaban can help prevent recurrence of ischemic stroke by inhibiting the formation of thrombin and preventing the growth of existing clots.\n\nHeparin and warfarin are also anticoagulants, but they have different mechanisms of action and are used in different situations. Heparin is used primarily for acute anticoagulation and is often used in combination with warfarin for long-term anticoagulation. Warfarin is used for long-term anticoagulation in patients with mechanical heart valves or atrial fibrillation. Abciximab is an antiplatelet agent that is used to prevent platelet aggregation and is used in the treatment of acute coronary syndrome. Clopidogrel is an antiplatelet agent that is used to prevent platelet aggregation and is used in the treatment of acute coronary syndrome and stroke prevention in patients with non-valvular atrial fibrillation.\n\nTherefore, the correct answer is ③ Edoxaban.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Abciximab.\n\nExplanation: Abciximab is a glycoprotein IIb/IIIa inhibitor that is commonly used during percutaneous coronary interventions (PCI) to prevent platelet aggregation and reduce the risk of thrombotic complications. In patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI, abciximab has been shown to improve clinical outcomes and reduce the risk of major adverse cardiovascular events (MACE). The other options, warfarin, alteplase, dabigatran, and rivaroxaban, are not typically used during PCI procedures.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Amlodipine.\n\nRationale: Amlodipine is a calcium channel blocker that can be used to treat hypertension and angina. It can also reduce left ventricular hypertrophy, which was confirmed in the patient's echocardiography results. The other options, digoxin, ramipril, ivabradine, and hydralazine, may also be used in the treatment of hypertension, angina, or heart failure, but they are not as appropriate for reducing left ventricular hypertrophy in this case.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Alanine Aminotransferase.\n\nRationale: Omalizumab is a monoclonal antibody that targets immunoglobulin E (IgE), and it is used to treat severe allergic asthma. Alanine aminotransferase (ALT) is an enzyme that is often monitored during omalizumab therapy because it can be elevated in cases of anaphylaxis, a potential side effect of the drug. Therefore, it is appropriate to check ALT levels during dose review to ensure that the patient is not experiencing any adverse effects.\n\nThe other options are not directly related to the use of omalizumab or the patient's asthma treatment:\n\n① Blood Urea Nitrogen (BUN) is a waste product that is produced by the kidneys and is not directly related to asthma treatment or omalizumab.\n\n② Serum Magnesium is an electrolyte that is important for muscle and nerve function, but it is not typically monitored during asthma treatment or omalizumab therapy.\n\n③ Serum Bilirubin is a waste product that is produced during the breakdown of red blood cells in the liver. It is not directly related to asthma treatment or omalizumab.\n\n⑤ Total Serum Immunoglobulin E (IgE) is a measure of the total amount of IgE in the blood, but it is not directly related to the use of omalizumab, which targets specific IgE antibodies.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Budesonide.\n\nExplanation:\n\nBudesonide is a corticosteroid that is less likely to cause oral thrush compared to other inhaled corticosteroids, which may be a concern for the patient who has difficulty rinsing her mouth after using the inhaler. Additionally, budesonide has a shorter duration of action compared to other inhaled corticosteroids, which may be beneficial for a patient with a busy schedule.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Tiotropium</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Theophylline</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Fluticasone nasal spray</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Cefuroxime + Metronidazole</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Rabeprazole</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Alprazolam</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sertraline</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Entecavir</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Mesalamine suppository</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Presence of tuberculosis infection</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Daclatasvir + Sofosbuvir</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ HCV RNA</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Spironolactone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Atorvastatin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Mesna</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Cardiovascular disease</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Metabolic acidosis with normal anion gap.\n\nMetformin is contraindicated in patients with renal impairment, as it can increase the risk of lactic acidosis. In this patient, the eGFR is 28 mL/min/1.73 m^2, indicating chronic kidney disease stage 3b. The patient's urinalysis also shows proteinuria, which is consistent with diabetic nephropathy. Metabolic acidosis with a normal anion gap is a common complication of diabetic nephropathy and is associated with increased risk of cardiovascular disease and mortality. Therefore, metformin use is contraindicated in this patient.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Potassium.\n\nLosartan is a potassium-sparing diuretic, which means it can increase potassium levels in the blood. Therefore, it is important to monitor the patient's potassium levels to avoid hyperkalemia (elevated potassium levels), which can be dangerous.\n\nThe other options are not directly related to losartan's mechanism of action or potential side effects:\n\n① Zinc is not directly affected by losartan.\n③ Retinol is not related to losartan's mechanism of action or potential side effects.\n④ Albumin is not directly affected by losartan.\n⑤ Thyroglobulin is not related to losartan's mechanism of action or potential side effects.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Ramipril</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Glucagon</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Glaucoma</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Liraglutide</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Lisinopril</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Levothyroxine</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Propranolol</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Increased concentration-dependent bactericidal action.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Cefalexin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ceftriaxone + linezolid</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ceftriaxone + Azithromycin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Isoniazid</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Vancomycin + Cefepime.\n\nRationale:\n\nThe patient's symptoms and laboratory results suggest meningitis, which requires prompt empirical antibiotic therapy. The appropriate choice of antibiotics should cover both gram-positive and gram-negative bacteria, as well as anaerobes.\n\nVancomycin is a potent antibiotic against methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria, which are common causes of meningitis. Cefepime, a third-generation cephalosporin, provides broad-spectrum coverage against gram-negative bacteria, including Pseudomonas aeruginosa, which is often isolated from cases of meningitis.\n\nSulfamethoxazole/trimethoprim (①) is not the best choice because it lacks coverage against gram-negative bacteria. Vancomycin + Cefazolin (②) may not provide adequate coverage against Pseudomonas aeruginosa. Ampicillin + Metronidazole (④) may not be effective against MRSA. Ampicillin + Cefuroxime (⑤) may not provide adequate coverage against Pseudomonas aeruginosa.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Oral fluconazole</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ranitidine</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Oral vancomycin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Moxifloxacin (oral)\n\nRationale:\n\nThe patient has severe acute pyelonephritis, which requires broad-spectrum antibiotic coverage. Moxifloxacin is a fluoroquinolone that covers both Gram-positive and Gram-negative bacteria, including E. coli and Klebsiella pneumoniae, which are common pathogens causing pyelonephritis. It is also orally administered, which is appropriate given the patient's vomiting and inability to eat.\n\nCefpodoxime and ceftriaxone are cephalosporins that cover Gram-positive and some Gram-negative bacteria, but may not be effective against certain strains of E. coli and Klebsiella pneumoniae. Fosfomycin is a nitroimidazole antibiotic that is effective against anaerobes, but may not be effective against aerobic bacteria like E. coli and Klebsiella pneumoniae. Vancomycin is a glycopeptide antibiotic that is effective against methicillin-resistant Staphylococcus aureus (MRSA), but it is not appropriate for pyelonephritis caused by Gram-negative bacteria.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Oral levofloxacin.\n\nRationale:\n\nThe patient has severe acute pyelonephritis, which requires broad-spectrum antibiotic coverage. Levofloxacin is a fluoroquinolone that is effective against a wide range of gram-negative and gram-positive bacteria, including E. coli and Klebsiella pneumoniae, which are common pathogens causing pyelonephritis.\n\nLinezolid (①) is a synthetic antibiotic that is effective against gram-positive bacteria, but it has no activity against gram-negative bacteria. Doxycycline (②) is a tetracycline antibiotic that is effective against a wide range of gram-negative and gram-positive bacteria, but it may not be effective against some strains of E. coli and Klebsiella pneumoniae. Clindamycin (④) is a lincosamide antibiotic that is effective against gram-positive bacteria, but it has no activity against gram-negative bacteria. Azithromycin (⑤) is a macrolide antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it may not be effective against some strains of E. coli and Klebsiella pneumoniae.\n\nTherefore, oral levofloxacin (③) is the most appropriate antibiotic for the patient to take after discharge, considering its broad-spectrum activity against gram-negative and gram-positive bacteria, including E. coli and Klebsiella pneumoniae.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Propranolol</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Donepezil</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Entacapone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Start with a 50% reduction in the daily dose of lamotrigine.\n\nRationale: When valproic acid and lamotrigine are used together, the dose of lamotrigine should be reduced by 50% due to the potential for increased risk of adverse effects. Therefore, the appropriate dose adjustment would be to start with a 50% reduction in the daily dose of lamotrigine.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Trazodone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Paliperidone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ① Change to an extended-release formulation</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ Lung capacity.\n\nRationale: Methylphenidate, a medication used to treat ADHD, can have a potential side effect on the respiratory system, particularly on lung capacity. It is important to monitor the patient's lung capacity regularly to ensure that the medication is not causing any adverse effects on respiratory function.\n\nTherefore, the correct answer is ⑤ Lung capacity.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Duloxetine</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Raloxifene</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Naproxen</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Finasteride + Tamsulosin.\n\nExplanation:\n\nFinasteride, a 5-alpha-reductase inhibitor, is appropriate for treating benign prostatic hyperplasia (BPH) as it reduces the size of the prostate and decreases the levels of dihydrotestosterone (DHT), a hormone that stimulates prostate growth. Tamsulosin, an alpha-1 adrenergic receptor antagonist, is effective in improving urinary symptoms such as hesitancy, weak stream, and incomplete bladder emptying, which are common in patients with BPH. The combination of Finasteride and Tamsulosin is a common treatment approach for BPH, as it addresses both the enlarged prostate and urinary symptoms.\n\nThe other options are not the most appropriate choices for this patient's condition:\n\n① Sildenafil is a phosphodiesterase type 5 inhibitor, used to treat erectile dysfunction, and is not directly related to BPH treatment.\n\n② Doxazosin is an alpha-1 adrenergic receptor antagonist, which can improve urinary symptoms, but it does not address the enlarged prostate.\n\n③ Desmopressin is a vasopressin receptor agonist, used to treat central diabetes insipidus, and is not related to BPH treatment.\n\n④ Oxybutynin + Terazosin is a combination of an anticholinergic and an alpha-1 adrenergic receptor antagonist, which can improve urinary symptoms, but it does not address the enlarged prostate.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Folic acid</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Prednisolone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Nilotinib</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Anastrozole</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Nivolumab.\n\nExplanation:\n\nNivolumab is an immune checkpoint inhibitor that targets the PD-1 receptor and is approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. The patient's EGFR mutation status is positive, and they have an ECOG performance status of 1, which indicates they are fit for treatment.\n\nErlotinib is a tyrosine kinase inhibitor that targets the EGFR receptor and is also approved for the first-line treatment of metastatic NSCLC with EGFR mutations. However, it is not the most appropriate choice for this patient due to the presence of brain metastases, as erlotinib has a lower penetration rate across the blood-brain barrier compared to other EGFR inhibitors.\n\nTopotecan is a topoisomerase I inhibitor that is approved for the treatment of small cell lung cancer, but it is not the most appropriate choice for this patient with non-small cell lung cancer.\n\nCapecitabine + oxaliplatin is a chemotherapy regimen that is approved for the treatment of metastatic colorectal cancer, but it is not the most appropriate choice for this patient with non-small cell lung cancer.\n\nCarboplatin + paclitaxel + crizotinib is a chemotherapy regimen that includes a platinum-based doublet and a tyrosine kinase inhibitor that targets the ALK receptor. It may be a reasonable choice for this patient, but it is not the most appropriate first-line treatment due to the lack of ALK rearrangement in the patient's tumor.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Loperamide oral preparation.</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Gabapentin</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Liver function</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Aprepitant + Ondansetron + Dexamethasone</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Hydrocortisone 1% cream</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Timolol eye drops</s>"
    },
    {
        "year": 2019,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Uric acid.\n\nRefeeding syndrome is a potentially life-threatening condition that can occur in individuals who have been fasting or malnourished for an extended period. It is characterized by a rapid shift in metabolism, electrolyte imbalances, and fluid shifts. Uric acid is one of the key laboratory values that should be monitored to diagnose refeeding syndrome, as it can rise rapidly in response to the reintroduction of nutrients.\n\nPhosphorus (①) and platelets (③) may also be monitored in patients with malnutrition or intestinal obstruction, but they are not as specific or sensitive indicators of refeeding syndrome as uric acid. Troponin (④) is a marker of myocardial damage and is not directly related to refeeding syndrome. Homocysteine (⑤) is an amino acid that may be elevated in patients with malnutrition, but it is not a specific marker of refeeding syndrome.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Good Pharmacy Practice (GPP)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Assessment</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Occurrence of adverse drug reaction.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② Amlodipine.\n\nRationale: Amlodipine is a calcium channel blocker that can cause dizziness and fatigue as side effects, especially when taken at bedtime. Taking it in the morning can help minimize these side effects, as the patient will be able to sleep better at night. Additionally, amlodipine has a long duration of action, so taking it in the morning will maintain its effect throughout the day.\n\nThe other options are not the best choices for morning administration:\n\n* Aspirin (①) is a nonsteroidal anti-inflammatory drug that can irritate the stomach and cause gastrointestinal bleeding, especially when taken on an empty stomach. Taking it in the morning may exacerbate these side effects.\n* Simvastatin (③) is a statin that can cause muscle pain and liver damage. Taking it in the morning may not necessarily prevent side effects, as the drug has a long half-life and can accumulate in the body.\n* Carvedilol (④) is a beta-blocker that can cause fatigue, slowed heart rate, and low blood pressure. Taking it in the morning may not be optimal, as the patient may experience these side effects throughout the day.\n* Hydrochlorothiazide (⑤) is a diuretic that can cause frequent urination and dehydration. Taking it in the morning may not be the best option, as the patient may need to urinate frequently throughout the day.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① PubMed</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Notes for dispensing.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Pantoprazole tablet</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Nifedipine OROS tablet.\n\nAccording to the Beers Criteria published in 2015, nifedipine is considered potentially inappropriate for elderly patients due to its risk of hypotension, bradycardia, and syncope. Therefore, it is appropriate to inquire with the doctor about the prescription of nifedipine OROS tablet for a 75-year-old elderly patient.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Minocycline capsule\n\nThe DUR check should flag the Minocycline prescription because it is a antibiotic and may have adverse effects or interactions with other medications, especially in a 10-year-old child. It is crucial to verify the medication with the doctor to ensure it is appropriate for the patient's age, weight, and medical history.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Skin itching – Hydroxyurea 250 mg capsule\n\nIt is important to consult a doctor about the appropriateness of drug selection during prescription review when the medication being prescribed is hydroxyurea, which is a chemotherapy drug used to treat certain types of cancer, including skin cancer. However, it is not appropriate to use hydroxyurea to treat skin itching, as it is not a recommended use for this medication. Instead, other medications or treatments may be more appropriate for this condition. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② Leucovorin injection.\n\nRationale: Leucovorin is a folinic acid derivative that is used to reduce the toxicity of methotrexate, a chemotherapy drug that is often used in combination with paclitaxel and carboplatin. Leucovorin works by reversing the harmful effects of methotrexate on the bone marrow, which can help to prevent or reduce the risk of adverse effects such as bone marrow suppression, anemia, and infection. In this case, leucovorin would be administered to reduce the risk of bone marrow toxicity associated with the chemotherapy regimen.\n\nMesna injection (①) is used to prevent or treat cyclophosphamide-induced hemorrhagic cystitis, which is not relevant to this chemotherapy regimen.\n\nDomperidone tablet (③) is used to stimulate the release of breast milk, which is not relevant to this chemotherapy regimen.\n\nAcetaminophen tablet (④) is used to manage pain and fever, which may be necessary during chemotherapy, but it is not the most appropriate supportive care medication for this regimen.\n\nChlorpheniramine tablet (⑤) is an antihistamine that is used to prevent or treat allergic reactions, which is not relevant to this chemotherapy regimen.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Creatinine Clearance</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Reduction in medication errors</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Preparing in a Class 100 environment using a horizontal laminar flow hood dedicated to anticancer drugs.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Isoniazid tablet</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Mix calcium into the nutrition fluid first, then mix in phosphorus later.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Pregabalin capsule</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Contraindicated for hypertensive patients</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Polycarbophil</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Ketoconazole</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Amiodarone tablets</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Take all medications together on an empty stomach.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Press the button while turning the transparent body until it clicks.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Mahaenggamseok-tang (麻杏甘石湯)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Clopidogrel tablet\n\nRationale: Clopidogrel is an antiplatelet medication that is contraindicated for use with sildenafil, as it may increase the risk of bleeding. Patient counseling is necessary to inform the patient of this contraindication and to ensure that they are aware of the potential risks associated with taking these medications together.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Atenolol tablet.\n\nRationale: Atenolol is a beta-blocker that is used to treat hypertension and angina. Sudden discontinuation of beta-blockers can lead to acute tachycardia, hypertension, and ischemic symptoms, especially in patients with a history of myocardial infarction. Therefore, patient counseling is necessary to educate the patient about the risks associated with suddenly stopping the medication.\n\nThe other options do not require patient counseling regarding the risk of acute tachycardia, hypertension, and ischemic symptoms if suddenly discontinued:\n\n① Valsartan is an angiotensin II receptor antagonist that is used to treat hypertension. It does not have a significant effect on heart rate or ischemic symptoms.\n\n② Aspirin is a nonsteroidal anti-inflammatory drug that is used to prevent platelet aggregation and ischemic events. It does not have a significant effect on heart rate or blood pressure.\n\n④ Clopidogrel is a platelet aggregation inhibitor that is used to prevent ischemic events. It does not have a significant effect on heart rate or blood pressure.\n\n⑤ Isosorbide mononitrate is a nitrate that is used to treat angina. It can cause a sudden decrease in blood pressure, which can lead to symptoms such as dizziness and lightheadedness, but it does not have a significant effect on heart rate or ischemic symptoms.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Process validation</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Cleaning and evaluation of manufacturing facilities.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Grade A</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 12 minutes</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Autoclave sterilization</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Storage conditions</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Decrease the friability.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 6</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 25 mg or more, 25% or more</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Release approval guarantees that the product was manufactured according to GMP.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Every 6 months</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Sealed Container – Hermetic Container – Closed Container</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Electron capture detector</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Gelatin</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Reduce the dispersion of quality characteristic values.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① F-test</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Dissolve 30 mg of the reference standard in the solvent and make up to 1 L.\n\nExplanation:\nThe method for preparing the standard solution of d-Chlorpheniramine Maleate in the identification test is to dissolve 30 mg of the reference standard in the solvent and make up to 1 L. This is stated in the monograph as \"Dissolve 30 mg of the reference standard in the solvent and make up to 1 L.\" Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Temperature specified in the Loss on Drying section.\n\nThe Loss on Drying section of the monograph specifies the temperature condition for drying the drug, which is 105°C for 30 minutes. Therefore, the correct answer is ⑤ Temperature specified in the Loss on Drying section.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Opening a pharmacy on the first floor of a commercial building near a subway station.\n\nThe 4Ps of marketing mix for pharmacy management are:\n\n1. Product: This refers to the goods and services offered by the pharmacy, such as medications, health supplements, and medical equipment.\n2. Price: This refers to the cost of the products and services offered by the pharmacy, including discounts and promotions.\n3. Promotion: This refers to the methods used to promote the pharmacy and its products and services, such as advertising, public relations, and sales promotions.\n4. Place: This refers to the location and distribution of the pharmacy, including its accessibility and convenience for customers.\n\nTherefore, the correct answer is ③ Opening a pharmacy on the first floor of a commercial building near a subway station, as it corresponds to the \"place\" element of the marketing mix.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ The current assets are 500 million won.\n\nExplanation:\n\nThe current assets of the pharmacy include the cash paid for the store (200 million won) and the inventory of medications (100 million won), which total 500 million won. This is the correct answer.\n\nThe capital (①) refers to the total amount of money invested in the business, which is 500 million won in this case.\n\nThe assets (②) refer to the total value of everything owned by the business, including both current and non-current assets. In this case, the assets would be 600 million won (200 million won in cash + 300 million won in long-term loan + 100 million won in inventory).\n\nThe current liabilities (④) refer to debts that must be paid within one year. In this case, the current liabilities would be 300 million won, which is the amount of the long-term loan that has not yet been paid.\n\nThe non-current assets (⑤) refer to assets that will not be converted to cash within one year. In this case, the non-current assets would be 200 million won, which is the amount of the long-term loan that has not yet been paid.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ When using the sum-of-the-years'-digits method, the depreciation expense is higher in the early years than in later years.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ (1 billion won - 800 million won) / (300 million won + 200 million won)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Annual stockout cost < Annual ordering cost.\n\nThe economic order quantity (EOQ) is the order quantity that minimizes the total inventory management cost in a pharmacy. To calculate the EOQ, we need to find the point where the annual stockout cost equals the annual ordering cost.\n\nTherefore, the correct answer is ② Annual stockout cost < Annual ordering cost.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Subscribers can choose their insurance premium amount according to the level of coverage.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Moral hazard can occur on both the consumer and provider sides.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Compensation for prescription drug dispensing consists of dispensing fee, basic dispensing fee, medication counseling fee, drug management fee, and pharmacy management fee.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Principle of justice</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 100/1,100 | 100/950</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ It can be used to detect signal information about adverse drug reactions.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 1,000 won | 1,000 won\n\nExplanation:\nUnder the actual transaction price reimbursement system, the National Health Insurance Service reimburses the pharmacy the actual price of the drug that was purchased, up to the insurance price cap. In this case, the drug price is capped at 1,000 won, and both pharmacies purchased the drug for less than the cap. Therefore, the reimbursement amount for both pharmacies will be the actual price they paid for the drug, which is 1,000 won for Pharmacy A and 800 won for Pharmacy B.\n\nSo, the correct answer is ③ 1,000 won | 1,000 won.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① 500,000 won + (700,000 won × 0.95) + (1,000,000 won × 0.95^2)</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Medication use counseling</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 0.8 QALY</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ c\n\nExplanation:\n\nThe incremental cost-utility ratio (ICUR) is calculated as follows:\n\nICUR = (Incremental Cost) / (Incremental Utility)\n\n= (30 million won - 10 million won) / (2 years - 1 year)\n\n= 20 million won / 1 year\n\n= 20 million won/QALY\n\nSince the threshold for the incremental cost-utility ratio is 40 million won/QALY, the new anticancer drug B is considered cost-effective compared to the existing anticancer drug A.\n\nTherefore, the correct answer is ③ c.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Export of pregnancy test reagents</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nAccording to the Pharmaceutical Affairs Act, collusion or similar collusive behavior between pharmacy owners and medical institution owners refers to any agreement, understanding, or practice that restricts or controls the sale or distribution of drugs, or any agreement that fixes prices or restricts competition.\n\nOption ③, \"A pharmacist opening a pharmacy on the same floor of a building where a medical institution and multi-use facilities exist,\" does not fit the definition of collusion or similar collusive behavior. This scenario does not involve any agreement or understanding between the pharmacy owner and the medical institution owner that restricts or controls the sale or distribution of drugs, nor does it fix prices or restrict competition. Therefore, it is not considered collusive behavior.\n\nOn the other hand, options ①, ②, ④, and ⑤ all involve some form of agreement, understanding, or practice that restricts or controls the sale or distribution of drugs, or fixes prices or restricts competition. Therefore, they are all considered collusive behavior and are prohibited under the Pharmaceutical Affairs Act.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ When dispensing for emergency patients and mental health patients with schizophrenia who may harm others.\n\nAccording to the Pharmaceutical Affairs Act, a pharmacist can dispense or sell medication without a prescription from a doctor or dentist in the following cases:\n\n* ① When dispensing for social service activities\n* ② When dispensing in areas without medical institutions\n* ③ When dispensing for disaster relief in areas where medical institutions have effectively ceased to exist due to a disaster\n* ⑤ When selling oral vaccines for infectious diseases as recognized by the Minister of Health and Welfare due to the risk of a mass outbreak of an infectious disease\n\nHowever, the Act does not allow a pharmacist to dispense or sell medication without a prescription for emergency patients and mental health patients with schizophrenia who may harm others. This is because these patients require careful assessment and monitoring by a medical professional, and a pharmacist may not have the necessary training or expertise to provide appropriate care. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Contents of medication counseling</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Pharmacy owners can sell pharmaceuticals outside their pharmacy or store with the approval of the head of a Si/Gun/Gu.\n\nThe correct answer is ④. According to the Pharmaceutical Affairs Act, pharmacy owners are not allowed to sell pharmaceuticals outside their pharmacy or store, regardless of whether they have the approval of the head of a Si/Gun/Gu. This is to ensure that pharmaceuticals are sold and dispensed only by authorized personnel in a controlled environment, and to prevent unauthorized sales and distribution of pharmaceuticals.\n\nThe other options are all correct statements about the sale of pharmaceuticals and medication counseling according to the Pharmaceutical Affairs Act:\n\n① The medicines that can be sold by drug sellers are limited to over-the-counter drugs.\n② Pharmacy owners can sell over-the-counter drugs without a prescription from a doctor or dentist.\n③ When selling over-the-counter drugs, pharmacy owners can provide medication counseling if they deem it necessary.\n⑤ Pharmacy owners must not sell prescription drugs to veterinary hospital owners except when dispensing according to a prescription from a doctor or dentist.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Cyclosporine injection, which requires the specialized knowledge of a veterinarian or an aquatic animal disease manager.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Prescription drug with the same active ingredient but different administration route from already approved drugs.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ A person who graduated from a 4-year university with a degree in biochemistry.\n\nAccording to the Pharmaceutical Affairs Act, a manufacturing manager of biological products must be a pharmacist or an oriental medicine pharmacist. Therefore, option ③, a person with a degree in biochemistry, is not eligible to be appointed as a manufacturing manager by a manufacturer producing biological products.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Tablets containing aspirin</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ In case of allowing unqualified persons to dispense or sell medicines.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Alkaloids extracted from opium</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ A doctor practicing medicine in a tertiary hospital.</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Food hygiene</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Secretary General of the National Assembly</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Prescription drugs – Purchase price</s>"
    },
    {
        "year": 2019,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Evaluation of the appropriateness of medical care benefits</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② fibronectin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ pyridoxal phosphate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① cerebroside</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ mitochondria</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ glucose 6-phosphate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② D-β-hydroxybutyrate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ ubiquinone : cytochrome c oxidoreductase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① acetyl-CoA carboxylase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② glycerol 3-phosphate acyltransferase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ lysine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ TATA box</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② excinuclease</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increased transcriptional activity of genes.\n\nAcetylation of lysine residues located at the amino terminals of histones H3 and H4 in nucleosomes can lead to increased transcriptional activity of genes. This is because acetylation of these residues can weaken the interaction between histones and DNA, leading to increased accessibility of transcription factors to the DNA and enhanced transcriptional activity.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① alkaptonuria</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ selectin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Inhibition of thromboxane A2 synthesis.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Lesch-Nyhan syndrome</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ C</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ dextran</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ames test</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Phage display</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ imipenem</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ colistin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ levofloxacin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② ergosterol</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② entecavir</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① C1q</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ CD28</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ PD-1</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Systemic lupus erythematosus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ trastuzumab</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Toxoid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Cell wall</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Streptococcus pneumoniae</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ norovirus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Epstein-Barr virus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Scarlet fever</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Acute glomerulonephritis</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ methotrexate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ NMDA receptor – Cl-</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ isoniazid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ ipratropium</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ clozapine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ fluoxetine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ lamotrigine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ tramadol</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② montelukast</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ folic acid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ enalapril</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② cimetidine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Inhibition of α-glucosidase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① alendronate</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ chloramphenicol – cefazolin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ sirolimus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① α1 receptor</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ No significant change | Increase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Agent, Host, Environment</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Sulfur dioxide</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Reference dose</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Micronucleus test</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① N-acetylcysteine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Arsenic (As)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ pectic substance</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② eicosapentaenoic acid</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Kwashiorkor</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Zinc (Zn)</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ vitamin B12</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Listeria monocytogenes</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ grayanotoxin</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Hydrogen peroxide</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Red yeast rice – Joint health</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Cryptosporidium parvum</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Ozone treatment</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Macrophage</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Thiamine</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Oral candidiasis</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Causing spasmodic contraction of respiratory muscles.</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Cardiomyopathy</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Thromboembolism</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Cor pulmonale</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Asthma</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Peptic ulcer</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Skip lesions</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Hepatitis C virus</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Lipase</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Dihydrotestosterone</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Neovascularization</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Insufficient mineralization of bone</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Acetylcholine receptor</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ α-synuclein</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Angina</s>"
    },
    {
        "year": 2020,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Formation of atherosclerotic plaque.\n\nThe patient's symptoms of chest pain, particularly during exercise, suggest angina pectoris, which is typically caused by atherosclerosis, the buildup of plaque in the coronary arteries. The high levels of triglycerides and LDL-C in the blood suggest a lipid disorder, which can contribute to the development of atherosclerosis. Therefore, the direct pathophysiological mechanism causing the patient's symptoms is the formation of atherosclerotic plaque in the coronary arteries, which is option ④.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ion-dipole interaction.\n\nPentobarbital sodium is a salt formed by the reaction of pentobarbital with sodium hydroxide. This reaction increases the solubility of pentobarbital in water and enhances its dissolution rate. The increased solubility and dissolution rate are due to the ion-dipole interaction between the negatively charged sodium ions and the polar pentobarbital molecules. The sodium ions interact with the electronegative atoms (such as oxygen and nitrogen) in the pentobarbital molecule, creating an ion-dipole interaction that enhances the solubility and dissolution rate of the drug. Therefore, option ② Ion-dipole interaction is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Stability varies depending on the crystal form.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Below the eutectic point, it exists as a single liquid phase.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ F=P-C+1</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Hygroscopicity</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Thixotropy</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ a-b+c</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ P T = 0.3P b o + 0.7P e o</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Debye-Hückel equation</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 0.7</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Dissolution</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ t1/2 is inversely proportional to a.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Specific acid catalysis</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 90°</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 30\n\nExplanation:\n\nThe Noyes-Whitney equation describes the release of a drug from a sphere into a surrounding solution. The equation takes into account the diffusion coefficient, the thickness of the diffusion layer, and the surface area of the sphere.\n\nWhen the diameter of the aspirin spherical particles is changed from 2 mm to 0.2 mm, the surface area of the particles decreases, which should result in a lower release rate. However, the diffusion coefficient and the thickness of the diffusion layer remain the same.\n\nTherefore, using the Noyes-Whitney equation, we can calculate the expected release amount of aspirin in 1 minute. The answer is 30 mg (option ③).\n\nNote: The other options, 3 mg (option ①), 15 mg (option ②), 150 mg (option ④), and 300 mg (option ⑤), are not correct answers based on the given information and the Noyes-Whitney equation.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② pH-partition theory</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ D</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ ES</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ eperisone</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nAcetaminophen can be synthesized from phenol using the following steps:\n\n1. Nitration: Phenol is treated with a mixture of sulfuric and nitric acids to form a nitrophenol.\n2. Reduction: The nitro group is reduced using hydrogen gas in the presence of a catalyst, such as palladium on carbon.\n3. Acetylation: The resulting phenol is then acetylated using acetic anhydride in the presence of a catalyst, such as sulfuric acid.\n4. Oxidation: The resulting acetaminophen is then oxidized using a strong oxidizing agent, such as potassium permanganate, to form the final product.\n\nTherefore, the correct order of reactions for synthesizing acetaminophen using phenol as the starting material is:\n\n③ acetylation – oxidation – nitration – reduction</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ donepezil</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Knoevenagel condensation – Strecker reaction.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ imidazole</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ methotrexate</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nR1=7-Cl and R2=Ph correctly represent the substituents and their positions for diazepam.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ ipratropium</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ D</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ pyrazine</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 5.5</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NaHCO3</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 50</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 0.1 mol/L KMnO4</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Regression curve method</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ A×M×100</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ -130°</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Measuring after removing dissolved oxygen</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Infrared spectroscopy</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Mass spectrometry detector</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Increase separation efficiency</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Control test</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 7\n\nExplanation:\n\nTo calculate the amount of drug A needed, we can use the formula:\n\nAmount (mg) = Concentration (M) x Volume (mL)\n\nIn this case, the concentration is 1.000 M, and the volume is 30.0 mL.\n\nTherefore, the amount of drug A needed is:\n\nAmount (mg) = 1.000 M x 30.0 mL = 30.0 g\n\nSince the molecular weight of drug A is 234.56, we can calculate the number of moles as follows:\n\nMoles = amount (g) / molecular weight (g/mol)\n\nMoles = 30.0 g / 234.56 g/mol = 0.128 mol\n\nThe number of significant figures in the calculated amount (mg) is the same as the number of significant figures in the molar concentration, which is 4. Therefore, the correct answer is ④ 7.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 5\n\nThe resolution (R) between two peaks can be calculated using the following equation:\n\nR = (tR2 - tR1) / (Wb1 + Wb2)\n\nwhere tR1 and tR2 are the retention times of the two peaks, and Wb1 and Wb2 are the peak widths at baseline.\n\nPlugging in the given values, we get:\n\nR = (10.0 - 5.0) / (0.45 + 0.55)\nR = 5.0 / 0.95\nR = 5.26\n\nSince the answer options are limited to integers, we round up to the nearest integer, which is 6. Therefore, the correct answer is ③ 5.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ hydrolysis | aspirin | salicylic acid</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Enhancement of dissolution rate</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Powders with uniform particle size.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Low shear granulation method</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ The diffusion rate of moisture inside the sample becomes slower than the evaporation rate at the surface.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Lower the viscosity of the dispersion medium.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Carrageenan</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Patch</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Reduce irritation</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Microencapsulation</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Temperature</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Sodium sulfite</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Drugs absorbed through the skin undergo first-pass hepatic metabolism, reducing their bioavailability.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ 8</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2.0</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Excretion only by tubular secretion</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Crospovidone</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ A drug with very slow absorption and elimination rates.\n\nRationale: A drug with very slow absorption and elimination rates would be suitable for development as a once-daily formulation, as it would maintain therapeutic levels in the body over a longer period of time, reducing the need for multiple doses per day.</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ sesquiterpenoid</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① lignan</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Hemp</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① tannin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Chrysanthemum cinerariaefolium (Pyrethrum)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Keller-Killiani reaction</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ paeoniflorin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① linamarin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① silybin</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ginkgo leaf</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Coptis japonica</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ergot</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Pathogenic Factor Differentiation (病因辨證)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Samul-tang (四物湯)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Xiaoqinglong Tang (小靑龍湯)</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Ephedra herb</s>"
    },
    {
        "year": 2020,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Ephedrine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Labetalol</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Hydrochlorothiazide</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Switch to diltiazem.\n\nRationale:\n\nAtenolol, a beta-blocker, is an appropriate medication for chronic stable angina. However, the patient's severe fatigue and sexual dysfunction suggest that the medication may be causing a negative impact on the patient's quality of life. Diltiazem, a calcium channel blocker, is an alternative medication that can also effectively control chest pain and may have fewer side effects compared to atenolol. Therefore, switching to diltiazem may be a better option for this patient.\n\nWarfarin, a blood thinner, may not be appropriate in this case as the patient does not have a history of atrial fibrillation or other indications for anticoagulation therapy. Amlodipine, another calcium channel blocker, may also have similar side effects as atenolol. Metoprolol, a beta-blocker, may have similar side effects as atenolol and may not address the patient's fatigue and sexual dysfunction. Rivaroxaban, an oral anticoagulant, may not be appropriate in this case as the patient does not have a history of atrial fibrillation or other indications for anticoagulation therapy.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Unfractionated heparin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ticagrelor</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Amiodarone.\n\nRationale: Amiodarone is a class III antiarrhythmic drug that is effective in maintaining sinus rhythm in patients with atrial fibrillation. It has a long half-life, which makes it suitable for long-term maintenance therapy. In contrast, digoxin (①) is a class I antiarrhythmic drug that is primarily used for rate control in atrial fibrillation, and it may not be effective in maintaining sinus rhythm. Verapamil (②) is a calcium channel blocker that can be used for rate control in atrial fibrillation, but it may not be effective in maintaining sinus rhythm. Flecainide (③) is a class I antiarrhythmic drug that can be used for conversion and maintenance of sinus rhythm, but it may have a higher risk of proarrhythmia compared to amiodarone. Propafenone (⑤) is a class III antiarrhythmic drug that can be used for conversion and maintenance of sinus rhythm, but it may have a higher risk of proarrhythmia compared to amiodarone, especially in patients with structural heart disease.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Edoxaban.\n\nReasoning:\n\nEdoxaban is an oral anticoagulant that is used for stroke prevention in patients with non-valvular atrial fibrillation. It is a direct thrombin inhibitor that works by inhibiting the production of thrombin, which is involved in the formation of blood clots.\n\nAspirin (①) is an antiplatelet agent that is commonly used for secondary stroke prevention, but it is not recommended as a primary stroke prevention medication for patients with non-valvular atrial fibrillation.\n\nAbciximab (③) is a glycoprotein IIb/IIIa inhibitor that is used for acute coronary syndrome and percutaneous coronary intervention, but it is not indicated for stroke prevention.\n\nCilostazol (④) is a phosphodiesterase inhibitor that is used for the treatment of intermittent claudication, but it is not recommended for stroke prevention.\n\nPrasugrel (⑤) is an antiplatelet agent that is used for acute coronary syndrome and percutaneous coronary intervention, but it is not indicated for stroke prevention.\n\nTherefore, the correct answer is ② Edoxaban.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Nimodipine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Alteplase (tPA)</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Fenofibrate.\n\nRationale:\n\nThe patient's lipid profile shows elevated triglycerides (TG) and low HDL-C, indicating a need for additional lipid-lowering therapy. Fenofibrate is a fibric acid derivative that is primarily used to treat hypertriglyceridemia and low HDL-C levels. It has been shown to reduce TG levels by 20-50% and increase HDL-C levels by 10-30%.\n\nGemfibrozil is another option that could be considered, but it has a similar mechanism of action to fenofibrate and may not provide additional benefits. Ezetimibe, an cholesterol absorption inhibitor, may also be considered, but it primarily lowers LDL-C levels and has less of an effect on TG and HDL-C levels. Fluvastatin, a statin, is primarily used to lower LDL-C levels and may not have a significant impact on TG and HDL-C levels. Cholestyramine, a bile acid sequestrant, is primarily used to lower LDL-C levels and has no effect on TG and HDL-C levels.\n\nTherefore, the most appropriate additional medication for this patient would be fenofibrate.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Isosorbide dinitrate\n\nRationale: Verapamil is a calcium channel blocker, which can increase the levels of isosorbide dinitrate, a nitrate, and cause excessive hypotension. Therefore, the dose of isosorbide dinitrate needs to be adjusted when co-administered with verapamil. The other medications do not require dose adjustment when co-administered with verapamil.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Dexibuprofen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Furosemide.\n\nRationale: The patient's sudden weight gain, shortness of breath, and leg edema suggest that she is experiencing fluid overload, which can be a side effect of the medications she is taking, particularly ramipril and bisoprolol. Furosemide, a diuretic, is appropriate to alleviate these symptoms by increasing urine production and reducing fluid retention. Ivabradine, spironolactone, and sacubitril/valsartan may also be considered, but they are not as directly effective in reducing fluid overload as furosemide. Hydralazine/isosorbide dinitrate is not typically used to treat fluid overload and may have adverse effects in this patient given her history of heart failure.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Rivaroxaban</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Enoxaparin.\n\nRationale: Enoxaparin is a low-molecular-weight heparin that is commonly used to treat deep vein thrombosis (DVT) in pregnant women. It is safe for use during pregnancy and has been shown to be effective in preventing recurrent DVT and pulmonary embolism. Warfarin, edoxaban, and clopidogrel are not typically used during pregnancy due to potential risks to the fetus. Aspirin/dipyridamole is not typically used for the treatment of DVT.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Budesonide inhaler</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ibuprofen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Mometasone nasal spray</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Salmeterol/fluticasone inhaler.\n\nRationale:\n\nThe patient's symptoms and pulmonary function test results indicate that they have moderate to severe COPD. The appropriate treatment for this stage of COPD is a combination of a long-acting beta-2 agonist (LABA) and an inhaled corticosteroid (ICS). Salmeterol/fluticasone inhaler is a combination product that contains both a LABA (salmeterol) and an ICS (fluticasone), making it the most appropriate choice for this patient.\n\nSalbutamol inhaler (①) is a short-acting beta-2 agonist that is used for quick relief of symptoms, but it is not appropriate for long-term management of COPD.\n\nBudesonide inhaler (②) is an ICS that is used for long-term management of COPD, but it does not contain a LABA.\n\nPrednisolone tablets (③) are a systemic corticosteroid that can be used for short-term management of COPD exacerbations, but they are not appropriate for long-term management.\n\nTiotropium inhaler (⑤) is an anticholinergic that can be used for long-term management of COPD, but it does not contain a LABA or an ICS. Roflumilast tablets (⑤) are a phosphodiesterase-4 inhibitor that can be used for long-term management of COPD, but they are not appropriate for this patient's current symptoms and pulmonary function test results.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Once a year</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Esomeprazole</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Hydrochlorothiazide</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Loperamide</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Lamivudine + Asunaprevir</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Hepatitis B immunoglobulin + Hepatitis B vaccine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Add prednisolone tablets</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Azathioprine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Terlipressin injection</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Norfloxacin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hydrochlorothiazide</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Failure to administer insulin.\n\nExplanation:\n\nThe patient's acid-base imbalance is likely due to diabetic ketoacidosis (DKA), a complication of type 1 diabetes that occurs when the body cannot produce enough insulin to regulate blood sugar levels. The patient's recent inability to take his insulin medication for 3 days due to travel, combined with his history of type 1 diabetes, suggests that he may have developed DKA. The patient's symptoms of severe abdominal pain, shortness of breath, and mental confusion are consistent with DKA. The arterial blood gas test results also support this diagnosis, as the pH is slightly acidic (7.18), and the PaCO2 is lower than the reference range (22 mmHg), indicating respiratory acidosis. Additionally, the HCO3- level is lower than the reference range (9 mEq/L), which is consistent with metabolic acidosis.\n\nThe other options are not the most likely causes of the acid-base imbalance:\n\n① Hypotension: Although the patient's blood pressure is lower than normal (98/57 mmHg), it is not likely the cause of the acid-base imbalance.\n\n② Smoking history: Smoking can contribute to respiratory acidosis, but it is not the most likely cause of the acid-base imbalance in this case.\n\n③ Drinking history: Drinking alcohol can also contribute to respiratory acidosis, but it is not the most likely cause of the acid-base imbalance in this case.\n\n⑤ Failure to administer furosemide: Furosemide is a diuretic medication that can cause hypokalemia (low potassium levels) and metabolic alkalosis. However, the patient's potassium level (3.3 mEq/L) is within the normal range, and the arterial blood gas test results do not suggest metabolic alkalosis. Therefore, failure to administer furosemide is not the most likely cause of the acid-base imbalance.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Cyclosporine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Add amlodipine.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Torasemide.\n\nTorasemide is a loop diuretic that helps to increase urine production and reduce fluid buildup in the body, which can help to alleviate uremic symptoms such as nausea, vomiting, and itching. It is also effective in reducing blood pressure and improving renal function, which can help to slow the progression of chronic kidney disease.\n\nThe other options are not appropriate for improving uremic symptoms in this patient:\n\n① Lactitol is a sugar substitute that is sometimes used as a laxative, but it is not effective in treating uremic symptoms.\n\n② Mannitol is a sugar substitute that is sometimes used as a laxative, but it is not effective in treating uremic symptoms.\n\n④ Spherical adsorptive carbon (KremezinⓇ granules) is a medication that is used to treat diarrhea, but it is not effective in treating uremic symptoms.\n\n⑤ Calcium polystyrene sulfonate is a medication that is used to treat high levels of potassium in the blood, but it is not effective in treating uremic symptoms.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ① Decrease the dose.\n\nExplanation:\n\nThe patient's hemoglobin level has increased from 9.4 g/dL to 10.1 g/dL, which is within the target range. However, the patient's serum creatinine level has increased, indicating a decline in renal function. The patient's eGFR has decreased to 36 mL/min/1.73 m^2, which is below the target range. These results suggest that the patient's kidney function is worsening, and the darbepoetin alfa therapy may be contributing to this decline.\n\nTherefore, it is appropriate to decrease the dose of darbepoetin alfa to minimize the risk of further renal damage. Administering red blood cell transfusions or increasing the dose of darbepoetin alfa and adding vitamin C, lenograstim, or ferrous sulfate would not be appropriate at this time, as they could exacerbate the patient's renal dysfunction.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Metformin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Duloxetine capsules</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Rosuvastatin\n\nRationale:\nThe patient's current medications include metformin, lisinopril, carvedilol, and atorvastatin, which are appropriate for the treatment of type 2 diabetes, hypertension, heart failure, and dyslipidemia. However, the patient's LDL-C level is still elevated (95 mg/dL) despite treatment with atorvastatin. Rosuvastatin is a more potent statin that can further lower LDL-C levels and improve cardiovascular outcomes. Therefore, adding rosuvastatin to the patient's regimen would be an appropriate choice.\n\nAmlodipine (①) is a calcium channel blocker that can be used to treat hypertension, but it is not the most appropriate choice for this patient's dyslipidemia.\n\nClopidogrel (②) is an antiplatelet agent that can be used to treat patients with cardiovascular disease, but it is not the most appropriate choice for this patient's dyslipidemia.\n\nPioglitazone (④) is a thiazolidinedione that can be used to treat type 2 diabetes, but it is not the most appropriate choice for this patient's dyslipidemia.\n\nEmpagliflozin (⑤) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that can be used to treat type 2 diabetes, but it is not the most appropriate choice for this patient's dyslipidemia.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Switch to methimazole.\n\nRationale:\n\nPropylthiouracil is a category B drug, which means that it has not been proven to be harmful to the fetus. However, it is not the drug of choice for pregnant women with hyperthyroidism, especially in the first trimester. Methimazole is a category A drug, which means that it has been proven to be safe for the fetus. Therefore, it is the appropriate drug therapy for this patient.\n\nIt is not appropriate to decrease or increase the dose of propylthiouracil (options ① and ②) or switch to potassium iodide (option ⑤) because these options do not address the concern of fetal safety. Adding methimazole (option ③) may be considered, but it is not the most appropriate option since the patient is already taking propylthiouracil and the goal is to switch to a safer medication.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① TSH</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Dapagliflozin.\n\nRationale: Dapagliflozin is a medication that helps the kidneys remove excess sugar from the bloodstream, which can help lower blood glucose levels. It is an appropriate option for patients with type 2 diabetes who have difficulty achieving blood glucose control with oral medications, such as metformin and sulfonylureas, and are concerned about weight gain. Liraglutide, glimepiride, and pioglitazone are also medications that can help lower blood glucose levels, but they work in different ways and may not be as appropriate for this patient's specific needs. Insulin glargine is a long-acting insulin that may be considered for patients who require insulin therapy, but it is not the most appropriate option for this patient who is reluctant to use injectable medications and has not yet tried other oral medications.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Atorvastatin.\n\nRationale: The patient has type 2 diabetes, hypertension, and a high risk of cardiovascular complications, as evidenced by his elevated HbA1c, SCr, and LDL-C levels. Atorvastatin is a statin, which is a medication that lowers cholesterol levels and reduces the risk of cardiovascular events, such as heart attacks and strokes. It is an appropriate choice for this patient, as it can help to reduce his risk of cardiovascular complications.\n\nLisinopril and carvedilol are both medications that can be used to treat hypertension, but they are not specifically indicated for the reduction of cardiovascular risk in patients with type 2 diabetes. Enoxaparin and dabigatran are both anticoagulant medications, which are not indicated for the reduction of cardiovascular risk in this patient population.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Serum creatinine.\n\nGentamicin is a nephrotoxic drug that can cause renal damage and impair renal function. Monitoring serum creatinine levels can help assess the drug's effect on the patient's kidney function and detect any potential nephrotoxicity.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ciprofloxacin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Amoxicillin/clavulanate</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ibuprofen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Cefepime + Levofloxacin + Gentamicin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Administer pneumococcal vaccine 13-valent, then pneumococcal vaccine 23-valent 12 months later.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Rifampicin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Caspofungin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Metronidazole</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Gentamicin + Cefazolin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Ceftriaxone\n\nExplanation:\n\nThe patient's symptoms and test results indicate bacterial meningitis caused by Streptococcus pneumoniae. The antibiotic susceptibility test shows that the isolate is susceptible to ceftriaxone (MIC 0.25 μg/mL), which is a third-generation cephalosporin. Ceftriaxone has a broad spectrum of activity against gram-positive bacteria, including Streptococcus pneumoniae, and is effective in treating bacterial meningitis.\n\nAmpicillin (MIC 4 μg/mL) and amoxicillin (not listed) are not effective against Streptococcus pneumoniae, as they have a higher MIC than ceftriaxone.\n\nGentamicin (not listed) is an aminoglycoside that is effective against gram-negative bacteria but has limited activity against gram-positive bacteria like Streptococcus pneumoniae.\n\nLevofloxacin (MIC 1 μg/mL) is a fluoroquinolone that is effective against gram-negative bacteria but has limited activity against gram-positive bacteria like Streptococcus pneumoniae.\n\nCephalexin (not listed) is a cephalosporin that is effective against gram-positive bacteria but has a narrower spectrum of activity than ceftriaxone and is not effective against Streptococcus pneumoniae.\n\nAztreonam (not listed) is a monobactam that is effective against gram-negative bacteria but has limited activity against gram-positive bacteria like Streptococcus pneumoniae.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Propranolol</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Sertraline</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Baclofen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Valproic acid</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Serotonin syndrome</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Switch to buspirone.\n\nExplanation: Venlafaxine is an antidepressant that is sometimes used to treat generalized anxiety disorder, but it may not be effective for everyone. If the patient's symptoms have not improved after a week, it may be necessary to switch to a different medication. Buspirone is a serotonin receptor agonist that is specifically approved for the treatment of generalized anxiety disorder, and it may be a good alternative to venlafaxine.\n\nIt is important to note that the decision to switch medications should be based on a thorough evaluation of the patient's symptoms and medical history, and should be made in consultation with a healthcare provider.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Domperidone</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Quetiapine</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Allopurinol + Naproxen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Smoking 1 pack (20 cigarettes) per day.\n\nRationale: Oral combined hormonal contraceptives are contraindicated in women who smoke due to the increased risk of cardiovascular disease, particularly in those who smoke more than 20 cigarettes per day. The risk of cardiovascular disease increases with age, smoking status, and hormonal contraceptive use. In this case, the patient is 37 years old, smokes 1 pack (20 cigarettes) per day, and has a history of gestational diabetes, which further increases the risk of cardiovascular disease. Therefore, option ⑤ Smoking 1 pack (20 cigarettes) per day is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Bazedoxifene/conjugated equine estrogen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Tamsulosin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Interferon-gamma release assay, chest X-ray.\n\nRationale:\n\nEtanercept is a biologic drug that suppresses the immune system and increases the risk of infections, including tuberculosis. Therefore, it is important to screen patients for latent tuberculosis infection (LTBI) before starting treatment. Interferon-gamma release assay (IGRA) is a blood test that measures the immune response to Mycobacterium tuberculosis antigens and is used to diagnose LTBI. Chest X-ray is also recommended to rule out active tuberculosis.\n\nThe other options are not relevant to the patient's condition or the consideration of etanercept treatment:\n\n① Blood pressure and blood glucose tests are not specific to etanercept treatment or the patient's medical history.\n\n② Fundus examination and visual field test are not related to the patient's joint swelling and pain, nor are they relevant to the consideration of etanercept treatment.\n\n③ Electrocardiogram and transesophageal echocardiogram are not typically performed before starting etanercept treatment, and they are not relevant to the patient's history of deep vein thrombosis or rheumatoid arthritis.\n\n④ Cystoscopy and esophagogastroduodenoscopy are not related to the patient's joint swelling and pain, nor are they relevant to the consideration of etanercept treatment.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ② Alendronate\n\nRationale: Alendronate is a bisphosphonate that is effective in treating osteoporosis and has a long-term safety profile. It is also less likely to cause gastrointestinal side effects compared to other bisphosphonates, which would be beneficial for a patient with gastroesophageal reflux disease that is not controlled by medication. Raloxifene (①) is a selective estrogen receptor modulator that may also be appropriate for the patient, but it may not be as effective in reducing fracture risk as alendronate. Zoledronic acid (③) is an intravenous bisphosphonate that is effective in treating osteoporosis but may require more frequent monitoring and has a higher risk of kidney toxicity. Bazedoxifene/conjugated equine estrogen (④) is a combination therapy that may be appropriate for the patient, but it may increase the risk of certain adverse events such as breast cancer and thromboembolic events. Estradiol/medroxyprogesterone (⑤) is a combination hormone therapy that may not be appropriate for the patient due to the risk of certain adverse events such as breast cancer and thromboembolic events.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Leucovorin oral medication</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Standard-dose cytarabine + idarubicin</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Imatinib</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Cisplatin + Etoposide</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Fluorouracil + Leucovorin + Nivolumab</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Tamoxifen</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② Octreotide injection.\n\nExplanation: Octreotide is a somatostatin analog that can help reduce the side effects of morphine, such as constipation, by stimulating the release of gut motility hormones and increasing gastrointestinal secretions. It is commonly used to treat opioid-induced constipation in patients with cancer pain.\n\nThe other options are not appropriate for preventing side effects of morphine:\n\n① Mesalazine suppository is used to treat inflammatory bowel disease and is not related to morphine side effects.\n\n③ Psyllium oral preparation is a fiber supplement that can help with constipation, but it is not as effective as octreotide in preventing opioid-induced constipation.\n\n④ Bisacodyl oral preparation is a stimulant laxative that can help treat constipation, but it may not be as effective as octreotide in preventing opioid-induced constipation and may cause abdominal cramping and diarrhea.\n\n⑤ Dioctahedral smectite oral preparation is an antidiarrheal medication that is not related to morphine side effects.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Switch to tacrolimus 0.1% ointment.\n\nTacrolimus is an immunosuppressant that can help reduce inflammation and itching associated with atopic dermatitis. It is often used as a second-line treatment for patients who have not responded to or have had adverse effects from topical corticosteroids. In this case, the patient has experienced worsening skin dryness and atrophy from the topical steroid ointment, making tacrolimus a suitable alternative.\n\nLidocaine cream (①) is a local anesthetic that can help relieve pruritus, but it does not address the underlying inflammation.\n\nPramoxine cream (②) is a topical anesthetic that can also help relieve pruritus, but it may not be effective in managing the inflammation and dryness associated with atopic dermatitis.\n\nTerbinafine cream (③) is an antifungal medication that is used to treat fungal infections, but it is not indicated for atopic dermatitis.\n\nDexamethasone 0.1% ointment (⑤) is a topical corticosteroid that may provide some relief from inflammation and itching, but it may not be as effective as tacrolimus in managing the patient's symptoms, given the patient's history of worsening skin dryness and atrophy from topical steroid use.</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Latanoprost</s>"
    },
    {
        "year": 2020,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Zinc (Zn)\n\nRationale: Zinc is an essential trace element that plays a crucial role in various physiological processes, including wound healing, immune function, and gastrointestinal health. Gastrectomy can lead to zinc deficiency due to the removal of the stomach, which is responsible for absorbing zinc from food. Additionally, diarrhea symptoms after surgery can further increase the risk of zinc deficiency. Supplementing with zinc can help prevent or treat deficiency and promote optimal healing and recovery in this patient population.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Drug safety monitoring</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Social history</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Recommendation to limit irritating foods.\n\nThe Plan section of a SOAP note should outline the proposed interventions or actions to address the patient's problem or issue. In this case, the pharmacist has advised the patient to reduce spicy and irritating foods to alleviate the remaining upper abdominal pain. Therefore, option ⑤ is the most appropriate answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Drug Interaction Facts</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Falls</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Montelukast chewable tablet</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Cimetidine tablet\n\nRationale: Cimetidine is a Category B drug, which means it has not been proven to be safe for use during pregnancy. It is not recommended for use during pregnancy, especially in the first trimester, due to its potential to cause fetal harm. The other options, pyridoxine, cefalexin, atorvastatin, and amoxicillin/clavulanate, are all Category A drugs, which means they have been proven to be safe for use during pregnancy. Therefore, the correct answer is ② Cimetidine tablet.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Naproxen tablet</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 9:50 AM</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 1.0~1.5\n\nThe correct answer is ③ 1.0~1.5 ng/mL. This range is appropriate for the treatment of heart failure, as well as for the patient's age and renal function. A digoxin level within this range would indicate that the patient is receiving an appropriate therapeutic dose, but not so high as to cause toxicity.\n\nHere's a brief explanation for the other options:\n\n① 0.1~0.5 ng/mL: This range is too low for the treatment of heart failure in an elderly patient.\n\n② 0.5~1.0 ng/mL: This range is somewhat appropriate, but the higher end of the range (1.0 ng/mL) may be too high for the patient's age and renal function.\n\n④ 1.5~2.0 ng/mL: This range is too high and may indicate digoxin toxicity, which can cause symptoms such as bradycardia, nausea, vomiting, and diarrhea, as the patient is experiencing.\n\n⑤ 2.0~2.5 ng/mL: This range is excessively high and would likely indicate severe digoxin toxicity, which could be life-threatening.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Itraconazole</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ c)\n\nExplanation:\nThe prescribed dose of clarithromycin dry syrup is 12 mL (125 mg) twice daily, which is incorrect for a 5-year-old boy weighing 20 kg. According to the reference information, the recommended dose for otitis media in pediatric patients is 15 mg/kg/day, divided into 2 doses. Therefore, the correct dose for this patient would be 30 mg (20 kg x 15 mg/kg) divided into 2 doses, which is 15 mg/5 mL x 2 = 30 mL.\n\nSo, the item in the patient's prescription that needs to be changed is the dose (c). The correct dose should be 30 mL twice daily for 10 days, not 12 mL twice daily for 10 days.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Expiration date is 14 days.\n\nThe prescription is for a 5-year-old boy, and the medication is Clarithromycin dry syrup 125 mg/5 mL. According to the reference information, the recommended dosage for children for otitis media is 15 mg/kg/day, divided into 2 doses. Therefore, the total days of medication should be 10 days (15 mg/kg/day x 2 doses/day x 10 days).\n\nHowever, the prescription states that the total days of medication is 14 days, which is longer than the recommended duration. Therefore, the auxiliary label \"Expiration date is 14 days\" should be modified to reflect the correct duration of 10 days.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Cyclosporine</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Oxycodone extended-release tablets</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Reconstitution</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Possible</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Diclofenac tablets</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Flumazenil injection</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Capecitabine tablet</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Vitamin C</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Tamoxifen tablet</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Zolpidem extended-release tablet</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Inhale using a spacer connected to the inhaler.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Samsoeum (蔘蘇飮)</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Hyperkalemia\n\nExplanation:\n\nThe antihypertensive medication included in this prescription is Spironolactone, which is a potassium-sparing diuretic. Spironolactone can cause hyperkalemia (elevated potassium levels) by increasing the reabsorption of potassium in the renal tubules. This can be a serious adverse drug reaction, as high potassium levels can lead to cardiac arrhythmias and other complications. Therefore, it is important to monitor potassium levels closely in patients taking Spironolactone, especially in elderly patients or those with pre-existing kidney disease.\n\nThe other options are not directly related to the antihypertensive medication included in this prescription:\n\n① Hyperglycemia: This is not a known adverse drug reaction of Spironolactone.\n\n③ Hypocalcemia: Spironolactone can cause hypercalcemia (elevated calcium levels) by increasing the reabsorption of calcium in the renal tubules. However, this is not a common adverse drug reaction.\n\n④ Hyperuricemia: Spironolactone can cause hyperuricemia (elevated uric acid levels) by increasing the reabsorption of uric acid in the renal tubules. However, this is not a serious adverse drug reaction.\n\n⑤ Hypernatremia: Spironolactone can cause hypernatremia (elevated sodium levels) by increasing the reabsorption of sodium in the renal tubules. However, this is not a common adverse drug reaction.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ Induction of serotonin syndrome.\n\nSildenafil is contraindicated with nitroglycerin, which the patient is already taking, because it may cause a dangerous drop in blood pressure, leading to hypotension, syncope, and even heart attack.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Penicillin preparations</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Air is designed to flow from areas of lower cleanliness to areas of higher cleanliness.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Factor influence table</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Number of airborne particles</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Physicochemical properties section</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Water for injection</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Accuracy</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Purified water</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Vial</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 10\n\nExplanation:\nThe limit for heavy metals (as lead) in d-chlorpheniramine maleate can be calculated using the following formula:\n\nLimit (ppm) = (Amount of lead in sample / Amount of drug taken for test) x (1000 / 100)\n\nIn this case, the amount of lead in the sample is 0.01 mg (from the lead standard solution), and the amount of drug taken for the test is 1.0 g. Therefore, the limit (ppm) can be calculated as follows:\n\nLimit (ppm) = (0.01 mg / 1.0 g) x (1000 / 100) = 10 ppm\n\nSo, the correct answer is ④ 10 ppm.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Loss on ignition</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Atomic absorption spectrophotometry</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Precision of the quantitative method.\n\nExplanation:\nThe given information states that the resolution between caffeine (internal standard) and phenobarbital is not less than 1.2, and the symmetry factor is not more than 2.0 when testing with 10 μL of the standard solution. This indicates that the method has sufficient precision to distinguish between the two compounds and that the peak shapes are symmetrical, which is an indication of good method precision. Therefore, option ③ Precision of the quantitative method is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ The state is unsatisfactory, and process improvement is necessary.\n\nExplanation:\nThe process capability index is calculated using the following formula:\n\nCp = (USL - LSL) / (6 x σ)\n\nwhere USL is the upper specification limit, LSL is the lower specification limit, and σ is the standard deviation.\n\nIn this case, the USL is 105.0 mg, the LSL is 95.0 mg, and the standard deviation is ±2.0 mg. Plugging in these values, we get:\n\nCp = (105.0 - 95.0) / (6 x 2.0) = 0.167\n\nThe process capability index (Cp) is a measure of how well the process is performing compared to the specification limits. A Cp value of 0.167 indicates that the process is operating within the specification limits, but there is room for improvement.\n\nTherefore, the correct assessment of the tablet production process is that it is unsatisfactory and requires process improvement. The appropriate action to take is to identify the root cause of the variability in the process and implement changes to improve the consistency and quality of the tablets produced.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Mixing degree of raw materials</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Offering discounts for bulk purchases of health functional foods.\n\nThe \"product\" among the 4Ps of marketing mix for pharmacy management refers to the goods and services that the pharmacy offers to its customers. Offering discounts for bulk purchases of health functional foods is a way to promote and sell products to customers, which aligns with the \"product\" aspect of the marketing mix.\n\nThe other options do not correspond to the \"product\" aspect of the marketing mix:\n\n① Putting up a sign outside the pharmacy building is related to the \"place\" aspect of the marketing mix, as it involves the physical location of the pharmacy.\n\n② Providing medication counseling to elderly patients with chronic diseases is related to the \"promotion\" aspect of the marketing mix, as it involves communicating the value of the pharmacy's services to customers.\n\n④ Posting the pharmacy's location information on the pharmacy website is related to the \"promotion\" aspect of the marketing mix, as it involves promoting the pharmacy's services to potential customers through its website.\n\n⑤ Rearranging the display locations of over-the-counter drugs and quasi-drugs within the pharmacy is related to the \"place\" aspect of the marketing mix, as it involves the physical layout of the pharmacy's products.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 2.4 million won</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nThe comprehensive income statement shows the net income for the period.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The purpose, use, and scope of responsibility for the funds are clear.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The number of hospital beds per 1,000 population is higher than the OECD countries' average.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Adverse selection</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Medication possession ratio method</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Principle of justice | Principle of respect for autonomy\n\nExplanation:\n\nCommittee Member A's opinion is based on the principle of justice, as they are concerned with the fair distribution of limited resources and the impact of the high-cost medication on the National Health Insurance fund, which is funded by citizens. They believe that decisions should be made with cost-effectiveness in mind to ensure that resources are allocated fairly and efficiently.\n\nCommittee Member B's opinion, on the other hand, is based on the principle of respect for autonomy, as they prioritize the individual patient's needs and believe that decisions should be made with the patient's best interests in mind. They argue that the focus should be on treating patients' diseases effectively, rather than considering the overall benefit or cost-effectiveness.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ The actual number of malignant breast cancer patients is 52.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 2\n\nExplanation:\n\nTo calculate the age-standardized mortality ratio (ASMR) for lung cancer in region A, we need to first calculate the age-specific mortality rates for region A. The age-specific mortality rates are calculated by dividing the number of deaths from lung cancer in each age group by the population in that age group, and then multiplying by 100,000.\n\nUsing the given data, we can calculate the age-specific mortality rates for region A as follows:\n\n* Age 20-59: 200 deaths / 500,000 population = 400,000 deaths per 100,000 population\n* Age 60 and above: 200 deaths / 900,000 population = 222,222 deaths per 100,000 population\n\nNext, we need to calculate the ASMR by weighting the age-specific mortality rates of region A by the population in each age group in the standard population. The standard population used in this case is the population of the region A in the table.\n\nASMR = (age-specific mortality rate in region A x population in region A) / (age-specific mortality rate in standard population x population in standard population)\n\nASMR = (400,000 x 500,000) / (2 x 1,400,000) = 2\n\nTherefore, the age-standardized mortality ratio for lung cancer in region A is 2.\n\nSo, the answer is ③ 2.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ After generic drugs are listed, the price of off-patent drugs with the same active ingredient is reduced.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nThe incremental cost-utility ratio of the base case analysis cannot be determined from the given figure. The figure shows the results of a sensitivity analysis, which is used to assess the robustness of the cost-utility analysis results by varying certain assumptions or inputs. The figure displays the results of the sensitivity analysis for different ranges of baseline blood pressure and drug prices, but it does not provide the incremental cost-utility ratio of the base case analysis. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nExplanation:\n\nThe correct answer is ③ (0.5×1.0)+(0.3×0.8)+(0.2×0.3).\n\nThe formula for calculating QALY is: (quality of life × time) + (quality of life × time) + ...\n\nIn this case, the quality of life for each branch is:\n\n* 0.5 (50% chance of 1-year survival)\n* 0.3 (30% chance of 1-year survival)\n* 0.2 (20% chance of 1-year survival)\n\nThe time for each branch is:\n\n* 1 year\n* 1 year\n* 1 year\n\nTherefore, the expected QALY for Drug B is:\n\n(0.5×1.0)+(0.3×0.8)+(0.2×0.3) = 0.5 + 0.24 + 0.06 = 0.8\n\nSo, the answer is ③ (0.5×1.0)+(0.3×0.8)+(0.2×0.3).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ The conversion factor is determined by the Health Insurance Review & Assessment Service, reflecting the consumer price index.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The dispensing and medication counseling fee for inpatients is paid according to the number of days of medication dispensed.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③\n\nThe net profit of Pharmacy A can be calculated by subtracting the cost of goods sold and total operating expenses from total sales.\n\n2018:\nTotal Sales = 10\nCost of Goods Sold = 7\nTotal Operating Expenses = 2\nNet Profit = 10 - 7 - 2 = 1\n\n2019:\nTotal Sales = 12\nCost of Goods Sold = 8\nTotal Operating Expenses = 2.5\nNet Profit = 12 - 8 - 2.5 = 1.5\n\nTherefore, the correct answer is ③: 1 (2018) and 1 (2019).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③\n\nThe gross profit margin in 2018 is calculated as follows:\nGross Profit Margin = (Gross Profit / Total Sales) x 100\nGross Profit Margin = (10 - 7) / 10 x 100 = 0.1\n\nTherefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Over-the-counter drugs</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Prescription drugs must be displayed in a separate cabinet, distinct from over-the-counter drugs.\n\nThe correct answer is ③. According to the Pharmaceutical Affairs Act, prescription drugs must be stored in a separate, locked cabinet or area that is only accessible to authorized personnel, such as pharmacists and pharmacy technicians. This is to prevent unauthorized access and ensure the safe and secure handling of controlled substances.\n\nThe other options are all requirements that a pharmacist managing a pharmacy must comply with according to the Pharmaceutical Affairs Act:\n\n① Pharmacists must wear a name tag displaying both their title and name to ensure they are easily identifiable to patients and other healthcare professionals.\n\n② Pharmacists must thoroughly supervise employees to prevent accidents related to public health and hygiene, such as ensuring that employees are properly trained in the handling and storage of medications, and that they are following proper infection control procedures.\n\n④ Medications with opened containers or packaging should not be mixed and stored together to prevent contamination and ensure the integrity of the medication.\n\n⑤ In case of side effects related to the use of medications, necessary safety measures must be devised, such as monitoring patients for adverse reactions and providing appropriate counseling and treatment.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Minister of Health and Welfare</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Dispensing for volunteer activities at elderly care facilities during summer vacation</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤\n\nThe statement \"The Minister of Health and Welfare can take necessary measures to ensure that pharmacists dispense an appropriate number of prescriptions to provide thorough medication counseling\" is incorrect.\n\nThe Pharmaceutical Affairs Act does not give the Minister of Health and Welfare the authority to regulate the number of prescriptions that pharmacists can dispense. Instead, the Act requires pharmacists to provide necessary medication counseling to patients either verbally or through a medication counseling document when dispensing medications. The Act also requires pharmacists to record the content of the medication counseling in the dispensing record and preserve it for 2 years.\n\nTherefore, the correct answer is ⑤.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 1 percent cost discount when settling pharmaceutical transaction amounts within 2 months from the transaction date.\n\nAccording to the question, the Ordinance of the Ministry of Health and Welfare specifies the scope of economic benefits that pharmacists or pharmacies can receive from pharmaceutical suppliers. However, a 1 percent cost discount when settling pharmaceutical transaction amounts within 2 months from the transaction date is not listed as one of the allowed economic benefits. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② When an herbal medicine dealer opens and sells herbal medicine according to a patient's request.\n\nAccording to the Pharmaceutical Affairs Act, herbal medicine dealers are not allowed to open and sell sealed pharmaceutical products. This is because herbal medicine dealers are not licensed pharmacists and do not have the necessary training or expertise to handle and dispense pharmaceutical products. The Act requires that pharmaceutical products be sold only by licensed pharmacists or pharmacy owners who have the necessary training and expertise to ensure the safe and effective use of these products.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ Research on the drug that does not involve human subjects.\n\nAccording to the question, the drug can be used for purposes other than clinical trials once it has been approved by the Minister of Food and Drug Safety. However, research on the drug that does not involve human subjects does not fall under this category, as it is not a use of the drug for clinical purposes. Therefore, option ⑤ is the correct answer.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Over-the-counter drugs with the same formulation, route of administration, and main ingredient content per tablet as prescription drugs.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Cancellation of registration for over-the-counter medicine sellers.\n\nAccording to the Pharmaceutical Affairs Act, a hearing must be held before an administrative disposition in the following cases:\n\n* Revocation of a pharmacist's license (①)\n* Business suspension of a pharmacy owner (②)\n* Order to prohibit the manufacture of a pharmaceutical item (③)\n* Cancellation of designation as a clinical trial institution (④)\n\nCancellation of registration for over-the-counter medicine sellers (⑤) is not listed as a case where a hearing must be held before an administrative disposition. Therefore, the correct answer is ⑤ Cancellation of registration for over-the-counter medicine sellers.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Pharmacist working in a medical institution</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Narcotic drug importer/exporter</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ The narcotics manager can have drug users undergo diagnostic tests at treatment and protection institutions.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Creation of conditions for the public to practice healthy living on their own.\n\nThe National Health Promotion Act aims to promote national health, improve public health and social security, disseminate correct health knowledge to the public, and cultivate a sense of responsibility for health among the public. However, creating conditions for the public to practice healthy living on their own is not a specific purpose of the Act. Therefore, the correct answer is ⑤ Creation of conditions for the public to practice healthy living on their own.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nThe correct answer is ⑤. The statement \"Public health and medical institutions are established to efficiently and systematically perform the collection, management, analysis, evaluation, and provision of information related to public health\" is not correct. Public health and medical institutions are established to provide healthcare services, not to collect, manage, analyze, evaluate, and provide information related to public health. That is the role of public health agencies, such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Minister of Health and Welfare</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② When the cause is due to an intentional criminal act.\n\nAccording to the National Health Insurance Act, a person's benefits may be restricted in the following cases:\n\n* When an accident is caused by minor negligence (①)\n* When receiving insurance benefits under other laws for injuries sustained in the line of public duty (③)\n* When receiving compensation under other laws for occupational diseases (④)\n* When failing to follow medical instructions from a healthcare institution due to gross negligence (⑤)\n\nHowever, the Act does not mention anything about restrictions on benefits for intentional criminal acts (②). Therefore, the correct answer is ② When the cause is due to an intentional criminal act.</s>"
    },
    {
        "year": 2020,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②\n\nThe task of surveillance and crackdown on narcotic drug handlers' handling of narcotic drugs is not a responsibility of public health centers according to the Regional Public Health Act. This task is typically carried out by law enforcement agencies or other relevant authorities.\n\nTherefore, the answer is ②.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Michaelis constant (Km)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ lysine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ ganglioside GM1</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ phosphofructokinase-1</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nNADH and NAD+ are both involved in the electron transport chain in muscle cells, which generates ATP during oxidative phosphorylation. NADH is the electron carrier that donates electrons to the electron transport chain, while NAD+ is the electron acceptor that receives the electrons and generates ATP. Therefore, option ③ NADH | NAD+ is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ malate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ glucose 6-phosphate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ (C)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② oxaloacetate</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DNA polymerase III</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Alkylation of guanine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ transfer RNA (tRNA)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ farnesylation</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Src homology 2 (SH2)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ NADH</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NADH</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ nucleotide-excision repair</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ (D)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② malonyl-CoA</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ (D)\n\nThe molecule that provides electrons to the electron transport chain Complex I is NADH. NADH is produced during the β-oxidation pathway, specifically during the step catalyzed by the enzyme 3-hydroxyacyl-CoA dehydrogenase (HADH). Therefore, the correct answer is (D) 3-hydroxyacyl-CoA dehydrogenase (HADH).</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Fimbriae</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Generalized transduction – Transposon</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Clostridium botulinum (botulism bacterium)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Salmonella Typhi</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Rabies virus</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① integrase</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Creutzfeldt-Jakob disease</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Chloroquine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Mutation in DNA gyrase</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Tobramycin</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Kanamycin</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Acyclovir</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Zanamivir</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ HLA-B</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ TGF-β</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ T cell differentiation defect and abnormal B cell response.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Etanercept</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Palivizumab</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ IgM antibodies against Rh antigen produced in the mother.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ rh immune globulin</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Receptor up-regulation</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Drug A has greater maximal efficacy than drug B.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① First-pass effect</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Tamsulosin</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Timolol</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Perampanel</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Entacapone</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Pain relief</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Hydroxyzine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Clopidogrel</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Telmisartan</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Ezetimibe – Blocking of sterol transporter NPC1L1</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Spironolactone</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Neurokinin 1 (NK1) receptor blockade</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Clomiphene</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Inhibition of sodium-glucose transporter 2 (SGLT2) in the proximal tubule.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Enfuvirtide</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Bevacizumab</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ (C)\n\nTerbutaline is a beta-2 adrenergic agonist that acts on airway smooth muscle to relax it and reduce airway resistance. The therapeutic action of terbutaline occurs at point (C) in the figure, where the NE molecule binds to the beta-2 adrenergic receptor on the surface of the airway smooth muscle cell, triggering a cascade of intracellular signaling events that ultimately lead to muscle relaxation.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ (E)\n\nExplanation:\n\nDesipramine is a norepinephrine reuptake inhibitor, which means it blocks the reabsorption of norepinephrine by the nerve terminals, increasing its concentration in the synapse. This increase in norepinephrine concentration can enhance its transmission and activation of post-ganglionic neurons, leading to an antidepressant effect. Therefore, the site of action where desipramine exerts its antidepressant effect is at the post-ganglionic neuron, which is option ④ (E).</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Chemical metabolites in urine or blood</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Brucellosis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Asbestos</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② hepatitis A virus</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ microcystin LR</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Vibration</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 7,12-dimethylbenz[a]anthracene</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ isoniazid</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Skin sensitization test</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ (D)\n\nThe correct answer is ④ (D). Cadmium inhibits the conversion of 25-hydroxyvitamin D3 to 1α,25-dihydroxyvitamin D3, which is the final step in the vitamin D activation process in the kidney.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ paraquat</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Benchmark dose</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ nicotinic acid</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Calcium</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Vibrio parahaemolyticus</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② hyoscyamine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Paragonimiasis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Diluted benzoyl peroxide</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① branched-chain α-keto acid dehydrogenase complex</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Pyridoxine</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Inflammatory bowel disease</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Direct activation of CD8+ T cells by recipient antigen-presenting cells.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Inactivation of tumor suppressor gene.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Herpes zoster (Shingles)</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Decreased plasma osmotic pressure.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Pulmonary embolism</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Hodgkin's lymphoma</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Macrophage</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Dilated cardiomyopathy</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Reduction in vascular diameter due to pulmonary arterial wall thickening.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Acute viral hepatitis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Chronic hepatitis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Immune complex deposition in the glomeruli</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Endometriosis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Weight loss</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Progressive degradation of articular cartilage and subchondral bone thickening.\n\nThe patient's symptoms of morning stiffness, pain in the knee and finger joints worsening with activity but subsiding with rest, and the presence of Heberden's nodes in the finger joints, are consistent with osteoarthritis (OA). OA is a degenerative joint disease characterized by progressive degradation of articular cartilage and subchondral bone thickening. The absence of inflammatory markers in the joints supports this diagnosis, as OA is generally considered a non-inflammatory condition.\n\nWhile lymph node enlargement (①) and bony ankylosis (②) may be associated with certain types of arthritis, they are not the main cause of joint dysfunction and pain in this patient. Destruction of articular cartilage by pannus (③) is a feature of rheumatoid arthritis, which is an inflammatory arthritis, and is not consistent with the patient's symptoms or test results. Activation of anti-citrullinated peptide antibody production (⑤) is associated with rheumatoid arthritis, but is not the main cause of joint dysfunction and pain in this patient.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Reduced interaction between the cytoskeleton and extracellular matrix within muscle fibers.</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Subarachnoid hemorrhage</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Liver cirrhosis</s>"
    },
    {
        "year": 2021,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Increased portal pressure</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Formation of eutectic mixture</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Temperature</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Particle size distribution</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Increase in solvent dielectric constant.\n\nExplanation:\n\nThe pHp of a solution is affected by the solvent dielectric constant, which is a measure of the solvent's ability to interact with ions. Ethanol has a lower dielectric constant than water, which means that it interacts less with ions and reduces the solubility of ionized species. As a result, the pHp of the phenobarbital solution decreases in the presence of ethanol.\n\nTherefore, option ③ Increase in solvent dielectric constant is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Dilatant flow</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Viscosity</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Raoult's law</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Molecular weight</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 27/40</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 0.08</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 1/400</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Decrease in membrane pore size.\n\nExplanation: A decrease in membrane pore size can increase drug diffusion by reducing the resistance to drug molecules passing through the membrane. This can increase the rate of diffusion and allow more drug molecules to pass through the membrane in a given time.\n\nThe other options do not accurately answer the question:\n\n① Decrease in porosity: A decrease in porosity would decrease the amount of drug molecules that can pass through the membrane, thereby decreasing drug diffusion.\n\n② Decrease in membrane thickness: A decrease in membrane thickness would not necessarily increase drug diffusion, as the rate of diffusion is determined by the membrane's properties, such as its pore size and permeability.\n\n③ Decrease in partition coefficient: A decrease in partition coefficient would not directly affect drug diffusion, as it is a measure of the distribution of drug molecules between the membrane and the surrounding solution.\n\n⑤ Decrease in drug concentration gradient: A decrease in drug concentration gradient would not increase drug diffusion, as it would reduce the driving force for diffusion. Drug diffusion occurs from an area of high concentration to an area of low concentration, so a decrease in the concentration gradient would reduce the rate of diffusion.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 20\n\nThe shelf life of a drug is the time period during which the drug remains stable and retains its potency. In this case, the concentration of the drug decreases over time, indicating that the drug is not stable.\n\nThe table shows that the concentration of the drug decreases by 1% every 0.5 months. Therefore, to determine the shelf life, we need to find the time it takes for the concentration to decrease by 90%, which is equivalent to a decrease of 10% from the initial concentration.\n\nUsing the given data, we can calculate the rate of decrease in concentration as follows:\n\nRate of decrease = (Concentration at 2 months - Concentration at 0 months) / Time taken to decrease = (98 - 100) / 0.5 = -0.02 mg/mL per month\n\nNow, we can calculate the time it takes for the concentration to decrease by 90% as follows:\n\nTime = (Initial concentration - Final concentration) / Rate of decrease = (100 - 90) / -0.02 = 20 months\n\nTherefore, the shelf life of the drug at room temperature is 20 months, which corresponds to option ③.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 1.0×10^3</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Tween 80</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ They cannot pass through a semipermeable membrane.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② The protein carries a positive charge at pH 5.\n\nExplanation:\n\nThe monomer of protein drug A has an isoelectric point (pI) of 8, which means that at pH 5, the protein carries a positive charge due to the presence of positively charged amino acid residues. This is a common property of proteins, and it is important to consider the charge of a protein when studying its physicochemical properties and behavior in solution.\n\nThe other options are not correct statements about the monomer of protein drug A at 25℃:\n\n① The monomer does not have a quaternary structure, as it is a single polypeptide chain.\n\n③ The tertiary structure of the monomer may not be the same at 80℃ and 25℃, as proteins can undergo conformational changes upon temperature changes.\n\n④ The secondary structure is not confirmed by size exclusion liquid chromatography, as this method is used to separate and analyze the size of proteins based on their hydrodynamic volume, not their secondary structure.\n\n⑤ The addition of sodium dodecyl sulfate (SDS) to the monomer solution would denature the protein and disrupt its native structure, making it unable to retain its secondary structure.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 2</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Simvastatin</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Risperidone</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Hydrogen bond</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ NH2NH2</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ pyrimidine</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Nifedipine</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Diclofenac</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Anticancer</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Adefovir</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Extension of chain length</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 0.1\n\nExplanation:\n\nThe solubility product constant (Ksp) of calcium carbonate is given as 4.9×10^-9. To find the minimum volume of water needed to completely dissolve 70 mg of calcium carbonate, we can use the formula:\n\nKsp = [Ca2+] [CO3 2-]\n\nwhere [Ca2+] and [CO3 2-] are the concentrations of calcium ions and carbonate ions, respectively.\n\nFirst, we need to convert the given amount of calcium carbonate (70 mg) to moles:\n\nmoles of CaCO3 = mass of CaCO3 (mg) / molecular weight of CaCO3 (g/mol)\nmoles of CaCO3 = 70 mg / 100.0 g/mol = 0.0007 mol\n\nNext, we can calculate the concentration of calcium ions:\n\n[Ca2+] = moles of CaCO3 / volume of water (L)\n\nWe want to find the minimum volume of water needed to completely dissolve 70 mg of calcium carbonate, so we set [Ca2+] equal to the solubility product constant (Ksp):\n\n0.0007 mol / volume of water (L) = 4.9×10^-9\n\nNow, we can solve for the volume of water:\n\nvolume of water (L) = 0.0007 mol / 4.9×10^-9 = 0.1 L\n\nTherefore, the minimum volume of water needed to completely dissolve 70 mg of calcium carbonate at 25℃ is 0.1 L. The correct answer is ③ 0.1.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 1.19</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ High-speed centrifugation – Ignition</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Salicylic acid</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 8.0</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 1.0×10-3</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Acyclovir</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Selenium Powder</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Ultrafiltration</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Electron capture detector</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Decrease packing particle size.\n\nExplanation: Decreasing the packing particle size can improve the resolution of the analytes by increasing the surface area available for interaction with the stationary phase and increasing the efficiency of the column. A smaller particle size also allows for better separation of closely eluting compounds, resulting in higher resolution.\n\nIn contrast, decreasing the column length (①) or increasing the mobile phase flow rate (③) may reduce the resolution by reducing the interaction time between the analytes and the stationary phase. Increasing the mobile phase strength (②) may also reduce the resolution by increasing the elution rate of the analytes and reducing their interaction with the stationary phase. Decreasing the packing particle surface area (⑤) would also reduce the interaction between the analytes and the stationary phase, leading to lower resolution.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Lipids\n\nThe main purpose of the pretreatment process described in the question is to remove lipids from the serum. The addition of acetonitrile and centrifugation helps to precipitate and remove lipid particles, which can interfere with the quantification of amoxicillin in the serum.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Pooled standard deviation</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Adsorption</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Change composition to water-methanol mixture (50:50)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Buccal tablet</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Inhalations, Transdermal absorptions</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Sodium starch glycolate</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ die friction</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Unlike tablets, lubricants are not added as there is no compression process.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Poloxamer</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Spirits are usually made by dissolving non-volatile drugs in a mixture of ethanol and water.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ poly(lactide-co-glycolide)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① benzalkonium chloride</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ C: Semipermeable membrane</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Clearance</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 0.75Css</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ CYP2C19 | Clearance</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Emulsifier</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ It is manufactured as an intramuscular injection for rapid bioavailability.</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ protoberberine alkaloid</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ emodin</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Liebermann-Burchard reaction</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Pinellia ternata</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Cinchona</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Rhubarb</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Rauvolfia serpentina</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ sinigrin</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Colchici Semen</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Rhubarb</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ergot</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Consolidation and astringent action (固攝作用)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Astragalus root (Radix Astragali, 黃芪)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Socheongryong-tang (小靑龍湯)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Yongdamsagan-tang (龍膽瀉肝湯)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Platycodon Root (Platycodi Radix)</s>"
    },
    {
        "year": 2021,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ ephedrine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Irbesartan.\n\nRationale:\n\nThe patient has not reached the target blood pressure despite being on medication therapy for hypertension, and the current medications include amlodipine, carvedilol, and atorvastatin. The patient has a history of drug allergy to losartan, which is an angiotensin II receptor antagonist. Therefore, another medication with a different mechanism of action should be added to the regimen.\n\nIrbesartan, an angiotensin II receptor antagonist, is an appropriate choice for blood pressure control in this patient. It has a different mechanism of action compared to losartan, which the patient is allergic to, and has been shown to be effective in reducing blood pressure in patients with hypertension.\n\nDiltiazem, a calcium channel blocker, may not be the best choice for this patient as it may lower the heart rate and increase the risk of bradycardia, especially in elderly patients. Hydralazine, a vasodilator, may cause reflex tachycardia and increase the risk of hypotension, especially in patients with hypertension. Furosemide, a diuretic, may not be effective in lowering blood pressure in this patient as the patient's sodium and chloride levels are already low. Hydrochlorothiazide, a diuretic, may also not be effective in lowering blood pressure in this patient and may cause hypokalemia.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Valsartan</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Diltiazem.\n\nRationale: Diltiazem is a calcium channel blocker that can be used to control chest pain in patients with stable angina. It works by relaxing the smooth muscle in the coronary arteries, which improves blood flow to the heart and reduces the demand for oxygen. In addition, diltiazem has a negative chronotropic effect, which can reduce the heart rate and minimize the risk of tachycardia-induced ischemia.\n\nThe other options are not the most appropriate choices for controlling chest pain in this patient. Atenolol (①) is a beta-blocker that can also be used to control chest pain, but it may not be as effective in patients with hypertension and dyslipidemia. Valsartan (②) is an angiotensin II receptor antagonist that can be used to treat hypertension and heart failure, but it is not typically used to control chest pain. Felodipine (④) is a calcium channel blocker that can also be used to control chest pain, but it may have a slower onset of action compared to diltiazem. Clopidogrel (⑤) is an antiplatelet agent that can be used to prevent thrombus formation in patients with acute coronary syndrome, but it is not typically used to control chest pain in stable angina patients.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Prasugrel</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ticagrelor.\n\nRationale: Ticagrelor is a P2Y12 inhibitor that is commonly used in combination with aspirin in patients with NSTE-ACS, as it has been shown to reduce the risk of cardiovascular events. The patient's history of dyslipidemia and gastroesophageal reflux disease does not contraindicate the use of ticagrelor. Abciximab is a glycoprotein IIb/IIIa inhibitor that is also used in NSTE-ACS, but it is typically reserved for patients who have a higher risk of cardiovascular events or those who have had a previous myocardial infarction. Prasugrel and dipyridamole are also P2Y12 inhibitors, but they have different dosing regimens and may not be appropriate for this patient's specific condition. Clopidogrel is a P2Y12 inhibitor that is commonly used in combination with aspirin, but it has a slower onset of action compared to ticagrelor and may not be as effective in patients with NSTE-ACS.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Medications\n\nExplanation:\nThe patient's medication regimen includes amlodipine, telmisartan, metoprolol, glimepiride, and atorvastatin. Among these medications, amlodipine, telmisartan, and metoprolol are known to increase the risk of bleeding. Therefore, the patient's medication regimen contributes to a higher HAS-BLED score, which is used to assess bleeding risk.\n\nThe correct answer is ③ Medications.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Rivaroxaban 15 mg once daily.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Pravastatin 40 mg once daily.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Add evolocumab.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Apixaban</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Skip one dose of warfarin and remeasure INR.\n\nExplanation:\n\nThe patient's INR has increased significantly, which may be due to the interaction between warfarin and ciprofloxacin. Ciprofloxacin is a potent inhibitor of the CYP3A4 enzyme system, which is responsible for metabolizing warfarin. As a result, the combination of both drugs may lead to increased levels of warfarin and, therefore, an increased INR.\n\nSince the patient has been taking ciprofloxacin for the past 5 days and plans to discontinue it today, it is likely that the increased INR is due to the drug interaction. Therefore, the appropriate action would be to skip one dose of warfarin and remeasure the INR to assess the effect of discontinuing ciprofloxacin on the patient's coagulation status.\n\nTransfusion of fresh frozen plasma (①) would not be appropriate, as there is no evidence of bleeding or coagulopathy. Administration of coagulation factor VII (②) would also not be appropriate, as the patient's INR is not low enough to warrant this intervention. Increasing the warfarin dose to 3 mg (③) would not be appropriate, as this would further increase the risk of bleeding. Oral administration of 5 mg vitamin K (④) would not be appropriate, as this would reverse the effects of warfarin and increase the risk of thrombosis.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Verapamil</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Spironolactone</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Itraconazole.\n\nItraconazole is a potent inhibitor of CYP3A4, an enzyme responsible for metabolizing many drugs, including some beta-blockers like carvedilol. By inhibiting CYP3A4, itraconazole can increase the plasma concentration of carvedilol, leading to increased beta-blockade and potentially worsening heart failure symptoms.\n\nThe other options are less likely to cause worsening heart failure symptoms in this patient:\n\n① Lisinopril is an ACE inhibitor, which can reduce blood pressure and improve heart failure symptoms.\n\n② Metformin is a medication for diabetes and is not typically associated with worsening heart failure symptoms.\n\n④ Spironolactone is a potassium-sparing diuretic that can help reduce fluid retention in heart failure patients.\n\n⑤ Pitavastatin is a statin that can help lower cholesterol levels and has no established link to worsening heart failure symptoms.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Change lisinopril to sacubitril/valsartan.\n\nRationale: The patient has hypertension, diabetes, and chronic heart failure, which are all indications for the use of sacubitril/valsartan. This medication has been shown to reduce the risk of death and hospitalization in patients with heart failure, and it is a more appropriate choice than the other options for this patient's condition.\n\nDigoxin may be considered for patients with heart failure and atrial fibrillation, but it is not the most appropriate choice for this patient who has a normal heart rate and no evidence of atrial fibrillation.\n\nLosartan is an angiotensin II receptor antagonist that is used to treat hypertension and diabetic nephropathy, but it is not specifically indicated for heart failure.\n\nVerapamil is a calcium channel blocker that can be used to treat hypertension and angina, but it is not the most appropriate choice for heart failure.\n\nFurosemide is a diuretic that can be used to treat heart failure, but it is not the most appropriate choice for this patient who has already been stabilized with appropriate inpatient treatment.\n\nTherefore, the best answer is ⑤ Change lisinopril to sacubitril/valsartan.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Salbutamol/ipratropium</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Reduce salmeterol, maintain fluticasone.\n\nRationale: The patient's asthma symptoms are well-controlled, and she has not required reliever medication frequently. Therefore, it is appropriate to reduce the dose of salmeterol, which is the long-acting beta-agonist component of the inhaler, while maintaining the fluticasone, which is the corticosteroid component. This step-down approach will allow the patient to continue to receive the benefits of corticosteroid therapy while reducing the potential side effects of long-acting beta-agonists.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Fluticasone nasal spray</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ② Intravenous aminophylline.\n\nRationale: Intravenous aminophylline is a bronchodilator that can help to quickly relieve bronchospasm and improve lung function in patients with acute exacerbation of COPD. It is commonly used in the short-term management of acute exacerbations to help reduce the recovery period and hospital stay. The other options, oral formoterol, oral prednisolone, fluticasone nebulizer, and intravenous azithromycin, may also be used in the management of COPD, but they are not as effective for quick relief of bronchospasm in acute exacerbations.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Aclidinium inhaler.\n\nRationale: Aclidinium is a long-acting anticholinergic agent that can help improve lung function and reduce symptoms in patients with COPD. It has a slower onset of action compared to other anticholinergics like ipratropium, which makes it suitable for twice-daily dosing. In this case, the patient has shown improvement in lung function, and the addition of aclidinium inhaler can help maintain the improvement and reduce the risk of exacerbations.\n\nIndacaterol and budesonide are also appropriate medications for COPD, but they may not be the best choice in this scenario since the patient has already shown improvement in lung function. Roflumilast is an oral medication that can help reduce exacerbations, but it may not be as effective in improving lung function as aclidinium. Extended-release theophylline can help improve lung function, but it may not be the best choice due to its potential side effects and the need for frequent monitoring.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Levofloxacin</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Phenytoin.\n\nOmeprazole is a proton pump inhibitor that can increase the blood concentration of phenytoin, a substrate of CYP2C19 enzyme, by inhibiting its metabolism. This may lead to increased risk of adverse effects such as dizziness, ataxia, and tremors. Therefore, option ① Phenytoin is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Octreotide</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Prucalopride.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Change entecavir to adefovir.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Budesonide enema\n\nExplanation:\n\nThe patient has severe active ulcerative colitis, which requires prompt treatment to induce remission and prevent complications. Budesonide enema is a topical corticosteroid that is effective in treating rectal inflammation and has a proven track record in the management of ulcerative colitis. It is also well-tolerated and has fewer systemic side effects compared to other corticosteroids.\n\nMesalazine suppository (①) may also be considered, but it may not be as effective as budesonide enema in treating the extensive superficial inflammation in the rectum, descending colon, and transverse colon.\n\nSulfasalazine tablet (②) is an oral medication that may take longer to act and may not be as effective in treating the acute inflammation in the colon.\n\nTacrolimus injection (④) is an immunosuppressant that may be used in the long-term management of ulcerative colitis, but it is not the most appropriate choice for acute treatment.\n\nMethylprednisolone injection (⑤) is a systemic corticosteroid that may be used in severe cases of ulcerative colitis, but it has more systemic side effects compared to budesonide enema and may not be necessary at this stage of treatment.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① White blood cells.\n\nRationale: Azathioprine is an immunosuppressive drug that can cause leukopenia (a decrease in white blood cell count) as a side effect. Therefore, monitoring white blood cells is necessary to detect any potential adverse effects on the patient's immune system.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Carbamazepine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Enalapril.\n\nExplanation:\n\nThe patient's acute kidney injury (AKI) is likely caused by Enalapril, an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors can cause renal function deterioration, particularly in patients with pre-existing kidney disease or other risk factors such as heart failure, hypertension, and advanced age. The patient's history of osteoarthritis and allergic rhinitis may also contribute to the risk of AKI.\n\nThe patient's urine output and weight gain are consistent with AKI, and the elevated serum creatinine (SCr) and blood urea nitrogen (BUN) levels support this diagnosis. The patient's SCr level has increased from 0.8 mg/dL to 1.8 mg/dL, and BUN has increased from 19 mg/dL to 53 mg/dL, indicating a significant decline in renal function. The FENa (fractional excretion of sodium) value of 0.8% suggests that the patient is not volume-depleted, which supports the diagnosis of AKI rather than dehydration.\n\nLoratadine, an antihistamine, is unlikely to cause AKI. Amlodipine, a calcium channel blocker, may have a minor role in the patient's AKI, but it is less likely than Enalapril. Metformin, a biguanide, is not typically associated with AKI. Acetaminophen, a nonsteroidal anti-inflammatory drug (NSAID), may also have a role in the patient's AKI, but Enalapril is a more likely culprit.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Calcium gluconate injection.\n\nRationale: The patient's symptoms of palpitations and muscle cramps, along with the ECG findings of T wave elevation and prolonged QRS interval, suggest that the patient is experiencing hypokalemia (low potassium levels). Calcium gluconate injection is the appropriate first-line treatment for hypokalemia, as it can quickly restore potassium levels and alleviate symptoms. The other options, while potentially useful in other scenarios, are not the most appropriate choice for this patient's condition.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Absolute neutrophil count.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Lanthanum carbonate.\n\nRationale: Lanthanum carbonate is a phosphate-binding agent that is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). It works by binding to dietary phosphate in the gut and preventing its absorption into the bloodstream. This can help to reduce the levels of phosphate in the blood, which can become elevated in patients with CKD, leading to secondary hyperparathyroidism and other complications.\n\nThe other options are not appropriate for controlling hyperphosphatemia in this patient:\n\n① Calcitonin: Calcitonin is a hormone that regulates calcium levels in the blood, but it does not directly affect phosphate levels.\n\n② Calcitriol: Calcitriol is the active form of vitamin D, which regulates calcium levels in the blood. However, it can also increase phosphate levels, which would not be appropriate for this patient.\n\n③ Calcium carbonate: Calcium carbonate is a calcium supplement that can help to raise calcium levels in the blood. However, it would not directly affect phosphate levels.\n\n⑤ Calcium polystyrene sulfonate: Calcium polystyrene sulfonate is a cation-exchange resin that can bind to phosphate in the gut and reduce its absorption. However, it is not as effective as lanthanum carbonate in controlling hyperphosphatemia and is not as commonly used for this indication.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Cinacalcet</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Metformin.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Dapagliflozin.\n\nDapagliflozin is a medication that helps the kidneys remove excess sugar from the bloodstream, which can lead to increased urination. It can also cause dehydration, decreased blood pressure, and increased heart rate. The other medications, while they may have some side effects, are not likely to cause the symptoms described.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Discontinue metformin, add glipizide.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Change methimazole to propylthiouracil\n\nRationale:\n\nThe patient's clinical symptoms have disappeared, and the test results show that her free T4 levels have normalized (1.5 ng/dL) and her TSH levels have increased (2.1 mIU/L), indicating that the hyperthyroidism has been effectively controlled. However, the patient's liver enzymes (AST/ALT) are still slightly elevated (32/30 IU/L), which may indicate a risk of liver damage associated with long-term methimazole use.\n\nPropylthiouracil is a thyroid suppressant that can be used as an alternative to methimazole in the treatment of hyperthyroidism. It has a different mechanism of action and may be less likely to cause liver damage compared to methimazole. Therefore, changing the patient's medication to propylthiouracil may be a more appropriate treatment option going forward.\n\nThe other options are not appropriate for the following reasons:\n\n① Discontinuing methimazole may lead to a relapse of hyperthyroidism symptoms.\n\n② Reducing the methimazole dose may not effectively control the patient's hyperthyroidism and may still pose a risk of liver damage.\n\n③ Adding propylthiouracil to the patient's current methimazole regimen may increase the risk of adverse effects and is not a standard treatment approach.\n\n⑤ Changing methimazole to levothyroxine may not be appropriate as levothyroxine is a thyroid hormone replacement medication used to treat hypothyroidism, not hyperthyroidism.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Lithium</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Allopurinol</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ Change metformin to sitagliptin.\n\nRationale:\n\nThe patient's current medication regimen includes metformin, which is an appropriate choice for glycemic control. However, the patient's HbA1c level is still above the target range, indicating that the current dose of metformin may not be sufficient to achieve optimal glycemic control.\n\nSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the amount of incretin hormones in the body, which helps to improve insulin secretion and glucose tolerance. It is a reasonable option for adding to the patient's current regimen to improve glycemic control, especially since the patient has a history of hypertension and dyslipidemia, which may also benefit from sitagliptin's effects on blood pressure and lipid levels.\n\nLiraglutide, insulin glargine, and empagliflozin are not the most appropriate options for this patient. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used for glycemic control, but it may not be as effective in patients with a history of pancreatitis. Insulin glargine is a long-acting insulin that may be appropriate for patients with type 1 diabetes or those who require insulin therapy, but it may not be the best choice for this patient who has been managed with oral medications so far. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps to reduce glucose levels by increasing urine production, but it may not be effective in patients with a history of urinary tract infections or kidney disease.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Linezolid + ceftriaxone</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① No antibiotic treatment necessary\n\nRationale:\n\nThe patient is asymptomatic, and the E. coli count in her urine is within the normal range for a healthy pregnant woman. In the absence of symptoms, it is not appropriate to initiate antibiotic treatment. Antibiotics are only recommended for asymptomatic bacteriuria in pregnant women if they have a history of previous symptomatic UTIs or if they have underlying medical conditions that increase the risk of complications. Since the patient in the scenario does not have any symptoms or underlying conditions, the appropriate treatment is to monitor her closely and repeat the urine culture test in 1-2 weeks to ensure that the bacterial count remains stable.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Azithromycin.\n\nRationale:\n\nThe patient's symptoms and positive rapid antigen test for group A beta-hemolytic Streptococcus suggest a diagnosis of acute pharyngitis caused by Streptococcus pyogenes. Azithromycin is a macrolide antibiotic that is effective against Streptococcus pyogenes and is a first-line treatment option for acute pharyngitis.\n\nAmoxicillin/clavulanate (④) is also effective against Streptococcus pyogenes, but it is not the most appropriate choice due to the patient's history of anaphylactic reaction to amoxicillin.\n\nCefpodoxime (①) and ciprofloxacin (②) are both broad-spectrum antibiotics that cover a wide range of bacterial pathogens, but they are not the most appropriate choices for treating acute pharyngitis caused by Streptococcus pyogenes.\n\nSulfamethoxazole/trimethoprim (⑤) is an antibiotic combination that is effective against a wide range of bacterial pathogens, but it is not typically used as a first-line treatment for acute pharyngitis.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Vancomycin injection.\n\nRationale:\n\nThe patient has developed hospital-acquired pneumonia, and the hospital has a high rate of methicillin-resistant Staphylococcus aureus (MRSA) among isolated S. aureus strains. Therefore, it is appropriate to start empirical antibiotic therapy with a drug effective against MRSA. Vancomycin is a glycopeptide antibiotic that is effective against MRSA and is often used as a first-line agent for the treatment of hospital-acquired pneumonia caused by MRSA.\n\nCefotaxime and ertapenem are both broad-spectrum cephalosporins that are effective against a wide range of gram-positive and gram-negative bacteria, but they may not be effective against MRSA. Levofloxacin is a fluoroquinolone antibiotic that is effective against gram-negative bacteria, but it may not be effective against MRSA. Tigecycline is a glycylcycline antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but its efficacy against MRSA is variable.\n\nTherefore, the most appropriate empirical antibiotic for this patient would be vancomycin injection.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ciprofloxacin</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Pyridoxine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Discontinue ceftriaxone and add colistin</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ No antibiotics, supportive care.\n\nHemolytic uremic syndrome (HUS) is a serious complication of enterohemorrhagic E. coli (EHEC) infection, and antibiotics are not recommended as they may worsen the condition. Supportive care, such as fluid replacement, blood transfusions, and management of related complications, is the appropriate treatment approach.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Ibuprofen</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Fluconazole</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Itraconazole</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Frovatriptan</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Carbidopa/Levodopa</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Valproic acid</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Paliperidone</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Paroxetine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① modafinil</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Methylphenidate</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Aripiprazole</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Add memantine.\n\nExplanation:\n\nThe patient's MMSE score of 8 points indicates severe cognitive impairment, and the presence of delusions, agitation, and aggressive behavior suggests a neuropsychiatric symptom profile consistent with Alzheimer's disease. Donepezil, an acetylcholinesterase inhibitor, is a appropriate medication for the treatment of cognitive symptoms of Alzheimer's disease, but it may not be effective in managing the neuropsychiatric symptoms. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in reducing neuropsychiatric symptoms in patients with Alzheimer's disease, and is therefore the appropriate choice for this patient.\n\nIt is not appropriate to reduce the dose of donepezil (option ①) as the patient's cognitive symptoms are already severe, and a lower dose may not be effective in managing the neuropsychiatric symptoms. Ginkgo leaf extract (option ③) has not been shown to be effective in managing neuropsychiatric symptoms of Alzheimer's disease, and its use is not supported by evidence. Galantamine (option ④) and rivastigmine (option ⑤) are also acetylcholinesterase inhibitors, and may have similar efficacy to donepezil in managing cognitive symptoms, but they have not been shown to be effective in managing neuropsychiatric symptoms.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hydroxychloroquine</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Alendronate.\n\nRationale:\n\nThe patient has osteoporosis with a T-score of -3.0 at the lumbar spine and -2.3 at the hip, indicating a high risk of fracture. The patient also has chronic kidney disease (CKD) with a creatinine clearance of 28 mL/min, which may affect the choice of medication.\n\nAlendronate is a bisphosphonate that is commonly used to treat osteoporosis. It has a strong evidence base for reducing fracture risk and is well tolerated in patients with CKD. The drug is excreted primarily in the urine, but the risk of nephrotoxicity is low, even in patients with moderate renal impairment.\n\nDenosumab (①) is a monoclonal antibody that inhibits the activity of RANK ligand, a protein involved in bone resorption. It is also used to treat osteoporosis, but its use in patients with CKD is not well established, and it may be less effective in this population.\n\nIbandronate (③) is another bisphosphonate that is used to treat osteoporosis. It has a similar mechanism of action to alendronate but has a shorter half-life and may be less effective in patients with severe renal impairment.\n\nTeriparatide (④) is a parathyroid hormone analog that is used to treat severe osteoporosis. It has a positive effect on bone density and fracture risk, but it is not commonly used in patients with CKD due to concerns about hyperparathyroidism and hypercalcemia.\n\nCalcium carbonate (⑤) is a nutritional supplement that is used to treat hypocalcemia. It is not directly related to osteoporosis treatment and would not be the best choice for this patient.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 7 days</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Silodosin</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hydrochlorothiazide</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ Add allopurinol.\n\nExplanation: Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid in the body, which can help prevent future gout attacks. The patient's history of gout and elevated uric acid levels suggest that they are at risk for future attacks. Adding allopurinol to their medication regimen can help reduce this risk.\n\nThe other options are not the most appropriate recommendations for this patient. A high-protein diet may increase uric acid levels and exacerbate gout symptoms (①). Colchicine is an anti-inflammatory medication that can be used to treat gout flares, but it is not indicated for long-term prevention of gout attacks (②). Restricting purine-rich foods may help reduce uric acid levels, but it is not a specific recommendation for this patient (③). Benzbromarone is a uricosuric medication that increases uric acid excretion, but it is not commonly used for long-term prevention of gout attacks (⑤).</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Posaconazole.\n\nRationale: Posaconazole is a substrate for the efflux protein P-glycoprotein, which is encoded by the MDR1 gene. The MDR1 gene is also overexpressed in multidrug-resistant cancer cells. In patients with a low left ventricular ejection fraction (LVEF), the risk of Posaconazole-related cardiotoxicity is increased. Therefore, in patients with an LVEF of 35% or less, the dose of Posaconazole should be reduced or the drug should be discontinued.\n\nThe other options are not related to the patient's condition or the drugs mentioned in the question:\n\n① Cytarabine is an antimetabolite that is not associated with cardiotoxicity.\n\n② Idarubicin is an anthracycline that can cause cardiotoxicity, but it is not related to the patient's LVEF.\n\n④ Palonosetron is a serotonin receptor antagonist used to prevent chemotherapy-induced nausea and vomiting. It is not related to the patient's LVEF.\n\n⑤ Ciprofloxacin is a fluoroquinolone antibiotic that is not associated with cardiotoxicity.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ QT interval prolongation.\n\nExplanation: Dasatinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, can prolong the QT interval. Levofloxacin, a fluoroquinolone antibiotic, can also prolong the QT interval and increase the risk of torsades de pointes, a potentially life-threatening arrhythmia. The combination of these two drugs may increase the risk of QT interval prolongation and torsades de pointes. Therefore, it is important to monitor the patient's QT interval closely when administering levofloxacin intravenously to a patient taking dasatinib.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Docetaxel + Carboplatin + Trastuzumab</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Hemoptysis</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Hematochezia</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Osimertinib</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Cetuximab</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Pregabalin</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Tacrolimus 0.03% ointment.</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Timolol</s>"
    },
    {
        "year": 2021,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Increase lipid emulsion.\n\nExplanation:\n\nThe patient's direct bilirubin concentration of 2.6 mg/dL indicates a possibility of lipid-soluble vitamin deficiency, specifically vitamin E deficiency. Vitamin E is a lipid-soluble vitamin that plays a crucial role in preventing oxidative stress and protecting red blood cells from hemolysis. In patients with short-bowel syndrome receiving parenteral nutrition, it is essential to ensure adequate intake of lipid-soluble vitamins.\n\nTherefore, the appropriate measure in parenteral nutrition therapy would be to increase the lipid emulsion to provide adequate amounts of vitamin E and other lipid-soluble vitamins. This will help to prevent further oxidative stress and potential hemolysis.\n\nIncreasing glutamine (①) may help to support the gut mucosa and reduce inflammation, but it would not address the potential vitamin E deficiency.\n\nIncreasing amino acids (②) may help to support protein synthesis, but it would not address the potential vitamin E deficiency.\n\nDiscontinuing zinc administration (④) would not address the potential vitamin E deficiency and may even worsen the patient's nutritional status.\n\nDiscontinuing copper administration (⑤) would not address the potential vitamin E deficiency and may even worsen the patient's nutritional status.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Creatine kinase.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Alprazolam.\n\nAlprazolam, a benzodiazepine, can cause cognitive impairment, including memory loss, confusion, and difficulty concentrating. It can also increase the risk of falls and fractures in older adults. In a patient with pre-existing cognitive impairment due to hepatic encephalopathy, alprazolam may worsen these symptoms.\n\nThe other options are less likely to worsen cognitive impairment:\n\n① Perindopril, an ACE inhibitor, may improve cognitive function in patients with hypertension.\n\n② Metformin, a biguanide, has no significant effect on cognitive function.\n\n③ Sitagliptin, a DPP-4 inhibitor, has no significant effect on cognitive function.\n\n⑤ Ofloxacin, a fluoroquinolone antibiotic, has no significant effect on cognitive function.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Chest X-ray examination results.\n\nThe 'R' part of the FARM format refers to the \"Results\" section, where the pharmacist should record the outcome or results of the intervention or patient counseling. In this case, the chest X-ray examination results would be the most appropriate option to include in the 'R' part of the FARM format, as it provides information about the patient's medical condition and the effectiveness of the intervention.\n\nThe other options do not relate to the results of the intervention or patient counseling and therefore would not be appropriate for the 'R' part of the FARM format.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Benzathine penicillin G</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Paroxetine</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Valproic acid</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 1 month</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Rivaroxaban – Voriconazole</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Oxaliplatin</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② 2-5 mg/L</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Alfuzosin\n\nThe Beers Criteria suggest that Alfuzosin, a selective alpha-1 blocker, may not be appropriate for patients with benign prostatic hyperplasia (BPH) and hypertension, as it may increase the risk of symptomatic hypotension. Therefore, it is appropriate to inquire with the physician regarding the appropriateness of this medication for this patient.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Dispensing the amount to be used within 24 hours, packaged in units for each patient's single dose.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 15 mL</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ethambutol</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Possible\n\nExplanation:\n\nThe WHO-UMC method is a systematic approach to assessing the causality of adverse drug reactions. In this case, the patient developed a skin rash after starting lamotrigine treatment, and the rash improved after discontinuing the medication. The absence of other medications, chemicals, or accompanying diseases that could have caused the rash suggests that lamotrigine may be the probable cause. However, without further information or evidence, it is impossible to say with certainty that lamotrigine was the cause of the rash. Therefore, the best answer is ② Possible.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Occurrence of adverse drug reaction</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Gradually reduce and then discontinue xylometazoline.\n\nExplanation:\n\nThe patient's symptoms of nasal congestion improved with the use of xylometazoline, but the drug-related problem (DRP) occurred on the 7th day, with a worsening of nasal congestion symptoms. This suggests that the patient may have developed tolerance or tachyphylaxis to the medication.\n\nThe solution to this problem is to gradually reduce and then discontinue xylometazoline, as it is no longer effective in managing the patient's symptoms. This will allow the patient to explore other treatment options or to adjust the dosage of fexofenadine, if necessary.\n\nTherefore, option ⑤ Gradually reduce and then discontinue xylometazoline is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ Zolpidem\n\nThe maximum dose of Zolpidem recommended for adults is 10 mg per day. The prescribed dose of 5 mg per day is half of the maximum dose. Therefore, this medication should be inquired about with the doctor regarding its dosage, as it exceeds the maximum dose.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ② Amlodipine\n\nRationale: Amlodipine is a calcium channel blocker that may increase the risk of nephrotoxicity when used with iodine-containing contrast agents. It is recommended to discontinue amlodipine before the imaging test to minimize this risk. The other medications, ramipril, metformin, zolpidem, and rosuvastatin, are not typically contraindicated with iodine-containing contrast agents.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Simethicone liquid</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Mupirocin ointment</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Terbinafine cream</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cetirizine syrup</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Acyclovir tablet</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Do not lie down within 1 hour after taking.\n\nExplanation: Lansoprazole LFD tablets are enteric-coated, which means they are designed to dissolve in the small intestine and should not be crushed or chewed. Patients should be instructed to swallow the tablets whole and not lie down for at least 1 hour after taking to prevent the medication from entering the stomach too quickly.\n\nTherefore, option ③ Do not lie down within 1 hour after taking is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sanjoin-tang (Sour Jujube Decoction)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Inspection of testing facilities</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DMF (Drug Master File)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Intermittent supply of unidirectional airflow</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ E</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ It is conducted on 10-30 manufacturing batches that have been manufactured and sold.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ D value of the biological indicator</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Establishment of quality standards and various standards</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Even if the immediate container is damaged, the product can be repackaged if the medication itself is not damaged.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Sample storage facility</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ignition residue</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sterile water for injection meets the management standards for water for injection.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nThe correct answer is ④. The Pharmacopoeia states that the loss on drying test for Aspirin should be performed using silica gel for 5 hours, and the mass change should not be more than 0.5%. The weighing bottle should be dried at room temperature, not at 105°C for 30 minutes, before accurately weighing the sample. Therefore, option ④ is not correct.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Purity test | Identification | Assay</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Split-plot design</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 2.00</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② 1.0\n\nExplanation:\n\nThe lead standard solution contains 0.01 mg/mL of lead. According to the method, we need to add not more than 5 ppm of lead to the control solution.\n\nTo calculate the volume of lead standard solution required, we can use the following formula:\n\nVolume (mL) = (Concentration of lead in mg/mL x Amount of drug in g) / (1000 x 5)\n\nSubstituting the values given in the question, we get:\n\nVolume (mL) = (0.01 mg/mL x 2.0 g) / (1000 x 5)\nVolume (mL) = 0.02 mL\n\nTherefore, the correct answer is ② 1.0 mL.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Gas chromatography method</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Positioning</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Tangible assets invested in the pharmacy by the pharmacy owner are equity.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ The credit card fees paid by patients are fixed costs.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nThe net profit margin is calculated by subtracting the cost of goods sold and operating expenses from sales revenue, and then dividing the result by sales revenue.\n\nNet profit = Sales revenue - Cost of goods sold - Operating expenses\n= 1 billion won - 600 million won - 200 million won\n= 200 million won\n\nNet profit margin = Net profit / Sales revenue\n= 200 million won / 1 billion won\n= 0.3\n\nTherefore, the correct answer is ③ 0.3.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 200 bottles</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Externality</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Prevention of catastrophic medical expenses.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Wholesalers cannot offer cost discounts to pharmacies based on payment terms.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Actual transaction price reimbursement system</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④\n\nThe meta-analysis results show that A has a higher eradication effect than B at a 5% significance level, which means that the null hypothesis that A and B have the same eradication effect can be rejected. The odds ratio of 3.68 [1.87, 7.26] indicates that A has a significantly higher eradication effect than B. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ When analyzing from the healthcare system perspective, productivity loss costs are included.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① 900\n\nExplanation:\n\nTo calculate the incremental cost-utility ratio, we need to calculate the difference in cost and utility between A and B.\n\nThe difference in cost between A and B is 4,000 - 1,000 = 3,000.\n\nThe difference in utility between A and B is 0.6 - 0.5 = 0.1.\n\nTherefore, the incremental cost-utility ratio is 3,000 / 0.1 = 900.\n\nSo, the answer is ① 900.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Principle of non-maleficence.\n\nThe principle of non-maleficence states that pharmacists should not cause harm to patients or others. Dispensing a medication in a dose that is 10 times the prescribed dose could potentially cause harm to the patient, and therefore violates this principle.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Transtheoretical Model (Stages of Change)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② Case-control study</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Odds Ratio | (20/1000)/(10/1000)</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Orphan drugs</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Diagnosis</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Whether it is a medication with the same ingredients as those already prescribed or administered to the patient.\n\nAccording to the Pharmaceutical Affairs Act, a pharmacist must verify in advance, without justifiable reason, the following information about medications when dispensing according to a prescription:\n\n* Whether it is a medication ordered to be recalled or disposed of by the Minister of Food and Drug Safety (①)\n* Whether it contains ingredients that the Minister of Food and Drug Safety has announced as contraindicated for concurrent use (②)\n* Whether it is a medication designated by the Minister of Food and Drug Safety as subject to new drug re-evaluation (③)\n* Whether it contains ingredients that the Minister of Food and Drug Safety has announced as contraindicated for specific age groups or pregnant women (⑤)\n\nTherefore, the correct answer is ④ Whether it is a medication with the same ingredients as those already prescribed or administered to the patient. This information is not required to be verified by the pharmacist in advance, as it is not specified in the Pharmaceutical Affairs Act.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Patient's name as written on the prescription</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Prevention of infectious diseases in local communities</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Operate a retail business according to the Korean Standard Industrial Classification as announced by the Commissioner of Statistics Korea under the \"Statistics Act\"</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Pharmaceutical manufacturers can sell medicines to their employees.\n\nExplanation:\n\nUnder the Pharmaceutical Affairs Act, pharmaceutical manufacturers are not allowed to sell medicines directly to their employees. They can only sell medicines to licensed wholesalers or pharmacies. This is to ensure that medicines are distributed and sold through legitimate channels and to prevent unauthorized sales and use.\n\nTherefore, option ② is incorrect.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Medical use</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Tests to observe clinical effects of drugs currently on the market within the approved range.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Manufacturer's trade name</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Research and investigation for the development and utilization of drug safety information.\n\nThe Korea Institute of Drug Safety & Risk Management's business activities, according to the Pharmaceutical Affairs Act, do not include research and investigation for the development and utilization of drug safety information. The Institute's primary focus is on drug safety monitoring, risk management, and adverse reaction reporting.\n\nTherefore, the correct answer is ⑤ Research and investigation for the development and utilization of drug safety information.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ②</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Medical practitioner handling narcotic drugs</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Expiration</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Health education</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤\n\nThe correct answer is ⑤. The Framework Act on Health and Medical Services aims to improve the health and medical services of citizens, but it does not directly provide insurance benefits for the prevention, diagnosis, treatment, rehabilitation, and health promotion of citizens' diseases and injuries. That is the role of health insurance programs, which are not directly related to the Framework Act on Health and Medical Services.\n\nTherefore, option ⑤ is not correct, and the other options (①, ②, ③, and ④) are all correct regarding the basic principles and definitions in the Framework Act on Health and Medical Services.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nThe \"Medical Benefit Act\" provides medical benefits to certain individuals, including those who are not covered by National Health Insurance. Therefore, a person receiving medical benefits according to the \"Medical Benefit Act\" would not be considered a subscriber or dependent who is covered by National Health Insurance among citizens residing in Korea.</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Non-benefit</s>"
    },
    {
        "year": 2021,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Safety management of pharmaceuticals.\n\nPublic health centers are responsible for preventing and managing infectious diseases, promoting health and health education, maintaining and promoting maternal and infant health, and preventing and managing infertility. However, safety management of pharmaceuticals is not a function or task of public health centers. This responsibility falls under the purview of pharmaceutical regulatory agencies or drug control authorities.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② myosin</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② K_m</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ P-type ATPase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ NADH</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① glucose 6-phosphatase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ malate</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ fluorouracil</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② β-hydroxy-β-methylglutaryl-CoA</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ phenylalanine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ S-adenosylmethionine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ DnaG</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ minichromosome maintenance (MCM) proteins</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Excessive production of cAMP due to ADP-ribosylation of Gs protein.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ tyrosinase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ glucocerebrosidase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ hypoxanthine-guanine phosphoribosyltransferase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ isocitrate dehydrogenase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① aconitase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Bacillus anthracis</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Ebola virus</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Chlamydia trachomatis</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ urease</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ It has a single-stranded positive-sense RNA genome.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Rhinovirus</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Herpes simplex virus</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Retrovirus</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Chloramphenicol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① dihydrofolate reductase</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Itraconazole</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ FoxP3</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① CD28</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① IFN-α</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Excessive formation of immune complexes</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ CTLA-4 immunoglobulin (CTLA-4 Ig)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Hepatitis B vaccine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① G-CSF</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① Clostridium tetani (Tetanus bacteria)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ Inhibition of GABA and glycine release in target cells.\n\nThe symptoms described, including flaccid paralysis, deteriorating vision, weakening of peripheral muscles, and difficulty breathing, are consistent with the effects of a toxin that inhibits the release of gamma-aminobutyric acid (GABA) and glycine, which are neurotransmitters that play a critical role in regulating muscle contraction and relaxation. The inhibition of GABA and glycine release would lead to an increase in muscle contraction, resulting in symptoms such as muscle weakness and paralysis. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 1\n\nExplanation:\n\nThe pKa of the drug is 3.0, which means that the drug is a weak acid. In an acidic environment, such as the stomach with a pH of 2.0, the drug will be mostly ionized.\n\nThe ratio of non-ionized form to ionized form of the drug can be calculated using the Henderson-Hasselbalch equation:\n\npH = pKa + log10([ionized form]/[non-ionized form])\n\nRearranging the equation to solve for [ionized form]/[non-ionized form], we get:\n\n[ionized form]/[non-ionized form] = 10^((pH - pKa))\n\nPlugging in the values given in the question, we get:\n\n[ionized form]/[non-ionized form] = 10^((2.0 - 3.0)) = 10^(-1.0) = 0.1\n\nTherefore, the ratio of non-ionized form to ionized form of the drug in the stomach is 0.1, which corresponds to option ③ 1.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ glycine conjugation</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Rivastigmine – Inhibition of cholinesterase.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Midodrine – α1 – Treatment of orthostatic hypotension</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Atenolol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Tizanidine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Enhanced opening of Cl- ion channels by GABA</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Rasagiline – COMT inhibition</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Diphenhydramine exacerbates extrapyramidal symptoms of antipsychotic drugs.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Dicumarol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Propranolol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Spironolactone</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Febuxostat – Inhibits uric acid production</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Sucralfate</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ezetimibe</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Salmeterol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ritonavir</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cetuximab</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ B=phentolamine, C=atropine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ It competitively antagonizes A.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Infant mortality rate</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 95%\n\nExplanation:\nThe specificity of a diagnostic test is the proportion of true negatives (individuals without the disease who test negative) among all negative test results. In this case, the total number of individuals without the disease is 900 (855 + 45), and the number of true negatives is 855. Therefore, the specificity can be calculated as follows:\n\nSpecificity = (True negatives) / (Total negative test results)\n= 855 / 900\n= 0.95\n\nSo, the correct answer is ④ 95%.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ NO</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ozone treatment</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 50\n\nExplanation:\nThe biological index of water pollution (BIP) is a measure of the degree of water pollution based on the presence and abundance of certain biological organisms. In this case, the sample contains 200 blue-green algae, 300 diatoms, 300 ciliates, and 200 zooglea.\n\nAccording to the given table, the BIP value for blue-green algae is 20, diatoms is 30, ciliates is 40, and zooglea is 50. To calculate the BIP for this sample, we need to add the number of each organism multiplied by its corresponding BIP value.\n\nBIP = (200 x 20) + (300 x 30) + (300 x 40) + (200 x 50)\nBIP = 4000 + 9000 + 12000 + 10000\nBIP = 35000\n\nTherefore, the BIP for this sample is 35000, which corresponds to option ④ 50.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Discomfort index</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ cholic acid, glutamine, UDP-α-D-glucuronic acid (UDP-GA)</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Increased enterohepatic circulation of carbon tetrachloride.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① acetaminophen</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Net protein utilization</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Phenylketonuria</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Ascorbic acid.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Tyramine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Carbonyl value</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Clostridium perfringens</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Water dropwort</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② Methanol</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Administration of fomepizole and hemodialysis</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① IFN-γ</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Goodpasture's syndrome</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 47,XXY</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Deficiency of pulmonary surfactant</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② von Willebrand disease</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Decreased erythropoietin production.\n\nExplanation:\n\nThe patient's anemia is likely caused by decreased erythropoietin production, which is a common complication of chronic kidney disease. Erythropoietin is a hormone produced by the kidneys that stimulates the production of red blood cells. In patients with chronic kidney disease, the decreased production of erythropoietin can lead to anemia. The other options are not relevant to the patient's condition:\n\n① Folate deficiency: Folate deficiency can cause anemia, but it is not related to chronic kidney disease.\n\n② Vitamin A deficiency: Vitamin A deficiency can cause night blindness, but it is not related to anemia in this patient.\n\n③ Increased hemoglobin S synthesis: This is not a valid option, as it does not relate to the patient's condition.\n\n④ Excessive megaloblast production: This is not a valid option, as it does not relate to the patient's condition.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Disseminated intravascular coagulation</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Kawasaki disease</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Atherosclerosis</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Pulmonary interstitial fibrosis</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Erosion</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Gastric mucosal atrophy</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Venous metastasis.\n\nThe most common route for metastasis from the colon to the liver is through the venous system. Cancer cells can enter the venous bloodstream and travel through the inferior vena cava to the liver, where they can form metastases. This is known as venous metastasis.\n\nTherefore, option ③ Venous metastasis is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① APC</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Decreased estrogen</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Peripheral myelin protein 22 (PMP22) abnormality</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Macular degeneration</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① Addison's disease</s>"
    },
    {
        "year": 2022,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Adrenocortical insufficiency</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Hydrogen bonding, Van der Waals forces</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Crystal polymorphism</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Mixed liquid phase of A and B, solid phase A</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Hydrolysis</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Coordination bonding ability</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 5aRT</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ (a+b)/2</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.57</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 25\n\nExplanation:\n\nThe partition coefficient (K) is defined as the ratio of the concentration of the drug in the organic solvent (chloroform) to the concentration of the drug in the aqueous solvent (water). At 25°C, the partition coefficient (K) of drug A is 10, meaning that drug A is 10 times more soluble in chloroform than in water.\n\nWhen 55 mg of drug A is dissolved in a mixture of 50 mL of water and 50 mL of chloroform at 25°C and reaches equilibrium, the amount of drug A present in the chloroform layer can be calculated using the following equation:\n\nAmount of drug A in chloroform layer = (Concentration of drug A in chloroform) x (Volume of chloroform)\n\nThe concentration of drug A in chloroform can be calculated using the partition coefficient:\n\nConcentration of drug A in chloroform = (K x Concentration of drug A in water) / (1 + K)\n\nSubstituting the given values, we get:\n\nConcentration of drug A in chloroform = (10 x 55 mg/50 mL) / (1 + 10) = 550 mg/50 mL = 11 mg/mL\n\nNow, we can calculate the amount of drug A present in the chloroform layer:\n\nAmount of drug A in chloroform layer = 11 mg/mL x 50 mL = 550 mg\n\nTherefore, the correct answer is ③ 25.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ The stage with the lowest activation energy</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 6</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increase in spreading coefficient</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Lyophobic colloid</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nWhen attempting to improve the characteristic (b) by adding a linear polymer suspending agent instead of the existing suspending agent, the goal is to reduce the viscosity of the suspension and make it less inconvenient to pour.\n\nOption ③ states that the suspending agent should increase the viscosity of the suspension when shear stress is applied. This means that the agent will help to thicken the suspension and make it more stable, which is the opposite of what is desired.\n\nOption ①, ②, ④, and ⑤ do not relate to the desired property of reducing viscosity.\n\nTherefore, the correct answer is ③.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ First-order | Pseudo-zero-order</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nBenzyl cyanide is an appropriate starting material for the synthesis of phenobarbital. The reaction involves the treatment of benzyl cyanide with sodium hydrosulfite to form the corresponding 2-phenyl-2-butanol, which can then be converted to phenobarbital through a series of steps.\n\nTherefore, option ③ benzyl cyanide is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Midazolam</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ D</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Agonist action</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ②</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Increased cell wall permeability due to increased lipid solubility.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nThe diuretic effect of a diuretic skeleton increases when an electron-withdrawing substituent is introduced at R1, which enhances the electrostatic attraction between the positively charged nitrogen atom and the negatively charged oxygen atoms, thereby increasing the polarity of the molecule. This can be achieved by introducing a σ(+) substituent at R1.\n\nFurthermore, introducing a substituent that increases the lipophilicity of the molecule at R2, such as a π(+) substituent, can also enhance the diuretic effect. This is because a more lipophilic molecule can more easily cross cell membranes and reach the site of action, where it can interact with the target protein and increase urine production.\n\nTherefore, the correct answer is ③, which describes a combination of a σ(+) substituent at R1 and a π(+) substituent at R2. This combination maximizes the electrostatic attraction between the nitrogen atom and the oxygen atoms, while also increasing the lipophilicity of the molecule, leading to a greater diuretic effect.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② tyrosine</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① amide</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.1 mol/L H2CO3</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 0.04</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 0.03</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 0.1\n\nExplanation:\n\nThe Volhard method is a titration method used to determine the amount of silver nitrate in a sample. The reaction involves the reduction of silver(I) ions (Ag+) by thiocyanate ions (SCN-) to form silver thiocyanate (AgSCN). The reaction is as follows:\n\nAgNO3 + 3SCN- → AgSCN + 3NO3-\n\nTo determine the number of moles of silver nitrate corresponding to 100 mL of 0.1 mol/L NH4SCN, we need to perform a molarity calculation.\n\nMolarity of NH4SCN = 0.1 mol/L\nVolume of NH4SCN = 100 mL\n\nNumber of moles of NH4SCN = Molarity x Volume\nNumber of moles of NH4SCN = 0.1 mol/L x 100 mL\nNumber of moles of NH4SCN = 10 mol\n\nSince the reaction is 1:3, the number of moles of silver nitrate required to react completely with 10 mol of NH4SCN is 10/3 = 3.33 mol.\n\nTherefore, the number of moles of silver nitrate corresponding to 100 mL of 0.1 mol/L NH4SCN is 3.33 mol.\n\nThe correct answer is ③ 0.1.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 0.1 mmol/mL.\n\nExplanation:\n\nThe iodometric titration method involves titrating the iodine liberated from the disinfectant with a known volume of sodium thiosulfate (Na2S2O3) solution. The amount of sodium thiosulfate consumed is directly proportional to the amount of iodine present in the disinfectant.\n\nThe molarity of the sodium thiosulfate solution is given as 0.05 mol/L, and the volume of the solution consumed is 1.0 mL. Therefore, the number of moles of sodium thiosulfate consumed can be calculated as:\n\nNumber of moles of sodium thiosulfate = Molarity x Volume\n= 0.05 mol/L x 1.0 mL\n= 0.05 mol\n\nSince 1 mole of sodium thiosulfate reacts with 1 mole of iodine, the number of moles of iodine present in the disinfectant can be calculated as:\n\nNumber of moles of iodine = Number of moles of sodium thiosulfate\n= 0.05 mol\n\nThe molar mass of potassium iodide (KI) is 166.00 g/mol. Therefore, the mass of KI corresponding to 1 mole of iodine can be calculated as:\n\nMass of KI = Molar mass of KI x Number of moles of iodine\n= 166.00 g/mol x 0.05 mol\n= 8.30 g\n\nFinally, the volume of 0.05 mol/L KIO3 solution required to react completely with the iodine in 1.0 mL of the disinfectant can be calculated as:\n\nVolume of KIO3 solution = Mass of KI / Molarity of KIO3\n= 8.30 g / 0.05 mol/L\n= 166.00 mL\n\nTherefore, 1.0 mL of 0.05 mol/L KIO3 solution contains 0.1 mmol of KI.\n\nSo, the correct answer is ③ 0.1 mmol/mL.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 32.1</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Inductively Coupled Plasma (ICP) spectroscopy</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Increase the number of analytical scans.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Partition chromatography – Difference in solubility of mixed components in liquid stationary phase and mobile phase.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Size of stationary phase particles</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Electron capture detector</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② 0.02</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Relative standard deviation</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Transition of outermost electrons in molecules.\n\nThe spectrophotometric method for thiamine hydrochloride measures the absorbance of light by the molecules in the solution. The absorbance is due to the transition of outermost electrons in the molecules, which is the main measurement principle applied in this method. Therefore, option ⑤ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 4.60\n\nThe molar extinction coefficient (ε) can be calculated using the following equation:\n\nε = A / (c \\* l)\n\nwhere A is the absorbance, c is the concentration (moles/L), and l is the path length (cm).\n\nGiven: A = 0.230, c = 337 mg/100 mL = 3.37 x 10^-3 mol/L, l = 1 cm = 0.01 m.\n\nNow, calculate ε:\n\nε = A / (c \\* l) = 0.230 / (3.37 x 10^-3 \\* 0.01) = 4.60 M^-1 ∙ cm^-1\n\nTherefore, the correct answer is ③ 4.60.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Fitz mill</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Roller compaction method</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Sorbitol</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Povidone</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② polysorbate 80</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Liquid paraffin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② polyanhydrides</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Form a solid dispersion with povidone and compress into tablets.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Tablet with drug bound to ion-exchange resin and coated with Eudragit L100.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ The tight junctions between cells are less compact than in the small intestine, resulting in higher permeability for hydrophilic drugs.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 200\n\nExplanation:\n\nRenal clearance (CLR) is the volume of blood cleared of a drug per unit time, typically expressed in mL/h. It can be calculated using the following equation:\n\nCLR = (AUC × V)/(C0 × t)\n\nwhere:\n\n* AUC is the area under the blood concentration-time curve (mg ∙ h/mL)\n* V is the volume of urine collected over the same time period (mL)\n* C0 is the drug concentration in the urine (mg/mL)\n* t is the time period over which the urine was collected (h)\n\nIn this case, we are given that the volume of urine collected over 24 hours is 1.2 L, the drug concentration in the urine is 4 mg/mL, and the AUC is 24 mg ∙ h/mL. Plugging these values into the equation above, we get:\n\nCLR = (24 mg ∙ h/mL × 1.2 L)/(4 mg/mL × 24 h) = 200 mL/h\n\nTherefore, the renal clearance of drug A is 200 mL/h, which corresponds to option ③.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 28\n\nExplanation:\n\nThe loading dose (D) of theophylline can be calculated using the equation:\n\nD = (Css x Vd) / (CLt x weight)\n\nSubstituting the given values:\n\nD = (10 mg/L x 0.5 L/kg) / (0.04 L/h/kg x 70 kg)\n\nD = 28 mg\n\nTherefore, the correct answer is ③ 28.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Increased elimination half-life, decreased dosing interval.\n\nExplanation:\n\nThe patient's variant genotypes of CYP2C9 (*2, *3, and *13 alleles) result in reduced enzymatic activity, leading to decreased metabolism of warfarin. This results in increased blood concentrations of warfarin, which can increase the risk of bleeding. Therefore, the appropriate clinical measure would be to decrease the dosing interval to maintain therapeutic anticoagulation.\n\nThe other options do not accurately describe the changes in warfarin pharmacokinetics or the appropriate clinical measures for a patient with variant genotypes of CYP2C9:\n\n① Incorrect. Increased blood concentration would require a decrease in maintenance dose, not an increase.\n\n② Incorrect. Decreased volume of distribution would not be expected with variant genotypes of CYP2C9.\n\n④ Incorrect. Increased clearance would result in decreased blood concentrations, not increased dosing interval.\n\n⑤ Incorrect. Decreased area under the blood concentration-time curve would result in decreased efficacy, not increased dosage.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Fluidization, gelation</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ① It exhibits typical thixotropy.\n\nExplanation: Thixotropy is the property of a semi-solid preparation to exhibit a decrease in viscosity over time when agitated or shaken, and then return to its original viscosity when left still. The presence of poloxamer 124, a nonionic surfactant, in the prescription suggests that preparation A is likely to exhibit thixotropy. The other options do not accurately describe the characteristics of preparation A based on the given prescription.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ psoralen</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ hesperidin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① atropine</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ geraniin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Cannabis</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Angelica dahurica root</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nThe correct answer is gentiopicroside. It is a secoiridoid, a type of compound found in the Gentianaceae family of medicinal plants, and is known for its bitter stomachic action.</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Saffron</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Sinomenium Stem (Bangi)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Hyperici Herba</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ santonin</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Flos Sophorae</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Pinellia ternata (半夏, Ban Xia)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Prepared Rehmannia Root (熟地黃)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ssanghwa-tang (雙和湯)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Cheonwangbosim-dan (天王補心丹)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Samhwang-sasim-tang (三黃瀉心湯)</s>"
    },
    {
        "year": 2022,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Aucklandiae Radix</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Indapamide</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ②</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Valsartan.\n\nRationale: Valsartan, an angiotensin II receptor blocker, is indicated to reduce the risk of death and hospitalization in patients with chronic heart failure (CHF) and left ventricular ejection fraction (LVEF) ≤40%. The patient's LVEF is 33%, which meets the criteria for valsartan therapy. Diltiazem, a calcium channel blocker, may be used for hypertension, but it is not specifically indicated for CHF. Bisoprolol, a beta-blocker, may be used for hypertension and CHF, but it is not as effective as valsartan in reducing mortality. Ivabradine, an \"If\" channel blocker, is used for angina, but it is not indicated for CHF. Hydrochlorothiazide, a diuretic, may be used for hypertension and edema, but it is not specifically indicated for CHF.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Sacubitril/valsartan.\n\nExplanation:\n\nSacubitril/valsartan is a combination medication that has been shown to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure and preserved ejection fraction (LVEF ≥40%). It works by reducing the workload on the heart and improving the heart's ability to pump blood effectively.\n\nIn contrast, digoxin, furosemide, and spironolactone are diuretics that help reduce fluid buildup in the body, but they do not directly address the underlying cardiovascular risk. Hydralazine/isosorbide dinitrate is a combination medication that is used to treat angina, but it is not specifically indicated for heart failure.\n\nTherefore, of the options provided, sacubitril/valsartan is the most appropriate medication to reduce the risk of cardiovascular death and hospitalization in a patient with chronic heart failure and preserved ejection fraction.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Bisoprolol</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Ramipril.\n\nRamipril is an ACE inhibitor, which is a medication that is commonly used to treat hypertension and heart failure. It is also used to reduce the risk of cardiovascular events, such as heart attacks and strokes, in people with high blood pressure or diabetes. In this case, the patient has been diagnosed with non-ST-segment elevation myocardial infarction, which means that they have had a heart attack. Adding ramipril to their current medication regimen would help to reduce the risk of future cardiovascular events.\n\nThe other options are not the best choices for this patient. Lacidipine is a calcium channel blocker, which is used to treat hypertension, but it is not typically used to treat heart failure or cardiovascular disease. Verapamil is also a calcium channel blocker, and it is not typically used to treat hypertension or heart failure. Indapamide is a diuretic, which is used to treat hypertension and heart failure, but it is not typically used to reduce the risk of cardiovascular events. Nitroprusside is a vasodilator, which is used to treat hypertension, but it is not typically used to treat heart failure or cardiovascular disease.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ②</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Metoprolol tablet.\n\nRationale:\n\nThe patient's history of stable angina and recent increase in chest pain suggests that the current medications are not effectively controlling the symptoms. The addition of a beta-blocker, such as metoprolol, can help to reduce the heart rate and cardiac output, which can help to alleviate anginal symptoms. Metoprolol is also a suitable choice because it has a once-daily dosing schedule, which can improve patient compliance.\n\nFelodipine, lisinopril, and verapamil are all calcium channel blockers, which may not be as effective in controlling anginal symptoms as a beta-blocker. Isosorbide dinitrate is a nitrate, which may have a similar mechanism of action as nitroglycerin, but it may not be as effective in this case because the patient is already using sublingual nitroglycerin tablets as needed.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Alteplase</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Warfarin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Flecainide oral.\n\nRationale: Flecainide is a class I antiarrhythmic drug that is effective in controlling heart rate in patients with atrial fibrillation. It is orally administered, which is convenient for the patient and allows for sustained control of heart rate over time. Diltiazem and adenosine are both effective in controlling heart rate, but they are given by injection and may require more frequent dosing. Dronedarone is an antiarrhythmic drug that is effective in controlling heart rate, but it has a slower onset of action compared to flecainide and may not be suitable for urgent control of heart rate. Nitroglycerin is a vasodilator that is not primarily used for heart rate control.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Change aspirin to enoxaparin.\n\nRationale:\n\nThe patient has non-valvular atrial fibrillation, which increases the risk of stroke. The current medication, aspirin, is not sufficient to prevent stroke in this case. Enoxaparin, a low-molecular-weight heparin, is recommended for stroke prevention in patients with non-valvular atrial fibrillation, especially those with a high risk of stroke, such as this patient with a history of transient ischemic attack.\n\nPrasugrel (②) and dipyridamole (③) are both antiplatelet agents, but they are not as effective as enoxaparin in preventing stroke in patients with non-valvular atrial fibrillation. Dabigatran etexilate (⑤) is an oral direct thrombin inhibitor that is also used for stroke prevention in patients with non-valvular atrial fibrillation, but it is not as effective as enoxaparin in this case. Maintaining current drug therapy (①) is not appropriate because it does not provide adequate protection against stroke.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ < 130 mg/dL</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Rosuvastatin 20 mg once daily.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Add tiotropium inhaler for daily use.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Change low-dose fluticasone/salmeterol inhaler to medium-dose twice daily.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Budesonide inhaler twice daily + Salbutamol inhaler as needed.\n\nRationale:\n\nThe patient's FEV1 of 81% indicates a moderate to severe COPD. The CAT score of 15 points suggests a moderate impact of symptoms on daily life. The patient's history of smoking and quit smoking 5 years ago indicates a need for long-term management of COPD.\n\nBudesonide inhaler twice daily is a corticosteroid that can help reduce inflammation in the lungs and improve lung function. Salbutamol inhaler as needed can provide quick relief of symptoms and help manage exacerbations. Combining both medications can provide a comprehensive approach to managing COPD.\n\nTherefore, option ④ Budesonide inhaler twice daily + Salbutamol inhaler as needed is the most appropriate initial drug therapy for this patient.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Ipratropium inhalation.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Pranlukast tablets</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Lansoprazole</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Rifaximin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Administer hepatitis B immunoglobulin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Glecaprevir/pibrentasvir for 8 weeks.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Mesalazine suppository</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Amoxicillin + Azithromycin + Metronidazole</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Decreased bone density.\n\nLong-term use of proton pump inhibitors (PPIs), such as esomeprazole, has been associated with an increased risk of osteoporosis and decreased bone density. This is because PPIs can interfere with the absorption of calcium and other minerals, which are essential for bone health.\n\nThe other options are not likely to occur with long-term use of esomeprazole in this patient:\n\n① Glaucoma: There is no established link between esomeprazole and glaucoma.\n\n② Parkinson's disease: There is no established link between esomeprazole and Parkinson's disease.\n\n③ Pulmonary fibrosis: While there have been rare cases of pulmonary fibrosis associated with PPI use, it is not a well-established adverse reaction.\n\n⑤ Pituitary tumor: There is no established link between esomeprazole and pituitary tumors.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Amlodipine\n\nExplanation:\n\nThe patient's low energy and abnormal blood gas analysis results, specifically the metabolic acidosis (elevated lactic acid and decreased pH) and respiratory acidosis (elevated PaCO2), suggest a medication-related cause. Amlodipine, a calcium channel blocker, is a likely culprit. Amlodipine can cause metabolic acidosis by inhibiting the sodium-potassium ATPase pump in the renal tubules, leading to decreased HCO3- reabsorption and increased lactic acid production. Additionally, Amlodipine can cause respiratory acidosis by decreasing respiratory drive and reducing alveolar ventilation.\n\nThe other options are less likely to cause these abnormal test results:\n\n* Aspirin may cause metabolic acidosis, but it is less likely to cause respiratory acidosis.\n* Losartan, an angiotensin II receptor antagonist, may cause metabolic acidosis, but it is less likely to cause respiratory acidosis.\n* Metformin, a biguanide, may cause lactic acidosis, but it is less likely to cause respiratory acidosis.\n* Atorvastatin, a statin, is less likely to cause metabolic or respiratory acidosis.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Furosemide</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Administer methoxy polyethylene glycol-epoetin beta.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Paricalcitol</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ Furosemide.\n\nFurosemide is a diuretic medication that can cause hypokalemia (low potassium levels) as a side effect, especially when taken in high doses or for extended periods. The patient's low potassium level (5.5 mEq/L) is consistent with this side effect.\n\nThe other options are less likely to cause hypokalemia:\n\n① Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is not known to affect potassium levels.\n\n② Mosapride is a prokinetic agent that can increase gastric motility and gastric emptying, but it is not associated with hypokalemia.\n\n③ Enalapril is an ACE inhibitor that can cause hyperkalemia (high potassium levels) as a side effect, but it is not likely to cause hypokalemia.\n\n⑤ Rosuvastatin is a statin medication that can cause myalgia and elevated liver enzymes, but it is not associated with hypokalemia.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② Add sevelamer.\n\nRationale: Sevelamer is a phosphate-binding agent that can help to lower serum phosphorus levels in patients with chronic kidney disease (CKD) and hyperphosphatemia. It is more effective than calcium carbonate in reducing phosphorus levels, and it has been shown to improve cardiovascular outcomes in patients with CKD. In this case, the patient's hyperphosphatemia is likely due to the use of calcium carbonate, which can increase serum phosphorus levels. Therefore, adding sevelamer to the patient's medication regimen would be the most appropriate drug therapy to treat the patient's hyperphosphatemia.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Insulin glargine</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Nitroglycerin\n\nExplanation: Nitroglycerin is a vasodilator that can cause hypotension, which may lead to hypoglycemia. However, the patient did not report feeling any particular hypoglycemic symptoms, which may indicate that the nitroglycerin is not the cause of the low fasting blood glucose level.\n\nThe other options are not likely to cause hypoglycemia:\n\n* Aspirin and atenolol are antiplatelet and antihypertensive medications, respectively, and are not known to cause hypoglycemia.\n* Ramipril is an ACE inhibitor that can cause hypotension, but it is less likely to cause hypoglycemia compared to nitroglycerin.\n* Rosuvastatin is a statin that can cause myalgia, but it is not associated with hypoglycemia.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Regular insulin.\n\nExplanation:\n\nThe patient has been experiencing vomiting, dyspnea, and tachycardia since last night, which suggests that they are experiencing diabetic ketoacidosis (DKA). DKA is a life-threatening metabolic complication that can occur in patients with Type 1 diabetes, especially when they have missed insulin doses or have an infection. The patient's blood sugar level of 374 mg/dL and positive ketone bodies in the urine further support this diagnosis.\n\nThe appropriate additional medication for this patient would be regular insulin, which is a short-acting insulin that can help to lower blood sugar levels quickly. Regular insulin can be administered intravenously or subcutaneously, and it is often used in the treatment of DKA.\n\nLiraglutide (①) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used to treat Type 2 diabetes. It is not appropriate for the treatment of DKA in Type 1 diabetes patients.\n\nInsulin detemir (③) is a long-acting insulin that is used to control blood sugar levels over an extended period. It is not appropriate for the treatment of DKA, as it may not act quickly enough to lower blood sugar levels in an emergency situation.\n\nSodium bicarbonate (④) is a base that can be used to treat metabolic acidosis, which is a complication of DKA. However, it is not the most appropriate medication for this patient, as the blood gas analysis shows that the patient's pH is already within the normal range.\n\nCalcium polystyrene sulfonate (⑤) is a cation-exchange resin that can be used to treat hyperkalemia (high potassium levels) in patients with renal impairment. It is not appropriate for the treatment of DKA.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Metformin + Empagliflozin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Ezetimibe.\n\nRationale: The patient's lipid profile shows elevated LDL-C and TG levels, which indicate a high risk of atherosclerotic cardiovascular disease. Ezetimibe is a cholesterol absorption inhibitor that can effectively reduce LDL-C and TG levels, thereby reducing the risk of cardiovascular events. The other options, Warfarin, Amlodipine, Furosemide, and Gemfibrozil, may also be useful in certain contexts, but they are not the most appropriate choices for addressing the patient's lipid abnormalities and preventing atherosclerotic cardiovascular disease.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Metoprolol</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 4-8 weeks</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Linezolid</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ceftriaxone</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Amoxicillin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Isoniazid + Rifampicin + Ethambutol</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Bedaquiline</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Linezolid + Cefepime.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Administer posaconazole for 8 weeks.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Rhabdomyolysis</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Imipenem/cilastatin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Ceftazidime + Amikacin</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Additional PCV13 at age 68.\n\nRationale: The patient has already received both PCV13 and PPSV23 vaccines in the past, which provides coverage against Streptococcus pneumoniae serotypes likely to cause community-acquired pneumonia. Administering another dose of PCV13 or PPSV23 during hospitalization is not necessary, as the patient's current vaccination status is up-to-date. Therefore, the appropriate plan is to administer an additional dose of PCV13 at age 68, as recommended by the Advisory Committee on Immunization Practices (ACIP) to maintain protection against pneumococcal disease.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Lamotrigine</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Nausea</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Phenytoin.\n\nRationale: Phenytoin, an anticonvulsant drug, is known to cause osteoporosis as a side effect, especially with long-term use. This patient has been taking phenytoin for 3 years, which matches the time frame of the onset of osteoporosis. Therefore, phenytoin is the most likely cause of osteoporosis in this patient.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Clozapine</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Benztropine</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Eszopiclone</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Lorazepam</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ② Add domperidone.\n\nExplanation: Domperidone is an antidopaminergic agent that can help to reduce the symptoms of Parkinson's disease, including tremors. In this case, the patient's tremors are not responding to levodopa, and adding domperidone may help to improve the symptoms. The other options are not appropriate for this situation. Decreasing the dose of levodopa (option ①) may worsen the symptoms, taking carbidopa/levodopa on an empty stomach (option ③) may not improve the symptoms, switching to an extended-release formulation (option ④) may not be necessary, and taking carbidopa/levodopa with a high-protein diet (option ⑤) may not have a significant effect on the symptoms.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Quetiapine</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Celecoxib capsule</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Change etanercept to adalimumab.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Denosumab.\n\nDenosumab is contraindicated for the treatment of osteoporosis in patients with Paget's disease because it may exacerbate the condition.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Tamsulosin + Tadalafil</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Estradiol hemihydrate/Dydrogesterone.\n\nRationale:\n\nThe patient's symptoms of facial flushing and night sweats suggest that she may be experiencing menopausal symptoms. Her medical history, including a total hysterectomy, and family history of osteoporosis, also support the possibility of menopause.\n\nEstradiol hemihydrate/Dydrogesterone is a combination hormone replacement therapy (HRT) that contains estradiol, an estrogen, and dydrogesterone, a progesterone. This combination is appropriate for women who have not had a hysterectomy, as it provides both estrogen and progesterone, which are needed to protect the uterus from excessive growth.\n\nIn contrast, estropipate, medroxyprogesterone, and estradiol valerate/cyproterone acetate are all estrogen-only HRTs, which may not be suitable for this patient's needs. Dydrogesterone, on its own, is a progesterone-only medication, which may not provide adequate estrogen replacement therapy for the patient's symptoms.\n\nTherefore, the most appropriate hormone therapy medication for this patient would be estradiol hemihydrate/dydrogesterone.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Bazedoxifene.\n\nRationale: Bazedoxifene is a selective estrogen receptor modulator (SERM) that is used to treat postmenopausal symptoms such as hot flashes and vaginal dryness. It has been shown to be effective in reducing the risk of osteoporosis and is generally well-tolerated. In this case, the patient has a history of venous thrombosis, which is a contraindication for hormone therapy. Bazedoxifene is a viable alternative for treating postmenopausal symptoms in patients with a history of thrombosis.\n\nTamoxifen (①) is a selective estrogen receptor modulator (SERM) that is used to treat breast cancer and reduce the risk of recurrence. It is not typically used to treat postmenopausal symptoms.\n\nSolifenacin (②) is an anticholinergic medication that is used to treat overactive bladder. It is not related to the treatment of postmenopausal symptoms.\n\nMirabegron (③) is a beta-3 adrenergic agonist that is used to treat overactive bladder. It is not related to the treatment of postmenopausal symptoms.\n\nEscitalopram (⑤) is a selective serotonin reuptake inhibitor (SSRI) that is used to treat depression and anxiety. It is not related to the treatment of postmenopausal symptoms.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Olaparib</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Mesna</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Pembrolizumab.\n\nExplanation:\n\nThe patient's KRAS and NRAS mutation status suggests that they are unlikely to benefit from anti-EGFR therapy, such as cetuximab (①) or panitumumab (not listed). Bevacizumab (②) is an anti-VEGF agent that can be considered for metastatic colorectal cancer, but it is not the most appropriate choice for this patient given the presence of KRAS and NRAS mutations.\n\nPembrolizumab (③) is an anti-PD-1 agent that has been shown to be effective in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors. Although the patient's tumor does not have MSI-H or dMMR status, pembrolizumab can still be considered as a potential treatment option based on its efficacy in patients with KRAS-mutated colorectal cancer.\n\nZiv-aflibercept (④) is an anti-VEGF agent that has been shown to be effective in combination with chemotherapy for metastatic colorectal cancer. However, it is not the most appropriate choice for this patient given the presence of KRAS and NRAS mutations.\n\nTrifluridine/tipiracil (⑤) is a combination of a thymidine synthase inhibitor and a thymidylate kinase inhibitor, which has been shown to be effective in patients with refractory colorectal cancer. However, it is not a suitable option for this patient given the presence of KRAS and NRAS mutations and the lack of evidence for its use in combination with FOLFOX chemotherapy.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Fluorouracil + Leucovorin + Irinotecan</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Aprepitant</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Serum creatinine.\n\nRationale: Pamidronate is a bisphosphonate that can cause kidney damage, particularly in patients with pre-existing renal impairment. Therefore, it is important to check the patient's serum creatinine level before administering pamidronate to ensure that the patient's kidney function is within a safe range for the drug to be administered. The other options are not relevant to the patient's condition or the administration of pamidronate.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Cytarabine + Hydroxyurea</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Tumor lysis syndrome.\n\nAllopurinol is a xanthine oxidase inhibitor that is used to prevent tumor lysis syndrome, a potentially life-threatening complication that can occur when large numbers of cancer cells are rapidly killed during chemotherapy. Tumor lysis syndrome is caused by the sudden release of potassium, phosphate, and uric acid into the bloodstream, which can lead to hyperkalemia, hypocalcemia, and kidney damage. Allopurinol works by inhibiting the conversion of purine nucleotides to uric acid, thus reducing the risk of tumor lysis syndrome.\n\nTherefore, option ③ Tumor lysis syndrome is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Dupilumab</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Latanoprost eye drops</s>"
    },
    {
        "year": 2022,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Hypophosphatemia</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Heparin</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Duplicate prescription of the same drug class.\n\nThe patient has been prescribed two different medications, both belonging to the same drug class (NSAIDs), which could lead to adverse effects or drug interactions. The orthopedic prescription is for Naproxen/Esomeprazole 500 mg/20 mg tablet, and the dental prescription is for Aceclofenac 100 mg tablet. Both medications are nonsteroidal anti-inflammatory drugs (NSAIDs), which could cause gastrointestinal problems, renal toxicity, or allergic reactions when taken together. Therefore, option ④ Duplicate prescription of the same drug class is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Occurrence of adverse drug reaction.\n\nExplanation:\n\nThe patient has developed an Aspergillus infection, which is a known adverse drug reaction associated with immunosuppressive medications, such as tacrolimus and mycophenolate mofetil, which the patient is taking for preventing rejection of the transplanted kidney. The patient's blood test results show an increase in serum creatinine and potassium levels, indicating kidney dysfunction, which is another potential side effect of these medications. Therefore, option ⑤ Occurrence of adverse drug reaction is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Annals of Pharmacotherapy.\n\nExplanation:\n\nThe question asks for information about the dosage of voriconazole based on renal function, which is a common clinical concern in patients with kidney transplants. Annals of Pharmacotherapy is a peer-reviewed journal that publishes original research, reviews, and case reports on all aspects of pharmacotherapy, including drug dosing and pharmacokinetics in patients with renal impairment. Therefore, it is the most appropriate source to consult for information on voriconazole dosing in patients with kidney transplants.\n\nDRUGDEX (①) is a comprehensive drug information database that provides information on drug dosing, interactions, and side effects. However, it may not have the most up-to-date information on drug dosing in specific patient populations, such as patients with kidney transplants.\n\nThe Lancet (②) is a medical journal that publishes original research and review articles on various medical topics, including infectious diseases and transplantation. However, it may not have detailed information on drug dosing and pharmacokinetics in patients with renal impairment.\n\nBasic Skills in Interpreting Laboratory Data (④) is a reference book that provides guidance on interpreting laboratory test results. While it may have some information on drug dosing and monitoring, it is not the most appropriate source for information on drug dosing in patients with kidney transplants.\n\nDrugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (⑤) is a reference book that provides information on the risks of various drugs during pregnancy and lactation. While it may have some information on drug dosing and pharmacokinetics, it is not the most appropriate source for information on drug dosing in patients with kidney transplants.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ The prescription can only be filled at a local pharmacy in the area where the medical institution is located.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Lansoprazole 15 mg orally disintegrating tablet.\n\nExplanation:\n\nThe patient who cannot swallow pills requires a medication that can be easily administered, and an orally disintegrating tablet is the best option. Lansoprazole 15 mg orally disintegrating tablet is already available in a form that can be easily administered to a patient with dysphagia, making it the best choice for compounding.\n\nThe other options are not suitable for compounding as they are not available in a form that can be easily administered to a patient with dysphagia:\n\n① Carvedilol 25 mg tablet: This medication is not available in an orally disintegrating form, and it would be difficult to crush the tablet and mix it with food or a liquid for the patient to take.\n\n② Valsartan 160 mg film-coated tablet: This medication is not available in an orally disintegrating form, and it would be difficult to crush the tablet and mix it with food or a liquid for the patient to take.\n\n③ Isosorbide dinitrate 40 mg extended-release tablet: This medication is not available in an orally disintegrating form, and it would be difficult to crush the tablet and mix it with food or a liquid for the patient to take.\n\n④ Rosuvastatin 5 mg OD tablet: This medication is available in an orally disintegrating form, but it is not the best option for compounding as it may not be as easy to administer as Lansoprazole 15 mg orally disintegrating tablet.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Pseudoephedrine.\n\nRationale: Pseudoephedrine is a sympathomimetic drug that can decrease milk production and may not be suitable for a breastfeeding mother. It is important to consult with the doctor to determine if this medication is appropriate for the patient's condition and to discuss alternative options that may be safer for the baby.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Caution for therapeutic class duplication.\n\nExplanation:\n\nThe prescription includes two medications, Simvastatin and Olmesartan, which are both used to treat hypertension. This is a caution for therapeutic class duplication because the patient is receiving two medications from the same therapeutic class, which may increase the risk of adverse effects or drug interactions. Therefore, option ④ is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Gentamicin blood concentration measured immediately after the day's administration.\n\nExplanation:\n\nTherapeutic drug monitoring (TDM) of gentamicin involves measuring the drug's blood concentration to ensure that it is within a therapeutic range. The goal is to maximize the efficacy of the drug while minimizing the risk of toxicity.\n\nWhen performing TDM for gentamicin 4 days after starting the treatment, the most appropriate option is to measure the gentamicin blood concentration immediately after the day's administration (④). This is because the concentration of the drug in the blood peaks shortly after administration and then gradually declines over time. Measuring the concentration immediately after administration provides the most accurate representation of the patient's current exposure to the drug.\n\nThe other options are not as relevant for TDM of gentamicin:\n\n① Dietary intake throughout the entire treatment period is not directly related to gentamicin blood concentrations and is not necessary for TDM.\n\n② Gentamicin blood concentration measured during the previous day's administration is not representative of the patient's current exposure to the drug.\n\n③ Gentamicin blood concentration measured immediately before the day's administration may not capture the peak concentration, which is typically reached shortly after administration.\n\n⑤ Creatine kinase blood concentration measured during administration 4 days ago is not relevant to gentamicin TDM, as creatine kinase is an enzyme that is not related to gentamicin pharmacokinetics or pharmacodynamics.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Dexamethasone</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ 4 mL</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ Contraindication for concurrent use of risedronate and calcium carbonate.\n\nRisedronate and calcium carbonate/cholecalciferol are both used to treat osteoporosis, but they have different mechanisms of action. Risedronate is a bisphosphonate that inhibits bone resorption, while calcium carbonate/cholecalciferol is a combination of calcium and vitamin D that promotes bone formation. Concurrent use of these medications may not be appropriate, as they may have opposing effects on bone metabolism. Therefore, it is important to discuss this issue with the prescribing physician during prescription review to ensure that the patient receives appropriate and safe treatment.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ After taking risedronate, maintain an upright posture and do not lie down for 30 minutes.\n\nExplanation: Risedronate is a bisphosphonate medication that is taken once a week for the treatment of osteoporosis. It is important to maintain an upright posture and avoid lying down for at least 30 minutes after taking the medication to prevent esophageal irritation and ulcers. This counseling point is critical for the patient's safety and to minimize the risk of adverse effects.\n\nThe other options are not relevant to the patient's medication regimen or may not be appropriate for the patient's condition. Option ① is not related to the medications prescribed. Option ② is incorrect because risedronate should be taken at least 30 minutes before the first food or drink of the day, and calcium supplements can be taken with food. Option ③ is incorrect because risedronate should be taken in the morning, and taking it after meals may not be effective. Option ④ is incorrect because nausea or vomiting is not a common side effect of risedronate.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Isoniazid tablet</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 6 mg/kg/day.\n\nCalculation:\n\nDaily dose = Total dose / Number of doses per day\n\nTotal dose = 6 mL x 3 days = 18 mL\n\nNumber of doses per day = 3\n\nDaily dose = 18 mL / 3 = 6 mg/kg/day\n\nTherefore, the daily dose of cefpodoxime prescribed for this child is 6 mg/kg/day.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Alprazolam</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Paclitaxel</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Fluorometholone.\n\nRationale: Fluorometholone is a topical corticosteroid that is commonly used to treat inflammation and dryness associated with dry eye syndrome. It can help to reduce the symptoms of eye irritation and foreign body sensation. The other options, tropicamide, cyclosporine, cyclopentolate, and sodium carboxymethylcellulose, may not be as effective in treating dry eye syndrome and its associated symptoms.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Dicyclomine tablet</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ The pregnancy test result is positive</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Ivermectin/Pyrantel pamoate</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Avoid driving or operating dangerous machinery.\n\nExplanation: Cyclosporine can cause drowsiness, dizziness, and fatigue, which may impair a patient's ability to drive or operate dangerous machinery. Therefore, it is important to advise patients to avoid these activities until they are certain that their ability to perform them is not affected.\n\nThe other options are not relevant to medication counseling for cyclosporine soft capsules:\n\n① Take before 4 PM: This is not a specific instruction related to cyclosporine soft capsules.\n\n② Place on the tongue and let it dissolve: Cyclosporine soft capsules are meant to be swallowed whole, not placed on the tongue to dissolve.\n\n③ Rinse the mouth well with water after taking: This is not a specific instruction related to cyclosporine soft capsules.\n\n⑤ Grapefruit juice consumption increases cyclosporine blood concentration: While grapefruit juice can increase cyclosporine blood concentration, this is not a critical piece of information that should be included in medication counseling for patients taking cyclosporine soft capsules.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Regular blood coagulation tests are essential.\n\nExplanation: Warfarin is an oral anticoagulant that works by inhibiting the production of vitamin K-dependent clotting factors in the liver. Regular blood coagulation tests, such as the International Normalized Ratio (INR), are essential to monitor the patient's response to the drug and ensure that the desired level of anticoagulation is achieved. This is important because warfarin can cause bleeding complications if the INR is too high, or blood clots if the INR is too low. Therefore, it is important to regularly monitor the patient's INR and adjust the warfarin dose accordingly.\n\nThe other options are not correct for the following reasons:\n\n① Take the same dose for life: Warfarin dosing needs to be individualized and regularly adjusted based on the patient's response to the drug, so taking the same dose for life is not appropriate.\n\n② Be cautious about vitamin D intake: While vitamin D can interact with warfarin, it is not the most important factor to consider when initiating warfarin therapy.\n\n④ Can be taken regardless of pregnancy status: Warfarin is contraindicated in pregnancy, as it can cause fetal bleeding and other complications. Therefore, it is important to ensure that women of childbearing potential are not pregnant before initiating warfarin therapy.\n\n⑤ When the drug takes effect, urine color changes to reddish-brown: This statement is not accurate. Warfarin does not cause a change in urine color, and its effect on blood coagulation is not directly visible in the urine.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Spironolactone</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Gami-ondam-tang (Jiawei Wendan Tang)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Manufacturing control standard document</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Separation</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 10^-9</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Active ingredient manufacturer</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Prospective validation</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ Differential scanning calorimetry (DSC)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① ICH</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ A time limit is set for storage between cleaning and sterilization.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Sterile purified water</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Light-resistant Hermetic Container</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Uniformity of dosage units test</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② COVID-19 vaccine</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 2</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 1</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ ST strategy</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 50 million won.\n\nThe beginning inventory can be calculated by subtracting the ending inventory from the cost of goods sold:\n\nBeginning inventory = Cost of goods sold - Ending inventory\n= 220 million won - 50 million won\n= 170 million won\n\nTherefore, the correct answer is ③ 50 million won.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Scientific management</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Fee-for-service system</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Evaluation of appropriateness of medical care benefits – National Health Insurance Service</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① Basic dispensing fee calculated per dispensing day.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Adverse selection</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Price-volume agreement system</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Actual transaction price reimbursement system</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Relative risk = (10/15)/(1,000/2,500)</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② A is cost-effective.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Non-reimbursed medication costs for dyslipidemia treatment.\n\nWhen changing the economic evaluation of dyslipidemia treatment from a healthcare institution perspective to a societal perspective, it is important to consider the non-reimbursed medication costs for dyslipidemia treatment. This includes the cost of medications that are not covered by insurance or other payment mechanisms, which can be a significant burden for patients and their families. Calculating these costs can help to provide a more comprehensive understanding of the total economic impact of dyslipidemia treatment on society.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Principle of respect for autonomy – Principle of beneficence.\n\nExplanation:\n\nIn this scenario, the pharmacist's action of informing the attending physician about the patient's non-adherence to their medication regimen could be seen as a conflict between the principle of respect for autonomy and the principle of beneficence.\n\nThe principle of respect for autonomy acknowledges the patient's right to make their own decisions about their health and treatment. By informing the physician without the patient's consent, the pharmacist may be seen as infringing on the patient's autonomy.\n\nOn the other hand, the principle of beneficence requires healthcare professionals to act in the best interest of their patients. By informing the physician, the pharmacist is attempting to ensure that the patient receives the best possible care and treatment outcomes, which aligns with the principle of beneficence.\n\nTherefore, option ③ Principle of respect for autonomy – Principle of beneficence is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Patient questionnaire</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ 300 people.\n\nExplanation:\nThe expected number of deaths due to colorectal cancer per 100,000 adults aged 20 and over in region A can be calculated by multiplying the population in each age group by the colorectal cancer mortality rate in the standard population, and then summing the results.\n\nFor the age group 20-39 years, the expected number of deaths = 500,000 x 2/100,000 = 1000.\nFor the age group 40-59 years, the expected number of deaths = 800,000 x 4/100,000 = 3200.\nFor the age group 60 years and over, the expected number of deaths = 900,000 x 12/100,000 = 10,800.\n\nTotal expected number of deaths = 1000 + 3200 + 10,800 = 15,000.\n\nTherefore, the correct answer is ④ 300 people, which is the closest option to 15,000.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ⑤ Since the value is less than 1, the risk of colorectal cancer in region A is lower than in the standard population.\n\nExplanation:\nThe standardized mortality ratio (SMR) is a measure of the relative risk of death from a specific cause in a population compared to a reference population. It is calculated as the observed number of deaths in the population divided by the expected number of deaths in the population, based on the age-specific mortality rates in the reference population.\n\nIn this case, the SMR for colorectal cancer among adults aged 20 and over in region A can be calculated as follows:\n\nSMR = (observed number of deaths from colorectal cancer in region A) / (expected number of deaths from colorectal cancer in region A based on the age-specific mortality rates in the standard population)\n\nSince the observed number of deaths from colorectal cancer in region A (300) is less than the expected number of deaths based on the age-specific mortality rates in the standard population (420), the SMR is less than 1 (300/420 = 0.714). This means that the risk of colorectal cancer in region A is lower than in the standard population.\n\nTherefore, the correct answer is option ⑤: Since the value is less than 1, the risk of colorectal cancer in region A is lower than in the standard population.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Pharmacy owners cannot obtain a wholesale license for handling herbal medicinal preparations.\n\nThe correct answer is ③. According to the Pharmaceutical Affairs Act, herbal medicinal preparations are considered to be drugs, and their handling and distribution are regulated accordingly. Pharmacy owners are not allowed to obtain a wholesale license for handling herbal medicinal preparations, as they are not considered to be wholesalers. Instead, they must follow the guidelines set by the Ministry of Food and Drug Safety for the handling and distribution of herbal medicinal preparations.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ They must have a separate storage facility for medicines.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Quantity of raw materials.\n\nThe \"Pharmaceutical Affairs Act\" requires that medication guidance documents include information on the storage method, side effects, including interactions, the name of the medication, including its appearance, and information on the procedure for medication side effect relief. However, it does not require the inclusion of the quantity of raw materials used in the medication. Therefore, option ② Quantity of raw materials is the correct answer.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ A medical institution owner provided patients with prescriptions information about the names and locations of nearby pharmacies.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Pharmaceutical wholesaler</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Application for priority sales item approval – Registered patent holder</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Commissioner of the Korea Disease Control and Prevention Agency</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ A person who has been sentenced to imprisonment or a heavier punishment for violating laws related to pharmaceutical affairs and whose sentence has not been completed.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Flower buds of Sophora japonica L.\n\nThe Narcotics Control Act classifies narcotics into several categories, including opium, coca leaves, cannabis, and synthetic drugs. Sophora japonica L, also known as the Japanese pagoda tree, does not contain any narcotic properties. Therefore, ③ Flower buds of Sophora japonica L. are NOT classified as a narcotic under the Narcotics Control Act.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Narcotic drug handling medical practitioner</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Restriction on labeling of flavoring substances.\n\nThe National Health Promotion Act aims to promote smoking cessation and reduce the harmful effects of smoking. The policies implemented under this act include:\n\n* Designation of non-smoking areas (①) to protect non-smokers from secondhand smoke.\n* Prohibition of installing smoking rooms for smokers (③) to discourage smoking and encourage smokers to quit.\n* Attachment of adult verification devices on cigarette vending machines (④) to prevent minors from purchasing cigarettes.\n* Display of warning images showing the harmful effects of smoking on cigarette packaging (⑤) to deter people from smoking.\n\nRestricting the labeling of flavoring substances (②) is not a policy implemented under the National Health Promotion Act for smoking cessation. Therefore, the correct answer is ②.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Transportation</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Even if the purchase price of medications other than herbal medicines exceeds the maximum price, the entire purchase amount is reimbursed to the pharmacy.</s>"
    },
    {
        "year": 2022,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ They must employ pharmacists according to the minimum staffing standards for professional personnel.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Formation of troponin complex</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Decrease | No change</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② glycosaminoglycan</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ pyruvate carboxylase</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Coenzyme B12 – Acyl group transfer reaction</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Gluconeogenesis</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② glycogen synthase kinase 3</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ propionyl-CoA</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Low-density lipoprotein (LDL)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ lanosterol</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ ribonucleotide reductase</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① RNA polymerase I</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Promotion of gene transcription</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Binding with pRb protein</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Non-enzymatic glycation</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Thiamine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Lesch-Nyhan syndrome</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Sterol regulatory element-binding protein (SREBP) gene</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ The tyrosine kinase activity of EGFR increased.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Administer a monoclonal antibody that inhibits EGFR activity. \n\nExplanation:\nEGFR is a transmembrane receptor that plays a crucial role in cellular signaling pathways, including cell growth, differentiation, and survival. In cancer cells, EGFR is often overexpressed or mutated, leading to uncontrolled cell growth and proliferation. Monoclonal antibodies that inhibit EGFR activity, such as cetuximab or panitumumab, can bind to the extracellular domain of EGFR and prevent ligand binding, thereby inhibiting downstream signaling pathways that promote cell growth and proliferation. This personalized treatment approach targets the specific molecular alteration in the cancer cells and can help to slow down or stop tumor growth.\n\nThe other options are not appropriate for this patient:\n\n① Recombinant active EGF would not be effective in inhibiting EGFR activity and may even promote cell growth and proliferation.\n\n② Caspase-3 activity is not directly related to EGFR signaling, so inhibiting caspase-3 activity would not be an effective treatment approach.\n\n④ Inhibiting the GTPase activity of Ras protein would not directly target EGFR signaling, and Ras mutations are not typically associated with EGFR-positive cancers.\n\n⑤ Increasing the ATP binding capacity of phosphorylase would not be relevant to EGFR signaling or cancer treatment.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Mycolic acid</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Clostridium tetani</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Telaprevir</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① hepatitis B virus</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Squalene epoxidase</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Inhibition of transpeptidase in cell wall biosynthesis.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Gentamicin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① Doxycycline</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Telithromycin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Fidaxomicin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ NKT cell</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ CR3</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① HLA-DM</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Interferon-γ (IFN-γ)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Systemic anaphylaxis</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Interleukin-12 (IL-12)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Rituximab</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Shigella dysenteriae</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ Production of Shiga toxin.\n\nExplanation:\nShiga toxin is a potent cytotoxin produced by Shigella species, which can cause severe watery diarrhea. The toxin inhibits protein synthesis by cleaving the 28S ribosomal RNA, leading to cell death and inflammation in the intestinal epithelium. This results in a loss of absorptive capacity and an increase in secretion, leading to profuse, watery diarrhea.\n\nThe other options do not accurately describe the mechanism of severe watery diarrhea caused by Shigella:\n\n① Streptolysin is a toxin produced by Streptococcus pyogenes, and is not associated with Shigella or severe watery diarrhea.\n\n② Decreased small intestine peristalsis would not cause severe watery diarrhea, as it would reduce the movement of food and fluids through the intestine, leading to constipation.\n\n③ Erythrocyte hemolysin is a toxin produced by some bacteria that can cause hemolytic anemia, but it is not associated with Shigella or severe watery diarrhea.\n\n⑤ Increase of cAMP in intestinal epithelial cells can increase chloride secretion and water absorption in the intestine, leading to diarrhea, but it is not the primary mechanism of severe watery diarrhea caused by Shigella.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ Tachyphylaxis</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Atropine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Increase in total peripheral resistance.\n\nAdrenaline (also known as epinephrine) and mirabegron are both adrenergic agonists, which means they activate adrenergic receptors. One of the common pharmacological actions of adrenergic agonists is the increase in total peripheral resistance (TPR), which is the opposition to blood flow in the peripheral circulation. This increase in TPR is achieved by the contraction of vascular smooth muscle cells, leading to vasoconstriction. Therefore, option ③ Increase in total peripheral resistance is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Metoprolol</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Haloperidol</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Citalopram</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ropinirole</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Alvimopan</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cimetidine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Blocking tumor necrosis factor-α (TNF-α) action.\n\nAnakinra, rilonacept, and canakinumab are all drugs that block the action of tumor necrosis factor-alpha (TNF-alpha), a cytokine that plays a key role in the inflammatory response.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Deferoxamine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Eptifibatide</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Increases intracellular calcium concentration in myocardial cells.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Enalapril – Angiotensin-converting enzyme (ACE) inhibition</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Aromatase inhibition</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Vildagliptin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Inhibition of DNA gyrase</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Nivolumab</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ③ Aldosterone receptor</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Nesiritide</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Trachoma</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Nitrogen dioxide</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ NH2Cl, NHCl2</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Manganese</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① troponin T</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Streptozotocin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① acrylamide</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 3×10^-3\n\nExplanation:\n\nTo calculate the reference dose, we need to use the following formula:\n\nReference dose = LOAEL × (1/10) × (1/10) × (1/10)\n\nwhere LOAEL is the Lowest Observed Adverse Effect Level, and the three factors of 10 are for interspecies variation, intraspecies variation, and the modification factor (which is set to 1 in this case).\n\nPlugging in the values given in the question, we get:\n\nReference dose = 0.3 mg/kg/day × (1/10) × (1/10) × (1/10)\n= 0.3 mg/kg/day × 0.1 × 0.1 × 0.1\n= 0.03 mg/kg/day\n\nTherefore, the reference dose is 0.03 mg/kg/day, which corresponds to option ③ 3×10^-3.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ The test substance itself is not mutagenic, but its metabolites are mutagenic.\n\nExplanation:\n\nThe given question describes the results of a bacterial reverse mutation test, which is used to determine the mutagenic potential of a chemical substance. The test involves exposing bacteria to the test substance and then selecting for mutants that have reversed a pre-existing mutation.\n\nThe results show that the test substance is not mutagenic in the absence of a liver S9 fraction (TA98, TA100, and TA1537), but it induces positive results in the presence of a liver S9 fraction (TA1535 and E. coli WP2 uvrA). This suggests that the test substance is not directly mutagenic but is metabolized to a mutagenic metabolite by the liver enzymes.\n\nTherefore, the correct answer is ⑤ The test substance itself is not mutagenic, but its metabolites are mutagenic.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Difference in distribution of metabolic enzymes among organs.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ histamine</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ascorbic acid</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Selenium</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Recovery of transporter inhibition.\n\nExplanation:\nSt. John's wort is an inducer of the P-glycoprotein (P-gp) efflux pump, which is responsible for the transport of certain drugs, including simvastatin, out of the body. When St. John's wort is discontinued, the inhibition of P-gp is reversed, leading to a decrease in the efflux of simvastatin and an increase in its plasma concentration. This can increase the risk of rhabdomyolysis, a serious side effect of simvastatin. Therefore, option ③ Recovery of transporter inhibition is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Bacillus cereus</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ tetrodotoxin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① α-amanitin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Aspartame</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Case-control study</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ The research period is shorter and the cost is lower.\n\nExplanation:\n\nCase 1 is a case-control study, which is a type of observational study that compares individuals who have a disease or condition (cases) with individuals who do not have the disease or condition (controls) and looks back in time to identify potential risk factors. This type of study is useful when the disease or condition is rare, and it is not feasible to conduct a cohort study.\n\nCase 2 is a cohort study, which is a type of observational study that follows a group of individuals over time to observe the development of a disease or condition. This type of study is useful when the disease or condition is common, and it is possible to follow a large group of individuals over a long period.\n\nCompared to Case 2, Case 1 has a shorter research period and lower cost because it does not require long-term follow-up of the subjects. In Case 1, the cases and controls are already identified, and the researchers only need to investigate the smoking history of the mothers and compare it with the birth weight of their infants. In contrast, Case 2 requires a long-term follow-up of the subjects to observe the incidence of lung cancer, which takes a longer time and is more expensive.\n\nTherefore, the correct answer is ③ The research period is shorter and the cost is lower.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cell swelling</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ An aggregate of epithelioid cells with central necrosis.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Platelets</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Molecular evolution through acquired mutations</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Renin</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Aplastic anemia</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Raynaud phenomenon</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increased elastase activity</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Metaplasia</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① APC</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Hepatic encephalopathy</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Gallstone</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Increased 5α-reductase activity</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Human Papillomavirus (HPV)</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Endometriosis</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Formation of pannus</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Myasthenia gravis</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Cataract</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Accumulation of fluid in alveoli due to pulmonary capillary congestion.</s>"
    },
    {
        "year": 2023,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Increased metabolic demand of the myocardium.\n\nFrank-Starling's law states that the heart adjusts its output in response to changes in venous return. When the body's demand for oxygen and nutrients increases, the heart responds by increasing its output to meet those demands. In the case of the patient described, the increased metabolic demand of the myocardium due to the patient's dyspnea and fatigue leads to an increase in cardiac output, which can cause cardiomegaly.\n\nTherefore, option ③ Increased metabolic demand of the myocardium is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Pseudoplasticity</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 50 atm, 90°C</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 33.3</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Deamidation reaction</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ionic strength.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 29.3R</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 1.0\n\nExplanation:\n\nTo make a 200 mL of 1% multivitamin injection isotonic with blood, we need to match the osmolarity of the injection with that of the blood. The osmolarity of a solution is determined by the concentration of solutes in the solution. In this case, we are given that the ΔT^{1%}_{f} of the multivitamin injection is 0.23℃, which means that the injection has a lower osmolarity than blood.\n\nTo increase the osmolarity of the injection and match it with that of blood, we need to add a solute that will increase the osmolarity of the injection without affecting its pH. Sodium chloride is a suitable solute for this purpose, as it is physiologically compatible and does not affect the pH of the injection.\n\nWe can calculate the amount of sodium chloride needed to achieve the desired osmolarity by using the following formula:\n\nOsmolarity (mOsm/L) = (mM/L) x (ΔT^{1%}_{f} - ΔT^{1%}_{b})\n\nwhere mM/L is the molar concentration of the solute (in this case, sodium chloride), ΔT^{1%}_{f} is the freezing point depression of the solute (0.58℃ for sodium chloride), and ΔT^{1%}_{b} is the freezing point depression of the blood (0.52℃).\n\nPlugging in the values, we get:\n\nOsmolarity (mOsm/L) = (mM/L) x (0.58℃ - 0.52℃)\nOsmolarity (mOsm/L) = (mM/L) x 0.06℃\n\nSince we want the osmolarity of the injection to match that of blood, we set the osmolarity of the injection equal to that of blood:\n\nOsmolarity (mOsm/L) = 0.52℃\n\nNow, we can solve for mM/L:\n\nmM/L = Osmolarity (mOsm/L) / (ΔT^{1%}_{f} - ΔT^{1%}_{b})\nmM/L = 0.52℃ / (0.58℃ - 0.52℃)\nmM/L = 1.0\n\nTherefore, we need 1.0 gram of sodium chloride to make a 200 mL of 1% multivitamin injection isotonic with blood.\n\nSo, the answer is ③ 1.0.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Introduce fatty acid residues as substituents.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Increase in the drug's diffusion coefficient for the gastrointestinal mucosa.\n\nExplanation:\nThe absorption rate of a drug through the gastrointestinal mucosa by simple diffusion decreases when the drug's diffusion coefficient for the gastrointestinal mucosa increases. This is because a higher diffusion coefficient indicates that the drug molecules are moving more quickly through the mucosa, resulting in a lower concentration gradient and therefore a lower absorption rate.\n\nThe other options do not affect the absorption rate of the drug through the gastrointestinal mucosa by simple diffusion:\n\n① Increase in the thickness of the gastrointestinal mucosa: This would decrease the surface area available for absorption, leading to a lower absorption rate.\n\n② Increase in the surface area of the gastrointestinal mucosa: This would increase the surface area available for absorption, leading to a higher absorption rate.\n\n③ Increase in the drug concentration within the intestine: This would increase the concentration gradient driving the absorption process, leading to a higher absorption rate.\n\n⑤ Increase in the drug's partition coefficient for the gastrointestinal mucosa: This would increase the distribution of the drug between the gastrointestinal mucosa and the surrounding tissues, leading to a lower absorption rate.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 20</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② General acid catalysis</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ It is inversely proportional to the density difference between the particle and the medium.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① The solubility in water increases at acidic pH.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③\n\nThe Higuchi drug release model states that the instantaneous rate of drug release per unit area (dQ/dt) is proportional to the concentration of the drug in the gel. Since the concentration of tretinoin in the gel is constant, the instantaneous rate of drug release per unit area (dQ/dt) will also be constant. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ D</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Diclofenac</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 5-Lipoxygenase inhibition</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Diclofenac</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Diclofenac</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Cimetidine</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Midazolam</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① A: There is no correlation between the size of the alkyl group and activity</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Propofol</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ⑤ Modification of stereochemistry.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③\n\nThe degree of dissociation (α) of aspirin can be calculated using the equation:\n\nα = (moles of H+ ÷ moles of aspirin) × 100\n\nGiven:\n\nmoles of H+ = 9 × 10^-3 mol/L × 1 L = 9 × 10^-3 mol\nmoles of aspirin = 0.3 mol\n\nNow, calculate α:\n\nα = (9 × 10^-3 mol ÷ 0.3 mol) × 100\nα = 300\n\nTherefore, the degree of dissociation (α) of aspirin is 300, which corresponds to option ③.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② NaH2PO4 and Na2HPO4</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Ammine complex ion</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② 5.10×10^-3</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② K2Cr2O7</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Salicylic acid</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③\n\nExplanation:\n\nThe formula for calculating the content of dydrogesterone is:\n\nContent (%) = (A / E) × (M / V) × 100\n\nwhere:\nA = absorbance (0.418)\nE = molar absorptivity (845)\nM = mass of dydrogesterone (50.3 mg)\nV = volume of solution (100 mL)\n\nSubstituting the values, we get:\n\nContent (%) = (0.418 / 845) × (50.3 / 100) × 100\nContent (%) = 0.495%\n\nTherefore, the correct answer is ③ 0.495%.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② +4.6°</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 0.8</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Reversed-phase chromatography</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Increase in longitudinal diffusion.\n\nExplanation:\n\nLongitudinal diffusion refers to the movement of solutes along the length of the column in a liquid chromatography system. When the mobile phase is replaced with one of lower viscosity, the diffusion coefficient of the solutes increases, leading to increased longitudinal diffusion. This results in better separation of the solutes and increased resolution.\n\nTherefore, option ④ Increase in longitudinal diffusion is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Mass spectrometry detector</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Gradient elution</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Adjust the pH of the mobile phase solution to be below 2.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Parallel test</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ 2.5</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 100\n\nExplanation:\nThe specific absorbance E1%1 cm is calculated using the formula:\nE1%1 cm = A / (C x L)\n\nwhere A is the absorbance, C is the concentration of the active pharmaceutical ingredient (in mg/mL), and L is the path length (in cm).\n\nIn this case, the concentration of the active pharmaceutical ingredient A is 10.0 mg/1000 mL = 0.01 mg/mL. The path length is 1 cm. The absorbance was measured 5 times and the average absorbance was 0.40 with a standard deviation of 0.01.\n\nTherefore, the specific absorbance E1%1 cm can be calculated as follows:\nE1%1 cm = 0.40 / (0.01 x 1) = 100\n\nSo, the correct answer is ③ 100.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Fluid bed granulation</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ethylcellulose</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Lollipop</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Carbon dioxide</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Liquid paraffin</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Beeswax</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Membrane permeability.\n\nThe everted intestinal sac technique is a method used to study the absorption of drugs across the intestinal membrane. It involves creating a sac from a segment of intestine, everted (turned inside out) and mounted in a diffusion chamber. The drug of interest is placed on one side of the sac, and the movement of the drug across the membrane can be measured over time.\n\nMembrane permeability is a critical factor in determining the absorption of a drug across the intestinal membrane. The everted intestinal sac technique allows researchers to study the permeability of the intestinal membrane to different drugs and to assess how various factors, such as pH, temperature, and concentration gradients, affect drug absorption.\n\nTherefore, option ② Membrane permeability is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Induction of sink conditions.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② A, B</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 200\n\nThe apparent volume of distribution (Vd) is calculated using the equation:\n\nVd = (C0 / A)\n\nwhere C0 is the blood concentration at time 0 (20 μg/L) and A is the dose administered (10 mg).\n\nVd = (20 μg/L / 10 mg) = 200 L\n\nTherefore, the correct answer is ③ 200.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 100</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Decrease in dosing interval</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Increased blood concentration due to reduced transport to liver cells.\n\nExplanation:\nThe 521T>C genetic variation in the SLCO1B1 gene leads to a decrease in the expression of the OATP1B1 transporter in the liver. As a result, simvastatin, which is a substrate of OATP1B1, is not transported out of liver cells as efficiently, leading to increased blood concentrations and a higher incidence of side effects.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Not dissolving in the stomach but releasing in the small intestine.\n\nThe formulation of oral solid dosage form A contains diclofenac sodium, which is an anti-inflammatory and analgesic drug. The other ingredients, such as lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, and magnesium stearate, are used as fillers, binders, and lubricants to help compress the tablet. The presence of cellacefate as a coating material suggests that the tablet is designed to release the drug in the small intestine, rather than in the stomach. Therefore, the main characteristic of oral solid dosage form A is that it does not dissolve in the stomach but releases in the small intestine.\n\nAnswer: ③</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ Sticking – Croscarmellose sodium.\n\nExplanation:\n\nThe phenomenon of constituent materials sticking to the punch of the tablet press during compression is known as \"sticking.\" It is caused by the adhesion of the powder particles to the surface of the punch, which can be due to several factors such as improper powder flow, inadequate lubrication, or excessive moisture.\n\nTo improve this issue, the amount of croscarmellose sodium, which is a disintegrant, should be increased. Croscarmellose sodium helps to break up the tablet into smaller particles, reducing the likelihood of sticking.\n\nTherefore, the correct answer is ⑤ Sticking – Croscarmellose sodium.</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ quinidine</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② cyanogenic glycoside</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Rhizome</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Bovis Calculus</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Paeoniae Radix</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Angelicae Dahuricae Radix</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Rhei Radix et Rhizoma</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Zanthoxylum fruit</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① aconitine</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ isoquinoline alkaloid</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cinnamon bark (Rou Gui)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Prunella vulgaris var. lilacina</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Nutritive qi (營氣)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Shaoyang disease (少陽病)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Polygala root (遠志, Yuan Zhi)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Samhwangsasim-tang (三黃瀉心湯)</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Amino acid-mevalonate combined pathway</s>"
    },
    {
        "year": 2023,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ gomisin A</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Heart rate</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Candesartan.\n\nRationale: Candesartan is an angiotensin II receptor antagonist that can effectively reduce blood pressure in patients with hypertension. It has a good safety profile and is less likely to interact with other medications the patient is taking, such as metformin, saxagliptin, and allopurinol. Verapamil and clonidine may also be effective in lowering blood pressure, but they may have more potential for adverse effects or drug interactions in this patient population. Furosemide is a diuretic that may be effective in lowering blood pressure, but it may also increase the risk of hypokalemia in patients with type 2 diabetes. Hydrochlorothiazide is a diuretic that may also be effective in lowering blood pressure, but it may have a higher risk of hypokalemia and hyperglycemia in patients with type 2 diabetes.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Rebamipide.\n\nRationale: Rebamipide, a proton pump inhibitor, can increase the blood concentration of digoxin by inhibiting its metabolism. The patient's digoxin blood concentration has increased from 0.9 ng/mL a month ago to 1.7 ng/mL, which suggests that the patient may be experiencing a drug interaction. The other medications, such as amoxicillin, pantoprazole, clarithromycin, and magnesium oxide, are less likely to cause this interaction. Bisacodyl, a laxative, is also unlikely to cause this interaction. Therefore, the best answer is ③ Rebamipide.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ivabradine.\n\nRationale:\n\nThe patient's worsening shortness of breath and increased discomfort in daily activities suggest that his heart failure symptoms are not well controlled. The addition of ivabradine, a medication that reduces heart rate by selectively blocking the \"funny\" channels in the sinus node, can help to reduce the patient's heart rate and alleviate his symptoms.\n\nLisinopril (①) is an ACE inhibitor that can reduce blood pressure and improve cardiac function, but it may not directly address the patient's symptoms of shortness of breath and fatigue.\n\nAmlodipine (②) is a calcium channel blocker that can reduce blood pressure and alleviate angina symptoms, but it may not have a direct effect on the patient's heart failure symptoms.\n\nIndapamide (④) is a diuretic that can help reduce fluid overload in heart failure patients, but it may not address the patient's primary symptoms of shortness of breath and fatigue.\n\nSpironolactone (⑤) is a potassium-sparing diuretic that can help reduce fluid overload and improve cardiac function, but it may not be the most appropriate choice for this patient given his normal potassium levels and the lack of evidence of fluid overload.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Prasugrel</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Nicardipine.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Rivaroxaban</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Pitavastatin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Romosozumab.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Protamine</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Enoxaparin.\n\nRationale:\n\nThe patient has a history of heparin-induced thrombocytopenia (HIT), which is a serious adverse reaction to unfractionated heparin. Therefore, it is not appropriate to use another heparin-based medication, such as fondaparinux.\n\nEdoxaban and abciximab are both oral anticoagulants, but they are not appropriate for preventing venous thromboembolism in a patient with severe ulcerative colitis who has just undergone intestinal resection.\n\nAlteplase is a thrombolytic agent that is used to treat acute deep vein thrombosis (DVT) and pulmonary embolism (PE). However, it is not appropriate for preventing venous thromboembolism in this patient population.\n\nEnoxaparin, a low-molecular-weight heparin, is the most appropriate medication for preventing venous thromboembolism in this patient. It has a lower risk of HIT compared to unfractionated heparin and is effective in preventing VTE in patients with inflammatory bowel disease.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① Amlodipine.\n\nRationale:\n\nThe patient has a history of myocardial infarction and hypertension, and is currently taking medications such as aspirin, lisinopril, carvedilol, clopidogrel, and nitroglycerin. The addition of amlodipine, a calcium channel blocker, would help to further manage the patient's hypertension and reduce the risk of future cardiovascular events.\n\nRosuvastatin (②) is a statin, which is used to treat high cholesterol. While the patient's LDL-C level is within the normal range, the addition of rosuvastatin may not provide significant benefits for the patient's current condition.\n\nTrimetazidine (③) is a medication used to treat angina pectoris. While the patient has a history of myocardial infarction, the current symptoms and vital signs do not indicate a need for this medication.\n\nChlorthalidone (④) is a diuretic, which may be beneficial for managing hypertension. However, the patient's current blood pressure is already well-controlled, and the addition of chlorthalidone may not be necessary at this time.\n\nIsosorbide mononitrate (⑤) is a medication used to treat angina pectoris. Similar to trimetazidine, it may not be necessary for the patient's current condition.\n\nTherefore, the best answer is ① Amlodipine.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Add morphine.\n\nRationale:\n\nThe patient's recent increase in chest pain frequency suggests that their current treatment regimen may not be effectively managing their angina. Morphine is a medication that can be used to treat stable angina by reducing the workload on the heart and decreasing the demand for oxygen. It is appropriate to add morphine to the patient's regimen to help manage their chest pain, especially given their history of myocardial infarction.\n\nIncreasing the dose of lisinopril (①) or carvedilol (②) may also be considered, as these medications are used to treat hypertension and heart failure, respectively. However, given the patient's current vital signs and laboratory results, it appears that their blood pressure and heart rate are already well-controlled.\n\nApixaban (④) is an anticoagulant medication that is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation or venous thromboembolism. It is not appropriate for managing stable angina.\n\nNimodipine (⑤) is a calcium channel blocker that is used to treat raynaud's phenomenon, a condition that affects blood flow to the fingers and toes. It is not appropriate for managing stable angina.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ② Digoxin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Apixaban.\n\nRationale: Apixaban is an oral anticoagulant that is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, which is the patient's underlying condition. It is the most appropriate medication for long-term maintenance of sinus rhythm and prevention of stroke in this case.\n\nAspirin (①) is an antiplatelet agent that can also be used to prevent stroke in patients with atrial fibrillation, but it may not be as effective as anticoagulants like apixaban in preventing stroke.\n\nDalteparin (③) and enoxaparin (not listed) are both parenteral anticoagulants that can be used for short-term anticoagulation, but they may not be suitable for long-term maintenance of sinus rhythm.\n\nCilostazol (④) is a phosphodiesterase inhibitor that can be used to treat intermittent claudication, but it is not indicated for prevention of stroke in atrial fibrillation.\n\nPrasugrel (⑤) is an antiplatelet agent that is used to prevent thrombotic events in patients with acute coronary syndrome, but it is not indicated for prevention of stroke in atrial fibrillation.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Discontinue fluticasone/salmeterol and switch to reslizumab.\n\nRationale:\n\nThe patient's history of severe asthma exacerbations and uncontrolled symptoms despite using high-dose fluticasone/salmeterol inhaler twice daily and salbutamol as needed, suggests that the current treatment is not effective in controlling the patient's asthma. The patient's elevated IgE levels and positive skin prick test result indicate that allergy plays a significant role in their asthma.\n\nReslizumab, an anti-IL-5 monoclonal antibody, is an appropriate addition to the patient's treatment regimen. It has been shown to be effective in reducing asthma exacerbations, improving lung function, and reducing blood eosinophil counts in patients with severe asthma.\n\nOmalizumab, another anti-IgE monoclonal antibody, may also be considered, but it is less effective in patients with severe asthma and elevated IgE levels. Discontinuing fluticasone/salmeterol and switching to omalizumab may not be the best option, as the patient's asthma is not well-controlled with the current treatment, and omalizumab may not provide adequate control.\n\nAdding reslizumab to the patient's current treatment regimen is a more appropriate option, as it targets a different mechanism in the inflammatory cascade and has been shown to be effective in patients with severe asthma.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Administer low-dose budesonide/formoterol inhaler as needed.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Fexofenadine oral preparation</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ④ Change umeclidinium/vilanterol inhaler to vilanterol/fluticasone inhaler.\n\nRationale: The patient's history of chronic bronchitis and recent acute exacerbations, along with the presence of neutrophilic inflammation (elevated neutrophil count) and airflow obstruction (reduced FEV1), suggest that the patient may benefit from the addition of an inhaled corticosteroid (ICS) to their treatment regimen. ICS can help to reduce inflammation and improve lung function. The combination of vilanterol (a long-acting beta2-agonist) and fluticasone (an ICS) in a single inhaler would be a suitable option for this patient.\n\nTherefore, option ④ Change umeclidinium/vilanterol inhaler to vilanterol/fluticasone inhaler is the appropriate measure for this patient.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ⑤ QTc interval prolongation.\n\nRoflumilast, a phosphodiesterase-4 inhibitor, is associated with an increased risk of QTc interval prolongation, which can lead to ventricular arrhythmias such as torsades de pointes. This is a potentially life-threatening adverse reaction.\n\nThe other options are not associated with roflumilast:\n\n① Bradycardia: Roflumilast may cause bradycardia, but it is not the main adverse reaction expected.\n\n② Optic neuritis: Roflumilast is not associated with optic neuritis.\n\n③ Increased appetite: Roflumilast is not associated with increased appetite.\n\n④ Weight loss: Roflumilast is not associated with weight loss.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Famotidine</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Tegoprazan</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Add furosemide 80 mg once daily.\n\nExplanation:\n\nThe patient's recent weight gain and increased ascites suggest that the current medications are not effectively managing fluid retention. Furosemide is a potent diuretic that can help remove excess fluid and reduce ascites. It is appropriate to add furosemide 80 mg once daily to the patient's current regimen.\n\nAmiloride (①) and indapamide (②) are also diuretics, but they may not be as effective as furosemide in removing ascites in this case. Changing spironolactone to furosemide (④) or indapamide (⑤) may not be necessary, as spironolactone is already being used to manage ascites. However, if the patient's response to furosemide is not satisfactory, changing spironolactone to furosemide or indapamide may be considered.\n\nTherefore, the correct answer is ③ Add furosemide 80 mg once daily.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Cefotaxime.\n\nExplanation:\n\nThe patient has spontaneous bacterial peritonitis (SBP), which is a life-threatening infection of the ascites fluid in patients with liver cirrhosis. The appropriate empirical antibiotic for SBP is a third-generation cephalosporin, such as cefotaxime. This is because third-generation cephalosporins have broad-spectrum activity against gram-negative bacteria, which are commonly isolated from ascites fluid in patients with SBP.\n\nAmpicillin (①) is not appropriate because it has limited activity against gram-negative bacteria.\n\nVancomycin (③) is not appropriate because it is used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections, which are not commonly isolated from ascites fluid in patients with SBP.\n\nCiprofloxacin (④) is not appropriate because, although it has activity against gram-negative bacteria, it has a delayed onset of action and may not be effective in the early stages of SBP.\n\nAzithromycin (⑤) is not appropriate because it has limited activity against gram-negative bacteria and is not effective against anaerobic bacteria, which may also be present in the ascites fluid.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Administer entecavir</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ② Tofacitinib.\n\nExplanation:\n\nTofacitinib is a janus kinase (JAK) inhibitor, which is a novel treatment option for moderate to severe Crohn's disease. It has been shown to be effective in inducing and maintaining remission, and has a good safety profile. In contrast, mesalazine (①) is a 5-aminosalicylic acid (5-ASA) medication that is typically used for mild to moderate Crohn's disease and has not been shown to be effective for more severe disease. Metronidazole (③) is an antibiotic that may be used for perianal Crohn's disease, but it is not appropriate for this patient as there is no perianal fistula. Cyclosporine (④) is an immunosuppressant that may be used for severe Crohn's disease, but it has a higher risk of side effects and is not the most appropriate choice for this patient. Methotrexate (⑤) is a chemotherapy medication that may be used for severe Crohn's disease, but it has a higher risk of side effects and is not the most appropriate choice for this patient.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Adalimumab.\n\nAs the patient has already achieved remission with adalimumab, it is likely that continuing this medication will help maintain remission. Adalimumab is a tumor necrosis factor (TNF) inhibitor, which has been shown to be effective in maintaining remission in Crohn's disease. The other options, mesalazine, golimumab, azathioprine, and ustekinumab, may also be effective in maintaining remission, but they have not been proven to be as effective as adalimumab in this particular case. Therefore, the best answer is ② Adalimumab.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Sodium bicarbonate.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ gentamicin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Mannitol</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Switch to epoetin beta.\n\nExplanation:\n\nThe patient's hemoglobin level has increased from 8.4 g/dL to 9.7 g/dL over the past month, which suggests that the current dose of epoetin alfa is effective in stimulating erythropoiesis. However, the patient's ferritin level is low (85 ng/mL), indicating that the patient may not have sufficient iron stores to support further erythropoiesis.\n\nSwitching to epoetin beta, which has a different mechanism of action compared to epoetin alfa, may help to improve the patient's anemia without increasing the risk of iron-induced toxicity. Epoetin beta stimulates the production of red blood cells by binding to the erythropoietin receptor on the surface of red blood cell precursors in the bone marrow, whereas epoetin alfa stimulates the production of red blood cells by increasing the production of erythrocyte precursors in the bone marrow.\n\nIncreasing the dose of epoetin alfa (option ②) may not be appropriate given the patient's low ferritin level and the risk of iron-induced toxicity. Decreasing the dose of epoetin alfa (option ①) may not be appropriate as it may not effectively manage the patient's anemia. Adding oral ferrous sulfate (option ④) may not be appropriate as the patient's transferrin saturation is already low, indicating that the patient may not be able to absorb enough iron from oral supplements. Adding intravenous ferric hydroxide sucrose complex (option ⑤) may not be appropriate as it may increase the risk of iron-induced toxicity.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Cinacalcet.\n\nExplanation: Cinacalcet is a calcium-lowering drug that is used to treat hyperparathyroidism. It works by decreasing the levels of parathyroid hormone (PTH) in the body, which in turn decreases the levels of calcium in the blood. The patient's low serum calcium concentration and high iPTH level (425 pg/mL) suggest that cinacalcet may be causing hypocalcemia.\n\nThe other options are not likely to cause hypocalcemia:\n\n* Sevelamer (①) is a phosphate-binding agent that is used to treat hyperphosphatemia in patients with chronic kidney disease. It does not affect calcium levels directly.\n* Amlodipine (②) is a calcium channel blocker that is used to treat hypertension. It does not affect calcium metabolism.\n* Irbesartan (④) is an angiotensin II receptor antagonist that is used to treat hypertension. It does not affect calcium metabolism.\n* Calcium polystyrene sulfonate (⑤) is a calcium-binding agent that is used to treat hypercalcemia. It does not cause hypocalcemia.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Basiliximab</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Pioglitazone.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Sitagliptin.\n\nRationale: Sitagliptin is an oral medication that works by increasing the amount of insulin produced by the body and reducing the amount of glucose produced by the liver. It is less likely to cause weight gain compared to other medications, which is important for this patient who has a strong aversion to weight gain. Additionally, sitagliptin does not require injectable medications, which aligns with the patient's preference.\n\nGlipizide and repaglinide are both sulfonylureas, which can cause weight gain and may not be suitable for this patient. Liraglutide is an injectable medication, which the patient has expressed a strong aversion to. Pioglitazone is a thiazolidinedione, which can cause weight gain and fluid retention, making it less desirable for this patient.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Insulin detemir.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Duloxetine capsule.\n\nRationale: Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that has been shown to be effective in treating diabetic peripheral neuropathy (DPN). It has been approved by the FDA for this indication and has been shown to improve pain, numbness, and tingling in patients with DPN. The other options, olanzapine, piroxicam, ketoprofen, and metoclopramide, may not be effective in treating DPN and may have adverse effects in this patient population. Therefore, the best answer is ② Duloxetine capsule.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Liraglutide.\n\nRationale: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been shown to improve glycemic control, reduce body weight, and lower the risk of major adverse cardiovascular events in patients with type 2 diabetes. It is also known to have a beneficial effect on diabetic peripheral neuropathy, which is a common complication of diabetes.\n\nIn contrast, acarbose, gemigliptin, and lobeglitazone are all oral hypoglycemic agents that work by increasing insulin sensitivity or decreasing glucose production in the liver. While they may be effective in improving glycemic control, they are less likely to have a direct beneficial effect on diabetic peripheral neuropathy.\n\nDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that works by increasing urinary glucose excretion. While it may be effective in improving glycemic control, it is less likely to have a beneficial effect on diabetic peripheral neuropathy compared to liraglutide.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Propranolol</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Acetaminophen</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Tendon rupture.\n\nRationale: Ciprofloxacin is a fluoroquinolone antibiotic that has been associated with an increased risk of tendon rupture, particularly in older adults. The risk is further increased in patients taking corticosteroids, such as prednisolone, which the patient in this scenario is taking. The patient's history of psoriasis and use of calcipotriol ointment may also increase the risk of tendon rupture. Therefore, tendon rupture is the most likely major adverse reaction to occur in this patient.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Levofloxacin 750 mg once daily for 5 days.\n\nRationale:\n\nThe appropriate treatment for asymptomatic bacteriuria in a patient with a urinary catheter is antibiotic therapy. The choice of antibiotic depends on the severity of the infection and the patient's medical history and allergies.\n\nLevofloxacin is a fluoroquinolone antibiotic that is effective against a wide range of bacteria, including Escherichia coli, which is the most common cause of urinary tract infections. A 5-day course of levofloxacin 750 mg once daily is a reasonable duration for treating asymptomatic bacteriuria in a patient with a urinary catheter.\n\nObserving the patient without antibiotic administration (option ①) is not appropriate, as bacteriuria can lead to symptomatic urinary tract infections, pyelonephritis, and sepsis, especially in elderly patients.\n\nFosfomycin (option ②) is not the drug of choice for this patient, as it is primarily used for the treatment of lower urinary tract infections and may not be effective against bacteria in the upper urinary tract.\n\nNitrofurantoin (option ④) is not recommended for this patient, as it is primarily used for the prevention of recurrent urinary tract infections in patients with a history of recurrent infections.\n\nCiprofloxacin (option ⑤) is not the drug of choice for this patient, as it is a broad-spectrum antibiotic that may be associated with increased risk of adverse effects and may not be necessary for the treatment of asymptomatic bacteriuria. Additionally, a 6-month course of antibiotics is excessive for the treatment of a urinary tract infection.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 7 days</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Esomeprazole\n\nRationale: Esomeprazole, a proton pump inhibitor, may interact with levofloxacin by reducing its absorption. Levofloxacin should be taken at least 2 hours before or 2 hours after esomeprazole to minimize this interaction. The other options do not have a significant interaction with levofloxacin.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Cefepime + Moxifloxacin + Vancomycin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Linezolid</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Change fluconazole to micafungin.\n\nRationale:\n\nThe patient's symptoms have worsened despite 5 days of fluconazole treatment, suggesting that the infection may not be responding to the current therapy. Micafungin, a echinocandin, is a broad-spectrum antifungal that is effective against Candida krusei, the identified pathogen. It is appropriate to change the treatment to micafungin to increase the chances of successful treatment.\n\nIncreasing the dose of fluconazole (option ①) may not be effective as the patient has already received a loading dose and the infection has not responded. Decreasing the dose of fluconazole (option ②) would not be appropriate as it may reduce the efficacy of the treatment. Adding flucytosine (option ③) may be considered, but it is not the most appropriate option as it is not as effective against Candida krusei as micafungin. Changing fluconazole to itraconazole (option ⑤) may not be effective as itraconazole has a narrower spectrum of activity compared to micafungin and may not be effective against Candida krusei.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Renal function.\n\nThe patient's creatinine clearance (CrCl) is 37 mL/min, which indicates that their renal function is impaired. Fluconazole is primarily eliminated through the kidneys, and its clearance is reduced in patients with renal impairment. Therefore, a lower dose of fluconazole is necessary to avoid accumulation of the drug and potential adverse effects.\n\nThe other options are not relevant to the patient's renal function and the need for a lower dose of fluconazole:\n\n① Gender: The patient's gender does not affect the dosing of fluconazole.\n\n② Age: The patient's age does not affect the dosing of fluconazole.\n\n③ Weight: The patient's weight does not affect the dosing of fluconazole.\n\n⑤ Interaction with amoxicillin: There is no known interaction between fluconazole and amoxicillin that would affect the dosing of fluconazole.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Metronidazole</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Ceftriaxone + Vancomycin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 7 days</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Escitalopram</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Quetiapine</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Pregabalin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ HLA-B*1502</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Thyroid-stimulating hormone.\n\nExplanation:\n\nLithium carbonate can cause hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones. The patient's symptoms of fatigue, weight gain, and menstrual irregularities are consistent with hypothyroidism. Therefore, it is appropriate to check the patient's thyroid-stimulating hormone (TSH) level to determine if hypothyroidism is the cause of her symptoms.\n\nThe other options are not directly related to the patient's symptoms or the potential side effects of lithium carbonate:\n\n① Intraocular pressure is not related to the patient's symptoms or the medication's side effects.\n\n② C-reactive protein is a measure of inflammation, but it is not related to the patient's symptoms or the medication's side effects.\n\n③ Arterial blood gas is not related to the patient's symptoms or the medication's side effects.\n\n⑤ Creatine kinase is an enzyme that can be elevated in muscle damage or disease, but it is not related to the patient's symptoms or the medication's side effects.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Zolpidem</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Loss of appetite</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Use the oral and injectable forms concurrently for 2 weeks, then use the injectable form alone.\n\nRationale:\n\nWhen switching from oral aripiprazole to long-acting injectable aripiprazole, it is recommended to overlap the two formulations for a brief period to ensure a smooth transition and minimize the risk of relapse. The overlap period should be long enough to allow the injectable formulation to reach steady-state levels, but not so long that it increases the risk of adverse effects.\n\nTwo weeks is a reasonable overlap period, as it allows for a gradual transition and minimizes the risk of adverse effects. Using the injectable form alone starting the day after discontinuing the oral form (option ①) may not provide sufficient time for the injectable form to reach steady-state levels, potentially leading to a relapse. Waiting 2 weeks (option ②) or 6 weeks (option ③) after discontinuing the oral form may be too long, as it could increase the risk of adverse effects. Concurrent use of the oral and injectable forms for 6 weeks (option ⑤) may also be too long and may increase the risk of adverse effects.\n\nTherefore, option ④, using the oral and injectable forms concurrently for 2 weeks, then using the injectable form alone, is the most appropriate method for switching from oral aripiprazole to long-acting injectable aripiprazole.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Clozapine</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Celecoxib.\n\nRationale: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain, inflammation, and stiffness associated with osteoarthritis. It is an appropriate medication to add to the patient's regimen, as it has been shown to be effective in reducing pain and improving functional ability in patients with osteoarthritis. The other options, tramadol, vitamin D, duloxetine, and diclofenac, may also be used to treat pain associated with osteoarthritis, but they have different mechanisms of action and may not be as effective in this case.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Thyroid function test</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Colchicine and verapamil.\n\nExplanation:\n\nThe combination of colchicine and verapamil is suspected to have increased the risk of myopathy due to drug interaction. Both drugs have the potential to cause myopathy as a side effect, and co-administration may increase this risk.\n\nColchicine is a drug used to treat gout and has been associated with myopathy, particularly at high doses or with prolonged use. Verapamil, a calcium channel blocker, has also been linked to myopathy, particularly in patients with pre-existing muscle disorders. When taken together, the risk of myopathy may be increased due to the additive effects of both drugs on muscle function.\n\nThe other options do not represent a likely drug interaction that could cause myopathy:\n\n② Colchicine and naproxen: Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that does not have a known interaction with colchicine.\n\n③ Colchicine and allopurinol: Allopurinol is a xanthine oxidase inhibitor used to treat hyperuricemia in gout patients. There are no known interactions between colchicine and allopurinol that would increase the risk of myopathy.\n\n④ Verapamil and allopurinol: Like naproxen, allopurinol does not have a known interaction with verapamil that would increase the risk of myopathy.\n\n⑤ Naproxen and allopurinol: This combination does not include colchicine, which is the key factor in the suspected drug interaction leading to myopathy in this scenario.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Solifenacin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Tamsulosin</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② Fesoterodine.\n\nRationale: Fesoterodine is a medication used to treat overactive bladder symptoms, which include urgency, frequency, and urgency urinary incontinence. It works by relaxing the bladder muscle and increasing the amount of urine that can be stored in the bladder. In this case, the patient's symptoms of frequent urination and feeling of incomplete bladder emptying suggest that he may have overactive bladder symptoms, which are not being adequately managed with his current medication regimen. Adding fesoterodine to his treatment plan may help to improve these symptoms.\n\nSildenafil (①) is a medication used to treat erectile dysfunction, and is not relevant to the patient's current symptoms. Finasteride (③) is a medication used to treat benign prostatic hyperplasia (BPH), but it may take several months to a year or more to see the full effects of the medication. Levofloxacin (④) is an antibiotic, and there is no indication of a urinary tract infection or other bacterial infection that would warrant its use. Desmopressin (⑤) is a medication used to treat central diabetes insipidus, and is not relevant to the patient's current symptoms.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Venetoclax + azacitidine</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Temporarily discontinue imatinib</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Bone density test.\n\nLetrozole is an aromatase inhibitor, which can cause bone loss and increase the risk of osteoporosis. Therefore, monitoring bone density is important to assess the risk of fractures and osteoporosis during treatment.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Osimertinib.\n\nThe patient's BRAF V600E mutation positive status makes Osimertinib the appropriate first-line chemotherapy. Osimertinib is a BRAF inhibitor that has been shown to be effective in patients with non-small cell lung cancer (NSCLC) harboring the BRAF V600E mutation.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Fluorouracil + Leucovorin + Irinotecan</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Forced expiratory volume in 1 second (FEV1)\n\nExplanation: Ziv-aflibercept can cause pulmonary toxicity, which may lead to interstitial lung disease or acute respiratory distress syndrome. Monitoring FEV1 is crucial to assess lung function and detect any decline in respiratory status.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Lapatinib + Exemestane</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Metoclopramide</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Topical calcipotriol + topical salicylic acid.\n\nRationale:\n\nTopical calcipotriol, a synthetic vitamin D analog, has been shown to be effective in treating mild to moderate acne vulgaris. It works by reducing the production of sebum and inflammation. Topical salicylic acid, a beta-hydroxy acid, helps to unclog pores and reduce inflammation. The combination of these two agents can effectively treat inflammatory acne lesions without the risk of systemic side effects associated with oral medications.\n\nTherefore, option ③ Topical calcipotriol + topical salicylic acid is the appropriate drug therapy for a 35-year-old woman with worsening acne on her face who is planning to get pregnant.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Timolol eye drops twice daily.</s>"
    },
    {
        "year": 2023,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Calcium citrate</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Tramadol</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Glomerular filtration rate.\n\nMetformin is a medication that can accumulate in patients with renal impairment, which can increase the risk of adverse effects. In patients with diabetic nephropathy, it is important to monitor their glomerular filtration rate (GFR) to ensure that the medication is not accumulating in their body and causing harm. Therefore, option ③ Glomerular filtration rate is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① b → a → c → d</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Nebulizer ampule</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ibandronate\n\nExplanation: Ibandronate is given once a month, and the dosing interval is 1 month. Therefore, it does not need modification in terms of dosing interval. However, the administration time is currently morning on an empty stomach, which may not be ideal for a patient with osteoporosis. It would be better to administer it at bedtime to minimize the risk of esophageal irritation and ulceration, which is a common side effect of bisphosphonates like ibandronate. Therefore, the dosing interval and administration time of ibandronate need to be modified.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Almagate\n\nExplanation: Almagate (aluminum hydroxide) can interact with warfarin by decreasing its absorption. Therefore, the dose of warfarin may need to be adjusted when taken with Almagate. The other options (Gabapentin, Amiodarone, Furosemide, and Spironolactone) do not have a significant interaction with warfarin that would require dose adjustment.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Carbamazepine.\n\nCarbamazepine is an anticonvulsant that can cause a high-protein meal to increase its serum concentration, which may lead to toxicity. Therefore, it is important to advise patients to avoid taking Carbamazepine with a high-protein meal.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Methotrexate</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Amlodipine</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ I: Clopidogrel administration</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Leucovorin.\n\nRationale: Leucovorin is a folinic acid derivative that is used to prevent methotrexate-induced neurotoxicity and gastrointestinal toxicity. It is also used to enhance the efficacy of chemotherapy drugs such as paclitaxel. In this case, the patient is receiving paclitaxel, and leucovorin would be included in the premedication regimen to prevent adverse reactions such as neurotoxicity and gastrointestinal toxicity.\n\nThe other options are not correct for the following reasons:\n\n* Mesna (①) is used to prevent bladder damage caused by cyclophosphamide and ifosfamide. It is not relevant to the chemotherapy regimen described.\n* Folic acid (②) is used to prevent methotrexate-induced neurotoxicity and gastrointestinal toxicity, but it is not as effective as leucovorin in this context.\n* Amifostine (④) is used to prevent chemotherapy-induced nephrotoxicity, but it is not relevant to the chemotherapy regimen described.\n* Chlorpheniramine (⑤) is an antihistamine that is used to prevent chemotherapy-induced nausea and vomiting, but it is not relevant to the chemotherapy regimen described.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Glomerular filtration rate</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Etoposide</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Blood alanine aminotransferase (ALT) concentration.\n\nExplanation: Amiodarone is known to cause liver damage and elevated liver enzymes, including ALT. Therefore, monitoring ALT levels is necessary to detect any potential liver damage or dysfunction. The other options are not directly related to the adverse reactions mentioned in the question.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Infuse slowly over 90 minutes.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Adverse drug reaction</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Doxazosin tablets</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Pseudoephedrine</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Loperamide</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Guaifenesin</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ① Bokryeong-eum (Poria Decoction)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Refrigerated, 10 days</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Gynecomastia may occur</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Apply to clean, hairless, and dry skin.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 5 days</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Fentanyl sublingual tablet</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Quality by Design (QbD) data</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Specification setting and calibration methods for measuring instruments.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Passing through ion exchange resin.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Intravenous preparations > Oral preparations > Ophthalmic preparations > Transdermal preparations</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Transfer pressure of the test liquid</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Detection limit</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ It is manufactured by placing purified water in containers and sterilizing.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Near-infrared spectroscopy</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ After tablet compression</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The sample is dried under the conditions specified in the loss on drying section for this drug.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ignition residue</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Dried yeast</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Ascorbic acid</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Create blocks where the effects due to factors are equal.\n\nExplanation:\n\nBlocking is a technique used to control for extraneous variables in experimental design. By creating blocks where the effects due to factors are equal, the experimenter can minimize the impact of unaccounted factors such as the experimenter's skill level, equipment degradation over time, and temperature on the experimental results. This method ensures that the groups being compared are similar in terms of these factors, thereby maintaining the objectivity of the experiment.\n\nRandomizing the order of experiments (option ②) can also help to control for some extraneous variables, but it may not be sufficient to completely eliminate their effects. Reducing the sample size (option ①) may make the experiment less powerful and increase the risk of Type II errors. Disregarding interactions between factors (option ③) may lead to a lack of understanding of the relationships between variables and may not adequately control for extraneous variables. Varying the number of data points for each group (option ④) may not be effective in controlling for extraneous variables and may introduce additional sources of variability.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Increase in standard deviation.\n\nThe process capability index (Cp) is a measure of the ability of a process to produce output within specified limits. It is calculated as the ratio of the upper specification limit (USL) to the standard deviation (σ) of the process.\n\nCp = USL / σ\n\nAn increase in standard deviation (σ) will result in a decrease in the process capability index (Cp), as the denominator of the ratio increases. Therefore, the correct answer is ③ Increase in standard deviation.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ④ 10^-4</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Sterilization at 111°C for 80 minutes.\n\nExplanation:\n\nThe lethality curve shows the relationship between the exposure time and the log reduction of microorganisms. The area under the curve (AUC) represents the total lethality of the process. In this case, the AUC is 8.0 minutes.\n\nTo achieve an equivalent sterilization effect, we need to find a process that results in a similar AUC.\n\n① Sterilization at 101°C for 160 minutes:\nThe D-value at 101°C is not given, but it is lower than 121°C. Therefore, the exposure time needed to achieve the same AUC would be longer than 160 minutes, making this option less effective.\n\n② Sterilization at 110°C for 40 minutes:\nThe D-value at 110°C is also not given, but it is lower than 121°C. Therefore, the exposure time needed to achieve the same AUC would be longer than 40 minutes, making this option less effective.\n\n③ Sterilization at 111°C for 80 minutes:\nThe D-value at 111°C is 0.5 minutes (not given in the question, but can be calculated using the Z-value and D121). The AUC for this process would be approximately 8.0 minutes (0.5 minutes x 80 minutes). This option provides an equivalent sterilization effect to the original process.\n\n④ Sterilization at 120°C for 8 minutes:\nThe D-value at 120°C is 0.25 minutes (not given in the question, but can be calculated using the Z-value and D121). The AUC for this process would be approximately 2.0 minutes (0.25 minutes x 8 minutes). This option is less effective than the original process.\n\n⑤ Sterilization at 131°C for 0.4 minutes:\nThe D-value at 131°C is 0.017 minutes (not given in the question, but can be calculated using the Z-value and D121). The AUC for this process would be approximately 0.68 minutes (0.017 minutes x 0.4 minutes). This option is much less effective than the original process.\n\nTherefore, the correct answer is ③ Sterilization at 111°C for 80 minutes.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ The current liabilities are 200 million won.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ 146 bottles</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 220 million won</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Diagnosis-Related Group (DRG) system</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Externality</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ①</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Essential drugs that must be stockpiled and supplied in preparation for national emergencies.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ They are suitable for controlling the effects of unforeseen confounding factors.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ②</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ According to the meta-analysis results, the risk of emergency room visits decreased after the introduction of medication management services.\n\nThe meta-analysis results show that the overall relative risk of emergency room visits after the introduction of medication management services was 0.85 [0.76, 0.95], indicating a decrease in the risk of emergency room visits. This conclusion is supported by the test for overall effect, which showed a statistically significant result (Z=2.85, p=0.004). Therefore, option ⑤ is the correct answer.\n\nThe other options are not correct interpretations of the meta-analysis results:\n\n① The heterogeneity among individual studies is low (I2=9%), indicating that the studies are generally consistent with each other.\n\n② Although statistical significance in risk difference was confirmed in 5 studies (A, B, D, E, and F), the meta-analysis results suggest that the overall effect is statistically significant, not just in individual studies.\n\n③ Study (C) was not given the highest weight in calculating the pooled estimate. The fixed-effect model assumes that each study has an equal weight.\n\n④ The results of the 7 studies are not inconsistent, as they all point to a decrease in the risk of emergency room visits after the introduction of medication management services. Therefore, quantitative synthesis is appropriate.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③\n\nRationale:\n\nWhen the annual discount rate is lowered from 5% to 3%, the cost of vaccine administration will be discounted less, resulting in a higher total cost over time. However, the effectiveness of the vaccine in terms of years of survival will also be discounted less, resulting in a higher total effectiveness. Since the cost and effectiveness are both discounted less, the incremental cost-effectiveness ratio (ICER) will be lower, making the vaccine more cost-effective. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② 1,923\n\nExplanation:\n\nTo calculate the incremental cost-utility ratio, we need to calculate the difference in costs and utility between drug A and drug B.\n\nThe total cost of drug A is 5,000 (insured medical expenses) + 2,000 (non-insured medical expenses) + 200 (transportation costs) + 5,000 (productivity loss due to premature death) = 12,200.\n\nThe total cost of drug B is 2,000 (insured medical expenses) + 1,500 (non-insured medical expenses) + 200 (transportation costs) + 7,000 (productivity loss due to premature death) = 10,700.\n\nThe difference in total cost between drug A and drug B is 12,200 - 10,700 = 1,500.\n\nThe difference in utility between drug A and drug B is 0.65 (utility weight for drug A) - 0.6 (utility weight for drug B) = 0.05.\n\nThe incremental cost-utility ratio is the difference in cost divided by the difference in utility: 1,500 / 0.05 = 30,000.\n\nSince the question asks for the incremental cost-utility ratio in terms of 10,000 won/QALY, we need to convert the result to 10,000 won/QALY. To do this, we divide the result by 10,000: 30,000 / 10,000 = 3.\n\nTherefore, the incremental cost-utility ratio of drug A compared to drug B is 3. This means that drug A costs 3 times as much as drug B per QALY gained.\n\nThe correct answer is ② 1,923, which is the calculated incremental cost-utility ratio rounded to the nearest 100 won.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Including information and procedures for compensation in case of health damage due to the administration of the test drug in the written consent form.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Principle of respect for autonomy – Principle of beneficence.\n\nExplanation:\n\nThe principle of respect for autonomy states that patients have the right to make their own decisions about their healthcare, including the right to refuse treatment or choose alternative treatments. In this case, Mr. A has made a conscious decision to try the dog dewormer as a last resort, despite the uncertainty of its therapeutic effect.\n\nThe principle of beneficence states that healthcare providers have a duty to act in the best interest of their patients and to do no harm. In this case, the pharmacist is torn between respecting the patient's wishes and ensuring that the patient receives effective and scientifically-based treatment.\n\nTherefore, the ethical conflict in this situation is between the principle of respect for autonomy and the principle of beneficence. The pharmacist must weigh the patient's right to make their own decision against the potential harm that may come from taking an unproven and untested treatment.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ 1.5\n\nCurrent ratio = Current assets / Current liabilities\n= 80,000 / 20,000\n= 4\n\nTherefore, the current ratio of Pharmacy A is 4, which corresponds to option ③ 1.5.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ 2.4 times\n\nInventory turnover ratio = Cost of goods sold / Average inventory\n= 120,000 / (50,000 + 30,000) / 2\n= 120,000 / 40,000\n= 2.4 times</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Reported the reopening on July 4.\n\nExplanation: According to the Pharmaceutical Affairs Act, a pharmacy owner is required to report any changes in the pharmacy's operating status, including closures and reopenings, to the relevant authorities. In this case, the pharmacy owner should have reported the reopening of the pharmacy on July 4, 2022, which is the earliest possible date after the pharmacy reopened on July 9, 2022.\n\nTherefore, option ③ Reported the reopening on July 4 is the correct answer.\n\nOption ① Reported the closure on May 30 is incorrect because the pharmacy did not close until June 3, 2022.\n\nOption ② Reported the closure on June 14 is incorrect because the pharmacy had already been closed for 11 days by June 14, and the owner should have reported the closure earlier.\n\nOption ④ Reported the reopening on July 14 is incorrect because the pharmacy reopened on July 9, and the owner should have reported the reopening earlier.\n\nOption ⑤ Did not make any separate reports is incorrect because the pharmacy owner is required to report any changes in the pharmacy's operating status to the relevant authorities.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ Have \"pharmacy student interns\" who perform compounding wear a name tag displaying both the title \"Pharmacy Student Intern\" and their name.\n\nThis option is not a pharmacy management obligation for pharmacy owners under the Pharmaceutical Affairs Act, as it does not relate to the management of the pharmacy or the responsibilities of the pharmacy owner. The other options all relate to the management and operation of the pharmacy, and are therefore relevant to the pharmacy owner's obligations under the Act.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Document proving the requester has designated representation rights.\n\nAccording to the Pharmaceutical Affairs Act, a pharmacist should receive the following documents from a designated representative of a patient to request access to the patient's prescription records:\n\n* Consent form from the patient (①)\n* Copy of the requester's identification (②)\n* Copy of the patient's identification (③)\n* Document proving the requester has legal representation rights (④)\n\nTherefore, the correct answer is ⑤ Document proving the requester has designated representation rights, as this is not mentioned in the Pharmaceutical Affairs Act as a required document for requesting access to a patient's prescription records.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Dispensing for emergency patients</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sellers of safe and readily available drugs.\n\nAccording to the Pharmaceutical Affairs Act, pharmaceutical wholesalers are only permitted to sell drugs to licensed pharmacies, over-the-counter drug retailers, and oriental medicine drug retailers. They are not allowed to sell drugs to sellers of safe and readily available drugs, as this category of drugs is not considered a legitimate channel for pharmaceutical distribution. Therefore, option ③ is the correct answer.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Over-the-counter medicines can be sold through health consultations aimed at diagnosis.\n\nAccording to the Pharmaceutical Affairs Act, over-the-counter medicines can be sold without a prescription, but they cannot be sold through health consultations aimed at diagnosis. Health consultations aimed at diagnosis are only allowed for prescription medicines. Therefore, option ③ is incorrect.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 45 days | 6 months</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Thoroughly manage the renewal of product licenses and notifications for manufacturing and selling pharmaceuticals.\n\nThe \"Pharmaceutical Affairs Act\" requires pharmaceutical manufacturing managers to accurately manufacture products according to established standards (①), maintain hygienic facilities to prevent cross-contamination (②), ensure that harmful substances are not released from the work area (④), and conduct necessary tests and inspections throughout the production process (⑤). However, renewal of product licenses and notifications is not explicitly mentioned as a compliance requirement for pharmaceutical manufacturing managers under the \"Pharmaceutical Affairs Act.\" Therefore, the correct answer is ③.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Live attenuated vaccine injection for rabies prevention in dogs</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Dimethoxybromoamphetamine (DMBA)</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Transportation of narcotics for licensed narcotics handlers.\n\nAccording to the Narcotics Control Act, a person who is not a licensed narcotics handler can deal with narcotics in the case of transporting them for licensed narcotics handlers. This is because the transportation of narcotics is a necessary step in the distribution process, and it is allowed as long as it is done in accordance with the regulations and guidelines set forth by the authorities.\n\nThe other options are not correct because:\n\n① Cultivation of cannabis: While cannabis is a narcotic, it is not covered under the Narcotics Control Act.\n\n② Manufacturing of non-pharmacopoeial narcotics: This is not allowed for persons who are not licensed narcotics handlers.\n\n③ Compounding of psychotropic drugs: Compounding of psychotropic drugs is allowed only for licensed pharmacists, and not for persons who are not licensed narcotics handlers.\n\n⑤ Issuing a prescription containing psychotropic drugs: This is allowed only for licensed medical practitioners, and not for persons who are not licensed narcotics handlers.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Advertisements for alcoholic beverages can display content offering prizes and monetary rewards to promote sales to drinkers.\n\nThe National Health Promotion Act aims to promote healthy behaviors and prevent harmful habits, including excessive alcohol consumption. Offering prizes and monetary rewards in advertisements for alcoholic beverages may encourage people to consume more alcohol, which contradicts the purpose of the Act. Therefore, this statement is NOT correct.</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Selective listing</s>"
    },
    {
        "year": 2023,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Ordering pharmacy owners to commence operations.\n\nAccording to the Regional Public Health Act, public health centers do not have the authority to order pharmacy owners to commence operations. The Act does not provide public health centers with the power to direct pharmacy owners to start their businesses.\n\nThe other options are all functions or tasks that can be performed by public health centers according to the Regional Public Health Act:\n\n① Receiving closure reports from pharmaceutical manufacturers: Public health centers can receive reports from pharmaceutical manufacturers regarding the closure of their operations.\n\n③ Ordering narcotics managers to dispose of and take measures regarding narcotics: Public health centers can order narcotics managers to dispose of and take measures regarding narcotics in accordance with the Act.\n\n④ Monitoring and cracking down on narcotics handling by retail narcotics dealers: Public health centers are responsible for monitoring and cracking down on narcotics handling by retail narcotics dealers to ensure compliance with the Act.\n\n⑤ Ordering pharmacy owners to recall, dispose of, or take measures regarding pharmaceuticals: Public health centers can order pharmacy owners to recall, dispose of, or take measures regarding pharmaceuticals in accordance with the Act.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Collagen</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ hexokinase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ glycogen synthase kinase 3</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ malonate</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② cyanide</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③\n\nExplanation:\n\nDuring the β-oxidation of n-pentadecanoic acid (C15:0) in animal cells, the fatty acid is first activated to form a thioester with coenzyme A (CoA). This is followed by a series of β-oxidation reactions, which result in the sequential removal of two-carbon units from the fatty acid chain. Each β-oxidation reaction produces one molecule of propionyl-CoA.\n\nSince n-pentadecanoic acid (C15:0) has 15 carbon atoms, it will undergo 7 rounds of β-oxidation before the final product, acetyl-CoA, is formed. Therefore, the number of molecules of propionyl-CoA produced during the β-oxidation of one molecule of n-pentadecanoic acid (C15:0) is 7.\n\nThe correct answer is ③ 3.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② NADPH</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Glutamic acid</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Tryptophan</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Lysine acetylation</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Alternative splicing</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② ubiquitination</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ operator</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Calcium ion</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Isoleucine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Glycine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Glucagon-like peptide 1 (GLP-1)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ p21</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 19,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ β-hydroxy-β-methylglutaryl-CoA synthase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-1",
        "question_number": 20,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Increase | No change.\n\nExplanation:\n\nWhen compound X is added, it binds to enzyme Y, which results in a change in the enzyme's conformation and increases its affinity for the substrate mevalonic acid. This leads to an increase in the apparent Km, as the enzyme has a higher affinity for the substrate and requires a higher concentration of substrate to reach half-maximal activity. However, the apparent Vmax remains unchanged, as the maximum rate of the reaction is not affected by the presence of compound X. Therefore, the correct answer is ③ Increase | No change.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ It binds to Toll-like receptor 3 (TLR3).</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Staphylococcus aureus (Golden staph)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Clostridium botulinum</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Hepatitis B virus</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Epstein-Barr virus</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Trichomonas vaginalis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Vancomycin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Clavulanic acid</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② DNA gyrase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ IgG</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Dendritic cells</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① TAP</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ IL-12</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Multiple sclerosis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increase in the duration of antigen presentation.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Adalimumab</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Ritonavir</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-2",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Ganciclovir</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Adrenergic receptor</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ⑤ Erythromycin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Decrease in heart rate.\n\nThe parasympathetic nervous system is responsible for promoting relaxation and reducing stress. When it is stimulated, it can slow down the heart rate, which is a physiological response that helps to conserve energy and promote relaxation.\n\nTherefore, option ③ Decrease in heart rate is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Bronchial smooth muscle relaxation.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Buspirone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Venlafaxine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Perampanel</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② Rasagiline</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Naltrexone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Granisetron</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Rivaroxaban</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Doxazosin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Amiodarone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Eplerenone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Inhibition of ovulation</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Liraglutide</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① It interferes with folate metabolism.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Serotonin receptor</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-3",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Necitumumab</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Comprehensive health screening</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ 67%\n\nExplanation:\nThe false positive rate is the proportion of individuals who test positive but do not have the disease. In this case, the false positive rate can be calculated as follows:\n\nFalse positive rate = (45 / 135) x 100% = 33.33%\n\nTherefore, the correct answer is ③ 67%.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Benzene</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Radon</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Phosphorus</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Genus Crenothrix</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Glucuronidation</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nExplanation:\nSorivudine is metabolized by dihydropyrimidine dehydrogenase (DPD) to 5-fluorouracil (5-FU), which is then converted to the active metabolite 5-fluorouridine (5-FUrd) by thymidylate synthase. Tegafur, a prodrug of 5-FU, is also metabolized by DPD to 5-FU. When sorivudine and tegafur are co-administered, the blood concentration of 5-FU increases due to the inhibition of DPD by sorivudine, leading to a fatal accident. Therefore, the correct answer is ② dihydropyrimidine dehydrogenase.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ⑤ α-amanitin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Methylmercury</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ parathion</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ melamine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Selenium</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Wilson's disease</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Tryptophan</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① ciguatoxin</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② ochratoxin A</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Sodium nitrite</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 79,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Thiamine</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-4",
        "question_number": 80,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② aldehyde dehydrogenase.\n\nDisulfiram works by inhibiting aldehyde dehydrogenase, which is involved in the metabolism of alcohol. This inhibition leads to a buildup of acetaldehyde, a toxic compound that causes unpleasant symptoms such as nausea, vomiting, and headaches when alcohol is consumed. By inhibiting aldehyde dehydrogenase, disulfiram helps to deter the patient from drinking alcohol.\n\nTherefore, the correct answer is ② aldehyde dehydrogenase.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Cyclooxygenase</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Contact dermatitis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Proliferation of mutated cells.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Obstruction of lymphatic vessels</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Chronic Myeloid Leukemia (CML)</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Arterial wall hypertrophy</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Increased pulmonary capillary pressure</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 89,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Increased contractility of myocardial cells.\n\nIn angina pectoris, the heart rate increases as a compensatory mechanism to meet the increased oxygen demand of the myocardium. This increased oxygen demand is caused by the increased contractility of the myocardial cells, which results in increased myocardial oxygen consumption. Therefore, option ④ Increased contractility of myocardial cells is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 90,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Decrease in pulmonary capillary permeability.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 91,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Peptic ulcer</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 92,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Autoimmune hepatitis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 93,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Type A</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 94,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Pancreatitis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 95,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Pyelonephritis</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 96,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ BRCA1</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 97,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Aldosterone</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 98,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Macular edema</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 99,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Increased osteoclast activity.\n\nThe patient's long-term use of glucocorticoids and NSAIDs can lead to an imbalance in bone metabolism, resulting in increased bone resorption and decreased bone density. This is due to the inhibition of osteoblast activity and the stimulation of osteoclast activity, leading to an increase in bone resorption. Therefore, option ④ Increased osteoclast activity is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 1,
        "subject_id": "1-5",
        "question_number": 100,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Decreased risk of osteoporosis.\n\nRationale: Stopping glucocorticoids, which are known to cause bone loss, would likely decrease the risk of osteoporosis. The patient's bone density was already decreased, and continuing glucocorticoids would further increase the risk of osteoporosis. The other options do not relate to the scenario or the expected outcome of stopping glucocorticoids.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Cool below boiling point and inject at pressure higher than atmospheric pressure.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Eutectic mixture</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Osmotic pressure</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Circular dichroism spectroscopy</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Binding site of the drug</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Clathrate</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Shear thinning</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ 5\n\nExplanation:\n\nThe ionic strength of a solution is determined by the concentration of ions in the solution. Atropine sulfate is a weak electrolyte, meaning it partially dissociates in water to produce ions. Sodium chloride, on the other hand, is a strong electrolyte, meaning it completely dissociates in water to produce ions.\n\nThe molar concentration of atropine sulfate and sodium chloride solutions are equal (0.005 mol/L), but the number of ions produced by each molecule is different. Atropine sulfate produces one ion (Atropine sulfate → Atropine + Sulfate), while sodium chloride produces two ions (Sodium chloride → Sodium + Chloride).\n\nTherefore, the ionic strength of the atropine sulfate solution is lower than that of the sodium chloride solution. The correct answer is ④ 5, indicating that the ionic strength of the atropine sulfate solution is 5 times lower than that of the sodium chloride solution.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Azeotropic mixture</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 11/168</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 0.42</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ [HA]₀ / [A-]w</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Half-life of drug B × 2.303</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 10,000\n\nThe decomposition rate constant (k) is given as 1.05×10^-5 h^-1, and the initial concentration (C0) is 200 units/mL. To find the time (t) it takes for the concentration to reach 180 units/mL, we can use the equation:\n\nt = ln(C0/C) / k\n\nwhere C is the final concentration (180 units/mL).\n\nSubstituting the given values, we get:\n\nt = ln(200/180) / (1.05×10^-5 h^-1)\n\nt = 0.105 / (1.05×10^-5 h^-1)\n\nt = 10,000 hours\n\nTherefore, the answer is ③ 10,000.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② γ_S = γ_LS - γ_L cosθ</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 3.0×10^-5</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ C3/C2</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-1",
        "question_number": 18,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ KDm/hm (C1-C5)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ MR</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Sandmeyer reaction</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ pyridazine</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Oxybutynin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Diltiazem</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 26,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Ipratropium</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 27,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Friedel-Crafts acylation</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Furosemide</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ thiazole</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ① Zolpidem</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ① (a)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 35,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ (c)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-2",
        "question_number": 36,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ Inhibition of condensation reaction.\n\nExplanation:\n\nThe ternary complex formed by 5-F-dUMP with N5,N10-methylenetetrahydrofolate and thymidylate synthase irreversibly inhibits the function of thymidylate synthase by blocking the condensation reaction between dUMP and dTMP, which is essential for the synthesis of thymidine dimers. This inhibition occurs because the 5-F-dUMP molecule binds to the active site of thymidylate synthase, preventing the enzyme from catalyzing the condensation reaction. As a result, thymidylate synthase is irreversibly inhibited, leading to a decrease in the synthesis of thymidine dimers, which are essential for DNA replication and repair.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 6.4</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 6.7×10^-22</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Eriochrome Black T (EBT)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Br2 – Na2S2O3</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 137.1\n\nExplanation:\n\nThe amount of isoniazid can be calculated using the formula:\n\nAmount of isoniazid = (Titrant volume - Blank volume) x Molarity of titrant\n\nIn this case, the titrant volume is 10.5 mL (0.1 mol/L perchloric acid), and the blank volume is 0.5 mL (0.1 mol/L perchloric acid). The molarity of the titrant is 0.1 mol/L.\n\nTherefore, the amount of isoniazid can be calculated as follows:\n\nAmount of isoniazid = (10.5 - 0.5) x 0.1 = 10 x 0.1 = 1 mol\n\nSince the molecular weight of isoniazid is 137.1, the amount of isoniazid in mg can be calculated as follows:\n\nAmount of isoniazid (mg) = 1 mol x 137.1 g/mol = 137.1 g\n\nTherefore, the correct answer is ③ 137.1.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 20.0</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ -1.0°</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Difference in affinity for the stationary phase.\n\nThe chromatographic separation mechanism that can isolate only the proteins that bind to a specific antibody from a mixed sample using a stationary phase with the antibody covalently attached is called affinity chromatography. In this method, the antibody is immobilized on a stationary phase, and the sample is passed through the column. The proteins that bind to the antibody will have a higher affinity for the stationary phase and will be retained, while the other proteins will pass through the column and be eluted. Therefore, option ① Difference in affinity for the stationary phase is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Separation occurs due to differences in penetrability into the pores of the gel packed as the stationary phase.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Chloroform</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Systematic error has a consistent direction and magnitude.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① It is obtained using the method of least squares.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 53,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ 33\n\nThe resolution between the n-tricosane and pentobarbital peaks can be calculated using the formula:\n\nResolution = (Peak width of pentobarbital at baseline) / (Retention time of n-tricosane - Retention time of pentobarbital)\n\n= (0.080 min) / (5.2 min - 5.6 min)\n= 33\n\nTherefore, the correct answer is ③ 33.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-3",
        "question_number": 54,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② It responds to substances that produce ions when burned.\n\nThe correct answer is ②. The detector used in the gas chromatography method described in the question is a flame ionization detector, which responds to substances that produce ions when burned. This detector works by burning the sample in a flame and measuring the ions produced, which are then detected and recorded as a signal. Therefore, option ② is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Coulter counter method</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Propylene glycol</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ D</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Use a surfactant with a hydrophilic-lipophilic balance (HLB) value of 7-9.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ It can absorb water to form a w/o type emulsion.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Hypromellose</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ poly(lactide-co-glycolide)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Extract</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② When the pH of the dissolution medium is decreased.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Drugs with uniform absorption rates throughout the entire gastrointestinal tract.\n\nExplanation: Sustained-release tablets are designed to release the drug slowly as it passes through the gastrointestinal tract. For this to happen, the drug must have a uniform absorption rate throughout the entire gastrointestinal tract. Therefore, option ③ is the correct answer.\n\nOption ①, hydrophilic protein drugs, may not be suitable for sustained-release tablets because they may be degraded or denatured during the manufacturing process, which could affect their efficacy.\n\nOption ②, drugs that are degraded by digestive enzymes in the gastrointestinal tract, may not be suitable for sustained-release tablets because they would be broken down too quickly to provide sustained release.\n\nOption ④, drugs that are substrates of gastrointestinal efflux pumps, may not be suitable for sustained-release tablets because they may be actively transported out of the gastrointestinal tract, which could limit their bioavailability.\n\nOption ⑤, drugs with high dosages that may result in tablets too large to swallow comfortably, may not be suitable for sustained-release tablets because the large size of the tablet may make it difficult for patients to swallow and may not provide consistent release of the drug.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ It creates temporary pores in the stratum corneum to promote drug penetration through the skin.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ The unstirred water layer on the gastrointestinal membrane surface inhibits the absorption of highly lipophilic drugs.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Binding to plasma proteins decreases the rate of drug transfer to tissues.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ①</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 75\n\nExplanation:\nThe total amount of drug A excreted in urine can be calculated using the equation:\nTotal amount excreted = (Dose administered x CLr) / (CL + CLr)\n\nSubstituting the given values:\nTotal amount excreted = (100 mg x 7.5 L/h) / (10 L/h + 7.5 L/h)\nTotal amount excreted = 75 mg\n\nTherefore, the correct answer is ④ 75.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Absorption rate constant (ka)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 71,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Promoting the formation of the coating film.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-4",
        "question_number": 72,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ It is a pseudolatex dispersion that can be used in pan coating methods.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ kuwanon G</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② capsaicinoid</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ flavonoid</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Opium powder (阿片末)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② glycyrrhizin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ reserpine</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Dioscoreae Rhizoma</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Laxative action</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Apricot kernel (Armeniacae semen)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ hesperidin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ icariin</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 84,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Ephedra (麻黃)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 85,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Kidney (腎臟)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 86,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Qi transformation function (氣化作用)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 87,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Angelica dahurica root (白芷)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 88,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Ssanghwa-tang (Shuang Hua Tang, 雙和湯)</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 89,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Shikimate pathway\n\nThe compounds identified in the question are all derived from the shikimate pathway. Tanshinone I, artemisinin, ginkgolide A, and ursolic acid are all synthesized through the shikimate pathway, which is a metabolic pathway that produces aromatic amino acids and other compounds.\n\nTherefore, the correct answer is ③ Shikimate pathway.</s>"
    },
    {
        "year": 2024,
        "session": 2,
        "subject_id": "2-5",
        "question_number": 90,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ④ tanshinone I\n\nExplanation:\n\nα-Santonin is a sesquiterpene, which means it has a basic skeleton of three isoprene units (C5) linked together. Tanshinone I, which is found in Salvia miltiorrhiza, also has a sesquiterpene skeleton and contains three isoprene units. Therefore, tanshinone I has the same number of carbon atoms in its basic skeleton as α-santonin.\n\nThe other options do not have the same number of carbon atoms in their basic skeleton as α-santonin:\n\n* Artemisinin (①) is a monoterpene, which means it has a basic skeleton of two isoprene units (C5) linked together. It has one fewer isoprene unit than α-santonin.\n* Ginkgolide A (②) is a triterpene, which means it has a basic skeleton of three isoprene units (C5) linked together, but it also has a side chain that contains additional carbon atoms.\n* (-)-Menthol (③) is a monoterpene, which means it has a basic skeleton of two isoprene units (C5) linked together. It has one fewer isoprene unit than α-santonin.\n* Ursolic acid (⑤) is a pentacyclic triterpene, which means it has a basic skeleton of five isoprene units (C5) linked together. It has two more isoprene units than α-santonin.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Verapamil + Valsartan\n\nRationale:\n\nThe patient's hypertension is severe (162/127 mmHg) and uncontrolled, and she has a history of dyslipidemia and severe chronic constipation. The patient's age and family history (father died of myocardial infarction at age 50) also suggest a high risk for cardiovascular disease.\n\nVerapamil, a calcium channel blocker, is an appropriate choice for blood pressure control in this patient. It has a vasodilatory effect on the peripheral vasculature and can reduce the heart rate, which is elevated in this patient. Valsartan, an angiotensin II receptor antagonist, can also contribute to blood pressure control and has a beneficial effect on the kidneys.\n\nThe other options may not be the most appropriate choices for this patient. Ramipril, an ACE inhibitor, may not be effective in lowering blood pressure as quickly as verapamil and valsartan. Hydrochlorothiazide, a diuretic, may not be effective in lowering blood pressure in the absence of fluid retention. Candesartan, an angiotensin II receptor antagonist, and lercanidipine, a calcium channel blocker, may have a similar effect on blood pressure as verapamil and valsartan, but they may not have the same beneficial effects on the kidneys. Hydralazine and isosorbide dinitrate, a combination of a vasodilator and a nitrate, may be effective in lowering blood pressure, but they may not be the most appropriate choice for this patient due to the potential for side effects and drug interactions.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Empagliflozin.\n\nRationale:\n\nThe patient has heart failure with reduced ejection fraction (HFrEF), and the goal of treatment is to reduce the risk of hospitalization due to heart failure and the risk of death from cardiovascular disease. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been shown to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with HFrEF, on top of standard of care, which includes medications like bisoprolol, furosemide, spironolactone, and sacubitril/valsartan.\n\nDigoxin, verapamil, and ivabradine are not indicated for the management of heart failure with reduced ejection fraction. Hydralazine may be used in combination with other medications to treat severe hypertension, but it is not a first-line medication for heart failure.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 3,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ After 12 hours</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 4,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 180 mg</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Clopidogrel.\n\nRationale: Clopidogrel is an ADP receptor antagonist that inhibits platelet activation and aggregation. It is commonly used in combination with aspirin in patients with NSTE-ACS to reduce the risk of cardiovascular events. The patient's history of dyslipidemia and gastroesophageal reflux disease does not contraindicate the use of clopidogrel. Tirofiban and abciximab are glycoprotein IIb/IIIa inhibitors that are also used in the management of NSTE-ACS, but they are typically used in more severe cases or in patients with a higher risk of cardiovascular events. Alteplase is a thrombolytic agent that is used to dissolve blood clots, but it is not typically used in the management of NSTE-ACS. Prasugrel is another ADP receptor antagonist that is used in patients with NSTE-ACS, but it has a more rapid onset of action and may be less suitable for this patient's condition.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Nadolol</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Aspirin + Clopidogrel</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Alteplase</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Pravastatin 10 mg once daily.\n\nRationale:\n\nThe patient's dyslipidemia is characterized by elevated LDL-C and TG levels, and low HDL-C levels. Pravastatin is a HMG-CoA reductase inhibitor that effectively reduces LDL-C and TG levels, and increases HDL-C levels. It is also well-tolerated and has a good safety profile.\n\nThe other options are not the most appropriate choices for this patient's dyslipidemia:\n\n① Lovastatin is a HMG-CoA reductase inhibitor that is less potent than pravastatin and may not effectively reduce the patient's elevated LDL-C and TG levels.\n\n② Simvastatin is a HMG-CoA reductase inhibitor that is similar to pravastatin in terms of efficacy, but it has a higher risk of muscle toxicity and interacts with many drugs, including cyclosporine, which the patient is currently taking.\n\n③ Pitavastatin is a HMG-CoA reductase inhibitor that is less potent than pravastatin and may not effectively reduce the patient's elevated LDL-C and TG levels.\n\n⑤ Rosuvastatin is a HMG-CoA reductase inhibitor that is more potent than pravastatin, but it may not be necessary for this patient's mild to moderate dyslipidemia, and it may increase the risk of muscle toxicity.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Verapamil</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Dalteparin</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 12,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Lisinopril.\n\nLisinopril is an ACE inhibitor, which can cause an increase in serum creatinine levels, particularly in patients with pre-existing kidney disease, such as diabetic nephropathy. The patient's serum creatinine level has increased from 1.4 mg/dL to 1.9 mg/dL, indicating a 35% increase, which is a significant change. This increase is likely due to the Lisinopril, as it is the only medication that has been shown to affect renal function.\n\nThe other medications, Tamsulosin, Teneligliptin, Pioglitazone, and Atorvastatin, are not known to cause significant changes in serum creatinine levels.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 13,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Add alirocumab.\n\nRationale:\n\nThe patient's LDL-C level is still elevated (110 mg/dL) despite being on atorvastatin 80 mg once daily, which suggests that the patient may benefit from additional LDL-lowering therapy. Alirocumab is a PCSK9 inhibitor that has been shown to effectively lower LDL-C levels in patients with hypercholesterolemia, and it can be used in combination with statins.\n\nTherefore, adding alirocumab to the patient's current regimen would be an appropriate treatment plan for managing his blood cholesterol levels.\n\nThe other options are not the best choices for the following reasons:\n\n① Maintaining current drug therapy may not be sufficient to achieve the patient's LDL-C goal.\n\n② Ezetimibe is a cholesterol absorption inhibitor that can be used in combination with statins, but it may not be as effective as alirocumab in lowering LDL-C levels in this patient.\n\n④ Changing atorvastatin to evolocumab, a PCSK9 inhibitor, may be a viable option, but it is not the most appropriate choice given the patient's current regimen and medical history.\n\n⑤ Changing atorvastatin to fenofibrate, a fibric acid derivative, may be appropriate for managing the patient's dyslipidemia, but it would not address the patient's elevated LDL-C levels specifically.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 14,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Metoprolol.\n\nRationale: Metoprolol is a beta-blocker that can effectively control heart rate in patients with atrial fibrillation. It is also commonly used to treat hypertension, angina, and heart failure. In this case, the patient has non-valvular atrial fibrillation, and the goal of treatment is to control the heart rate to prevent palpitations, fatigue, and shortness of breath. Metoprolol is a suitable choice for heart rate control in this patient, as it has a proven efficacy and safety profile in this indication.\n\nThe other options may not be the most appropriate choices for heart rate control in this patient:\n\n① Sotalol is a beta-blocker that is also used for heart rate control, but it has a greater risk of proarrhythmia in patients with atrial fibrillation.\n\n② Verapamil is a calcium channel blocker that can slow the heart rate, but it may not be as effective as a beta-blocker in controlling heart rate in patients with atrial fibrillation.\n\n④ Nicardipine is a calcium channel blocker that can slow the heart rate, but it may not be as effective as a beta-blocker in controlling heart rate in patients with atrial fibrillation.\n\n⑤ Spironolactone is a potassium-sparing diuretic that can reduce the risk of atrial fibrillation, but it is not primarily used for heart rate control.\n\nTherefore, the correct answer is ③ Metoprolol.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 15,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Amiodarone.\n\nRationale: Amiodarone is an anti-arrhythmic drug that is effective in converting atrial fibrillation (AF) to sinus rhythm. It has a class III anti-arrhythmic effect, which means it can slow the ventricular response and control the heart rate. In addition, amiodarone has a long half-life, which makes it a good choice for maintaining sinus rhythm over a prolonged period.\n\nDiltiazem and verapamil are calcium channel blockers that can slow the heart rate but are not as effective in converting AF to sinus rhythm as amiodarone. Ivabradine is a \"pure\" sinus node modifier that can slow the heart rate by selectively blocking the \"funny\" channels in the sinus node. However, it may not be effective in converting AF to sinus rhythm. Propafenone is a class IC anti-arrhythmic drug that can convert AF to sinus rhythm, but it has a shorter half-life than amiodarone and may require more frequent dosing. Dronedarone is a class III anti-arrhythmic drug that can convert AF to sinus rhythm, but it has a slower onset of action compared to amiodarone.\n\nTherefore, of the options provided, amiodarone is the most appropriate drug for converting to sinus rhythm in this patient.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 16,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Change fluticasone/salmeterol to mepolizumab.\n\nRationale:\n\nThe patient's poorly controlled asthma symptoms and recent exacerbations suggest that their current treatment plan is not effectively managing their disease. Mepolizumab, a monoclonal antibody that targets IL-5, may be an appropriate addition to the patient's treatment plan. Mepolizumab has been shown to reduce asthma exacerbations and improve lung function in patients with severe asthma.\n\nChanging fluticasone/salmeterol to mepolizumab addresses the patient's poor asthma control and provides an opportunity for improved disease management. The patient's elevated IgE levels and eosinophil count suggest that there is still an inflammatory component to their disease, which mepolizumab can help address.\n\nThe other options do not address the patient's poor asthma control and may not provide adequate relief for their symptoms. Adding galcanezumab, another monoclonal antibody that targets IL-5, may have a similar effect as mepolizumab, but there is no clear indication to support this option. Changing fluticasone/salmeterol to galcanezumab or subcutaneous immunotherapy may not effectively address the patient's inflammatory component and may not provide adequate relief for their symptoms. Adding mepolizumab is a more targeted approach to addressing the patient's disease severity and poor control.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 17,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Serum Immunoglobulin E (IgE)</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Azithromycin oral tablet.\n\nRationale: The patient's symptoms of sudden worsening of cough and dyspnea, along with the presence of purulent sputum, suggest an acute exacerbation of COPD. The appropriate medication to be administered in this case, in addition to oral steroids, is an antibiotic, as there is likely a bacterial infection present. Azithromycin is a macrolide antibiotic that is commonly used to treat respiratory infections, including those associated with COPD exacerbations. It is effective against a wide range of bacterial pathogens, including Haemophilus influenzae and Streptococcus pneumoniae, which are commonly isolated from patients with COPD exacerbations.\n\nIndacaterol and ciclesonide are both bronchodilators, which may be useful in managing the patient's chronic COPD symptoms, but they are not appropriate for treating an acute exacerbation. Montelukast is a leukotriene receptor antagonist, which may be useful in managing chronic COPD symptoms, but it is not effective against bacterial infections. Roflumilast is a phosphodiesterase-4 inhibitor, which may be useful in managing chronic COPD symptoms, but it is not effective against bacterial infections and may not be appropriate for acute exacerbations.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Change aclidinium inhaler to formoterol/aclidinium.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Add xylometazoline nasal spray.\n\nRationale: Xylometazoline is a nasal vasoconstrictor that can help to reduce nasal congestion and relieve symptoms of allergic rhinitis such as runny nose and sneezing. It can be used in combination with fluticasone, a corticosteroid, which is effective in reducing inflammation and swelling in the nasal passages. The addition of xylometazoline can provide quick relief of symptoms without the need for oral medication.\n\nTherefore, option ③ Add xylometazoline nasal spray is the appropriate drug therapy plan.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 14 days.\n\nThe appropriate duration of treatment for Helicobacter pylori eradication therapy is typically 14 days. This is because the bacteria have a relatively slow growth rate, and a longer treatment duration is needed to ensure that all of the bacteria are eliminated. A shorter treatment duration, such as 3, 5, or 7 days, may not be sufficient to eradicate the infection completely, and may result in a higher risk of treatment failure. A longer treatment duration, such as 28 days, may be unnecessary and may increase the risk of adverse effects. Therefore, 14 days is the most appropriate duration of treatment for Helicobacter pylori eradication therapy.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Bethanechol</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Lactulose.\n\nRationale: Lactulose is a laxative that can help reduce the risk of renal damage in patients with liver cirrhosis and spontaneous bacterial peritonitis by reducing the absorption of ammonia in the gut. It can also help reduce the risk of hepatic encephalopathy, a common complication in patients with liver cirrhosis.\n\nAlbumin (①) is not the best choice because it is not effective in preventing renal damage or reducing the risk of mortality in patients with spontaneous bacterial peritonitis.\n\nGentamicin (③) is an antibiotic that can be used to treat bacterial infections, but it is not specifically indicated for the prevention of renal damage or reduction of mortality in patients with spontaneous bacterial peritonitis.\n\nPropranolol (④) is a beta-blocker that can be used to treat certain cardiovascular conditions, but it is not relevant to the management of spontaneous bacterial peritonitis or renal damage.\n\nTerlipressin (⑤) is a vasopressin receptor agonist that can be used to treat certain gastrointestinal conditions, but it is not indicated for the management of spontaneous bacterial peritonitis or renal damage.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Prucalopride.\n\nRationale: Prucalopride is a serotonin receptor agonist that is specifically approved for the treatment of chronic constipation in patients with Parkinson's disease. It helps to increase the frequency of bowel movements and reduce the difficulty of defecation. In this case, the patient has not responded to other laxatives, and adding prucalopride may be an appropriate next step.\n\nDoxepin (①) is an antidepressant that can have a side effect of constipation, so it is not appropriate for this patient. Ramosetron (②) is a serotonin receptor antagonist that is used to treat irritable bowel syndrome, but it is not specifically approved for constipation in Parkinson's disease. Trimebutine (③) is a serotonin receptor agonist that is used to treat irritable bowel syndrome, but it has not been shown to be effective in Parkinson's disease. Metoclopramide (⑤) is a dopamine receptor agonist that can help with gastrointestinal motility, but it is not specifically approved for constipation in Parkinson's disease.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Vedolizumab injection + oral tofacitinib</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Sofosbuvir/velpatasvir for 12 weeks.\n\nExplanation:\n\nThe patient has compensated cirrhosis and genotype 1b HCV, which is considered a mild to moderate fibrosis. The NS5A resistance genotype is negative, indicating that the patient is likely to respond well to Sofosbuvir-based therapy. Sofosbuvir/velpatasvir is a recommended regimen for genotype 1b HCV, and 12 weeks of treatment is the recommended duration for patients with compensated cirrhosis.\n\nGlecaprevir/pibrentasvir is a recommended regimen for genotype 1 HCV, but it is not recommended for genotype 1b. Sofosbuvir + ribavirin is a less effective regimen for genotype 1b HCV, and 8 weeks of treatment may not be sufficient for optimal response. Tenofovir + besifovir is not a recommended regimen for HCV treatment. Entecavir + ledipasvir/sofosbuvir is a recommended regimen for HBV, but not for HCV.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ② Administer hepatitis B vaccine.\n\nExplanation:\nThe patient has been diagnosed with hepatitis C, and the clinical test results show that they are positive for anti-HBs and negative for HBsAg and anti-HBc. This indicates that the patient has been previously exposed to hepatitis B virus (HBV) and has developed immunity against it. However, the patient is still at risk of contracting HBV again, as they have compensated cirrhosis, which can weaken their immune system.\n\nTherefore, to prevent future HBV infections, it is appropriate to administer a hepatitis B vaccine to the patient. This will help to boost their immunity against HBV and reduce the risk of future infections.\n\nThe other options are not appropriate for the following reasons:\n\n① No preventive measures necessary: This option is not appropriate because the patient is still at risk of contracting HBV, and it is important to take preventive measures to protect them from future infections.\n\n③ Administer subcutaneous injection of interferon beta: Interferon beta is a medication that is used to treat HBV infections, but it is not appropriate for preventing future infections.\n\n④ Administer intravenous injection of hepatitis B immunoglobulin: Hepatitis B immunoglobulin (HBIG) is a medication that is used to prevent HBV infections in people who have been exposed to the virus. However, it is not appropriate in this case because the patient has already been exposed to HBV and has developed immunity against it.\n\n⑤ Administer hepatitis B vaccine + intravenous injection of hepatitis B immunoglobulin: This option is not necessary because the patient has already developed immunity against HBV, and the hepatitis B vaccine alone is sufficient to boost their immunity and protect them from future infections.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Amiloride.\n\nExplanation:\n\nThe patient has nephrogenic diabetes insipidus (NDI) and is currently taking lithium carbonate, which is a known cause of NDI. The lithium carbonate has been discontinued, and 5% glucose solution is being administered intravenously to treat the hypernatremia. However, the patient's urine output is still high (4,500 mL/24 hours), indicating that the NDI is still present.\n\nAmiloride is a potassium-sparing diuretic that can help reduce urine output and increase potassium levels in patients with NDI. It is an appropriate additional medication to consider in this case, as it can help manage the patient's NDI and hypernatremia.\n\nTolvaptan is a vasopressin receptor antagonist that can help reduce urine output and increase sodium levels in patients with NDI. However, it is not as effective in reducing urine output as amiloride and may not be as appropriate for this patient's high urine output.\n\nLisinopril is an ACE inhibitor that can help reduce blood pressure and proteinuria in patients with diabetes insipidus. However, it is not specifically indicated for NDI and may not be as effective in managing the patient's hypernatremia.\n\nFurosemide is a loop diuretic that can help reduce urine output and increase sodium levels in patients with NDI. However, it may not be as effective in reducing urine output as amiloride and may cause further electrolyte imbalances.\n\nCalcium polystyrene sulfonate is a cation-exchange resin that can help remove potassium from the gut and reduce serum potassium levels. However, it is not specifically indicated for NDI and may not be as effective in managing the patient's hypernatremia.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ⑤ Hydrochlorothiazide.\n\nRationale:\n\nThe patient's recent diagnosis of chronic kidney disease (CKD) and the laboratory results showing a decreased estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73m^2 indicate that the patient's kidneys are not functioning properly. Hydrochlorothiazide, a diuretic, can further decrease renal function and increase the risk of kidney damage in patients with CKD. Therefore, it would be appropriate to reduce the dosage of hydrochlorothiazide to avoid exacerbating the patient's kidney disease.\n\nThe other medications, losartan, saxagliptin, lobeglitazone, and rosuvastatin, are not necessarily contraindicated in patients with CKD, but hydrochlorothiazide is the medication that should be reduced in dosage given the patient's current condition.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Iron sucrose administration</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④ Tocilizumab.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 32,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Furosemide.\n\nRationale: The patient's severe swelling in his feet and weight gain suggest nephrotic syndrome, which is supported by the high urine albumin-to-creatinine ratio (ACR) of 122 mg/g. The patient's eGFR of 24 mL/min/1.73m^2 indicates chronic kidney disease (CKD) stage 3b.\n\nFurosemide, a loop diuretic, is the most appropriate medication to add to the patient's regimen to improve his symptoms. It will increase urine production, reduce fluid retention, and help manage nephrotic syndrome.\n\nMannitol (①) is an osmotic diuretic that may be used to reduce intracranial pressure in conditions such as stroke or brain tumor, but it is not appropriate for nephrotic syndrome.\n\nRamipril (②) is an ACE inhibitor that may be used to slow the progression of CKD, but it is not directly related to the patient's current symptoms.\n\nSpironolactone (④) is a potassium-sparing diuretic that may be used to treat hypokalemia, but it is not the most appropriate medication for nephrotic syndrome.\n\nHydrochlorothiazide (⑤) is a thiazide diuretic that may be used to treat hypertension, but it is not the most appropriate medication for nephrotic syndrome.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 33,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ① Sevelamer</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Change metformin to nateglinide.\n\nRationale:\n\nThe patient's HbA1c level of 7.3% indicates that her diabetes is not well-controlled. Metformin, which she is currently taking, is a first-line medication for type 2 diabetes. However, it may not be effective enough to control her blood sugar levels, especially in combination with her unstable angina and renal impairment (eGFR 73 mL/min/1.73m^2).\n\nNateglinide, a rapid-acting sulfonylurea, may be a better option for this patient. It has a shorter duration of action compared to other sulfonylureas, which may help to minimize the risk of hypoglycemia in a patient with unstable angina. Additionally, nateglinide has been shown to improve glycemic control and reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.\n\nIn contrast, acarbose (②) and dulaglutide (③) are not appropriate options for this patient. Acarbose is an alpha-glucosidase inhibitor that slows the absorption of glucose from the gut, but it may not be effective in lowering blood glucose levels in patients with renal impairment. Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used for the treatment of type 2 diabetes, but it may not be appropriate for this patient due to its potential to increase the risk of pancreatitis and thyroid C-cell tumors.\n\nIncreasing the dose of metformin (①) may not be effective in lowering blood glucose levels, especially if the patient's kidney function is declining. Ertugliflozin (⑤) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is used for the treatment of type 2 diabetes, but it may not be appropriate for this patient due to its potential to increase the risk of genital infections and diabetic ketoacidosis.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Increase the morning dose of insulin lispro.\n\nRationale:\nThe patient's blood glucose levels show a consistent pattern of hyperglycemia after meals, indicating a need for increased insulin dosage. The morning dose of insulin lispro should be increased to cover the breakfast meal, as the patient's blood glucose level is consistently low before breakfast. This will help to prevent hyperglycemia and maintain optimal blood glucose control.\n\nThe other options are not appropriate for the following reasons:\n\n① Maintaining the current medication regimen would not address the patient's hyperglycemia after meals.\n\n② Decreasing the dose of insulin glargine would not address the patient's hyperglycemia after meals and may lead to hypoglycemia.\n\n④ Increasing the evening dose of insulin lispro would not address the patient's hyperglycemia after breakfast.\n\n⑤ Changing the administration time of insulin glargine to bedtime would not address the patient's hyperglycemia after meals and may disrupt the patient's sleep.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Dapagliflozin.\n\nRationale:\n\nThe patient's HbA1c level has increased from 6.5% to 6.8% despite current treatment with glimepiride, indicating inadequate glycemic control. The patient also has albuminuria (ACR 45 mg/g), which suggests diabetic kidney disease. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, can help improve glycemic control and reduce the risk of albuminuria progression. It is also less likely to cause hypoglycemia compared to other options like metformin or repaglinide, which could be beneficial in a patient with hypertension and chronic kidney disease. Voglibose and lobeglitazone are not typically used as first-line treatments for type 2 diabetes, and their efficacy in reducing albuminuria is not well established. Atorvastatin, a lipid-lowering medication, is not directly related to diabetes management.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 37,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Pioglitazone.\n\nPioglitazone is a medication used to treat type 2 diabetes and is known to cause weight gain as a side effect. The patient's weight gain of 4 kg in the past month is consistent with this side effect. Additionally, pioglitazone can cause an increase in BNP (B-type natriuretic peptide) levels, which is a marker of cardiac strain. The patient's BNP level has increased from 97 pg/mL to 187 pg/mL, which may indicate that the patient's heart is under increased strain. The patient's decreased LVEF (left ventricular ejection fraction) of 40% compared to 55% one year ago may also be a sign of cardiac dysfunction. These abnormal findings in today's clinical tests may be related to the patient's use of pioglitazone.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 38,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ Octreotide.\n\nRationale: Octreotide is a somatostatin analog that can help control symptoms of diabetic autonomic neuropathy, such as nausea, vomiting, and gastroparesis, by reducing the release of acetylcholine from the neurons in the gut. It is commonly used to treat gastrointestinal symptoms associated with diabetic neuropathy.\n\nThe other options are not as appropriate for controlling symptoms of diabetic autonomic neuropathy:\n\n① Bethanechol is a cholinergic agent that can increase the release of acetylcholine, which may worsen symptoms of diabetic autonomic neuropathy.\n\n② Domperidone is a dopamine receptor antagonist that can help with gastrointestinal symptoms, but it is not specifically used to treat diabetic autonomic neuropathy.\n\n④ Misoprostol is a prostaglandin analog that can help protect the stomach lining and reduce inflammation, but it is not directly related to the treatment of diabetic autonomic neuropathy.\n\n⑤ Metronidazole is an antibiotic that is used to treat bacterial infections, but it is not related to the treatment of diabetic autonomic neuropathy.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 39,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Diazepam.\n\nRationale: Diazepam is a benzodiazepine that acts quickly to alleviate anxiety symptoms by enhancing the activity of the neurotransmitter GABA, which has a calming effect on the nervous system. It is commonly used to treat anxiety disorders and can provide rapid relief of symptoms. The other options, bupropion, pregabalin, risperidone, and imipramine, may also be used to treat anxiety disorders, but they may take longer to take effect and may have different mechanisms of action. In this case, the patient is already taking methimazole and propranolol, and diazepam may be a good option to quickly alleviate anxiety symptoms without interacting with the patient's current medications.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 40,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Complete blood count.\n\nRationale: Methimazole can cause agranulocytosis, a condition where the white blood cell count drops significantly. A complete blood count (CBC) would help determine if the patient's fever and sore throat are caused by agranulocytosis, which is a known adverse reaction to methimazole. The other options are not directly related to the patient's symptoms or the suspected adverse reaction to methimazole.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 10 days.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Doxycycline</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Amoxicillin</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 44,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Ethambutol\n\nExplanation:\n\nThe patient developed hepatotoxicity after one month of drug treatment, and the liver enzymes AST and ALT increased significantly. After stopping the medications, the liver enzymes decreased, but still remain slightly elevated three weeks later.\n\nEthambutol is known to cause hepatotoxicity, especially when used in high doses or for extended periods. Therefore, it would be wise to avoid restarting Ethambutol therapy, considering the patient's history of hepatotoxicity.\n\nThe other options are not necessarily related to the patient's hepatotoxicity issue:\n\n① Pyridoxine is a B-complex vitamin that is often used to treat peripheral neuropathy caused by isoniazid. It is not directly related to the patient's hepatotoxicity.\n\n② Rifampicin is an antibiotic that is effective against Mycobacterium tuberculosis. It is not known to cause hepatotoxicity.\n\n④ Isoniazid is an antibiotic that is effective against Mycobacterium tuberculosis. It can cause hepatotoxicity, but the patient's liver enzymes have already returned to almost normal levels, suggesting that isoniazid is unlikely to be the cause of the hepatotoxicity.\n\n⑤ Pyrazinamide is an antibiotic that is effective against Mycobacterium tuberculosis. It is not known to cause hepatotoxicity.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 45,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Dexamethasone</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ampicillin + Cefotaxime.\n\nReasoning:\n\nThe patient is a 5-day-old newborn with a bacterial infection, and the vital signs and blood test results indicate that the infection is severe. The patient's young age and the presence of meningitis (as indicated by the cerebrospinal fluid test results) suggest that the infection is likely to be caused by a gram-positive bacterium, such as Streptococcus pneumoniae or Haemophilus influenzae type b (Hib).\n\nAmpicillin is a penicillin-type antibiotic that is effective against a wide range of gram-positive bacteria, including Streptococcus pneumoniae and Hib. Cefotaxime is a cephalosporin-type antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, including many strains of Streptococcus pneumoniae and Hib. The combination of Ampicillin and Cefotaxime provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, making it an appropriate empirical antimicrobial therapy for a 5-day-old newborn with a severe bacterial infection.\n\nTigecycline (①) is a glycylcycline-type antibiotic that is effective against a wide range of gram-positive and gram-negative bacteria, but it is not approved for use in neonates. Sulfamethoxazole/Trimethoprim (②) is a combination antibiotic that is effective against a wide range of gram-negative bacteria, but it is not effective against Streptococcus pneumoniae or Hib. Vancomycin + Metronidazole (④) is a combination of an aminoglycoside and a nitroimidazole antibiotic, which is effective against a wide range of gram-positive and gram-negative bacteria, but it is not appropriate for empirical therapy in a 5-day-old newborn with a bacterial infection. Cefoxitin + Ciprofloxacin (⑤) is a combination of a cephamycin-type antibiotic and a fluoroquinolone-type antibiotic, which provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, but it is not approved for use in neonates.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Terbinafine cream</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hypokalemia</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ④ Ampicillin intravenous injection + Daptomycin intravenous injection.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 50,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Cefepime + Ciprofloxacin + Vancomycin.\n\nRationale:\n\nThe patient has ventilator-associated pneumonia (VAP), which is a serious infection that requires broad-spectrum antibiotics. The choice of antibiotics should cover both gram-positive and gram-negative bacteria, as well as methicillin-resistant Staphylococcus aureus (MRSA).\n\nCefepime is a broad-spectrum cephalosporin that covers gram-negative bacteria, including Pseudomonas aeruginosa, which is commonly isolated in VAP. Ciprofloxacin is a fluoroquinolone that covers gram-negative bacteria and is effective against Pseudomonas aeruginosa. Vancomycin is a glycopeptide that covers gram-positive bacteria, including MRSA.\n\nPiperacillin/tazobactam is a combination of a penicillin-derivative and a beta-lactamase inhibitor that covers gram-negative bacteria, but it may not be effective against Pseudomonas aeruginosa. Levofloxacin is a fluoroquinolone that covers gram-negative bacteria, but it may not be effective against MRSA. Tobramycin is an aminoglycoside that covers gram-negative bacteria, but it may not be effective against Pseudomonas aeruginosa.\n\nTherefore, the combination of Cefepime, Ciprofloxacin, and Vancomycin provides broad-spectrum coverage against both gram-positive and gram-negative bacteria, including MRSA, which is the most appropriate empirical antimicrobial therapy for ventilator-associated pneumonia.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 51,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ③ Atorvastatin.\n\nLinezolid is a reversible inhibitor of CYP3A4, and Atorvastatin is metabolized by CYP3A4. Co-administration of linezolid and Atorvastatin may result in increased plasma concentrations of Atorvastatin, increasing the risk of adverse effects such as myopathy and rhabdomyolysis. Therefore, it is necessary to monitor the patient closely and adjust the dose of Atorvastatin accordingly.\n\nThe other options do not have significant interactions with linezolid:\n\n① Lisinopril is metabolized by CYP3A4, but linezolid is not a strong inhibitor of CYP3A4, and the interaction is not likely to be clinically significant.\n\n② Tiotropium is not metabolized by CYP3A4 and does not have a significant interaction with linezolid.\n\n④ Escitalopram is metabolized by CYP3A4, but linezolid is not a strong inhibitor of CYP3A4, and the interaction is not likely to be clinically significant.\n\n⑤ Hydrochlorothiazide is not metabolized by CYP3A4 and does not have a significant interaction with linezolid.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Zolmitriptan</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Zonisamide.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Amitriptyline</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Entacapone</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Seizures</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Hypertriglyceridemia</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Switch fluoxetine to sertraline</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 59,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Ethosuximide</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 60,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Lamotrigine.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Paroxetine.\n\nRationale: Paroxetine, a selective serotonin reuptake inhibitor (SSRI), can increase the risk of gastrointestinal bleeding when taken with naproxen, a nonsteroidal anti-inflammatory drug (NSAID). This is because SSRIs can inhibit the activity of platelet serotonin, which plays a role in platelet aggregation and clotting. Additionally, naproxen can also increase the risk of gastrointestinal bleeding due to its irritating effect on the stomach lining. Therefore, the combination of paroxetine and naproxen may further increase the risk of gastrointestinal bleeding.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 62,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Baricitinib</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 63,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Administer 1.2 mg, followed by 0.6 mg after 1 hour.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Aceclofenac.\n\nAceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that can potentially worsen urinary incontinence due to its effect on the bladder and urinary tract. It may reduce the tone of the detrusor muscle, leading to urinary retention or worsening of incontinence.\n\nThe other options are not likely to worsen urinary incontinence:\n\n① Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease and has no known effect on urinary incontinence.\n\n② Vitamin D is a nutritional supplement that is not known to affect urinary incontinence.\n\n③ Risedronic acid is a bisphosphonate used to treat osteoporosis and has no known effect on urinary incontinence.\n\n⑤ Triamcinolone is a corticosteroid used to treat inflammatory conditions, and its effect on urinary incontinence is not well established. However, it is not likely to worsen urinary incontinence.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 65,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Carbamazepine</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 66,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① Raloxifene</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Doxorubicin</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Tamoxifen</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ EGFR mutation</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Cisplatin + Ifosfamide</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ② Oxaliplatin</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Pembrolizumab.\n\nReasoning:\n\nThe patient's diagnosis of stage 4 colon cancer with metastases to the liver and lungs, along with a negative KRAS, NRAS, and BRAF mutation status, indicates that they are unlikely to benefit from targeted therapies such as regorafenib (①) or pertuzumab + trastuzumab (⑤).\n\ndMMR/MSI-H status suggests that the patient's cancer may be more likely to respond to immunotherapy. Pembrolizumab (②) is an immune checkpoint inhibitor that has been approved for the treatment of MSI-H colorectal cancer, and is therefore the most appropriate first-line chemotherapy option for this patient.\n\nZiv-aflibercept (③) is an anti-angiogenic agent that may be considered for patients with colon cancer, but is not the most appropriate option for this patient given their dMMR/MSI-H status. Trifluridine/tipiracil (④) is a chemotherapy regimen that may be considered for patients with metastatic colorectal cancer, but is not targeted to the patient's specific genetic mutations.</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 73,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ② High-dose cytarabine + daunorubicin</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 74,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Dexrazoxane injection</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Triamcinolone acetonide 0.1% cream</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Betaxolol</s>"
    },
    {
        "year": 2024,
        "session": 3,
        "subject_id": "3-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 300 mL</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 1,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ SOB</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 2,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① MEDLINE</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 3,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ⑤ Red marks all over the body</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 4,
        "common_question": true,
        "input": "",
        "answer": 3,
        "response": " ③ Adverse drug reaction to allopurinol.\n\nExplanation:\n\nThe patient's symptoms of fever and red marks all over his body for the past 3 days, along with the recent start of allopurinol therapy, suggest an adverse drug reaction to allopurinol. The patient's genetic testing result, which confirmed the formation of the HLA-B*5801 allele, increases the likelihood of this adverse drug reaction.\n\nThe other options are not the most likely drug-related problem for this patient:\n\n① Excessive dose of amlodipine: The patient's dose of amlodipine is 1 tablet (5 mg) per day, which is within the normal dosing range for hypertension.\n\n② Insufficient dose of metformin: The patient's dose of metformin is 1 tablet (500 mg) per day, which is within the normal dosing range for diabetes.\n\n④ Adverse drug reaction to acetaminophen: The patient's symptoms do not suggest an adverse drug reaction to acetaminophen, and the drug has been used for a short period of time (3 days).\n\n⑤ Drug interaction between amlodipine and allopurinol: Although there could be a potential drug interaction between amlodipine and allopurinol, it is not the most likely cause of the patient's symptoms.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 5,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Patient Resident Registration Number</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 6,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Omeprazole tablet</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 7,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Ketorolac tablet</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 8,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ② Change candesartan to ramipril.\n\nExplanation:\nCandesartan is an angiotensin II receptor antagonist (ARB) that is not recommended for use during pregnancy due to its potential teratogenic effects. Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, is a safer alternative for pregnant women with hypertension. Atenolol, a beta-blocker, may not be effective in controlling blood pressure during pregnancy, and nifedipine, a calcium channel blocker, may have a negative impact on fetal growth. Hydrochlorothiazide, a diuretic, is not recommended for use during pregnancy due to its potential to cause fetal harm.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 9,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Eperisone.\n\nExplanation: Eperisone is a substrate of CYP3A4 and CYP2C19, which are metabolized by the liver and excreted by the kidneys. In patients with renal impairment, the clearance of eperisone may be decreased, leading to increased plasma concentrations and potential adverse effects. Therefore, in this case, the dose of eperisone should be adjusted based on the patient's creatinine clearance to avoid any potential harm.\n\nThe other options do not require dose adjustment based on the patient's renal function:\n\n① Acetaminophen/tramadol: Both acetaminophen and tramadol are primarily metabolized by the liver and excreted by the kidneys. However, the dosage of this combination product is not affected by mild to moderate renal impairment.\n\n② Pregabalin: Pregabalin is primarily eliminated by the kidneys, but its clearance is not significantly affected by renal impairment.\n\n④ Mosapride: Mosapride is primarily metabolized by the liver and excreted by the kidneys. However, its dosage does not need to be adjusted in patients with renal impairment.\n\n⑤ Fexuprazan: Fexuprazan is primarily metabolized by the liver and excreted by the kidneys. However, its clearance is not significantly affected by renal impairment.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 10,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ②\n\nThe problem with the prescription process for this patient is the use of contraindicated drugs in combination. Isotretinoin and doxycycline should not be used together due to the risk of esophageal irritation and ulceration. Therefore, option ② is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 11,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ 200\n\nExplanation:\nThe appropriate AUC_{0-24} of vancomycin for a patient with hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) and a vancomycin MIC of 1 mg/L would be around 200 mg·h/L. This is based on the fact that the MIC of vancomycin against MRSA is 1 mg/L, which indicates that the bacteria are susceptible to vancomycin. Therefore, a higher AUC value is required to ensure adequate exposure and efficacy.\n\nAUC stands for area under the concentration-time curve, and it represents the total exposure of the drug over a specific period. In this case, the AUC_{0-24} represents the area under the concentration-time curve from 0 to 24 hours.\n\nThe available options are:\n\n① 100: This is a low AUC value and may not provide adequate exposure and efficacy for a patient with hospital-acquired pneumonia caused by MRSA.\n\n② 150: This AUC value may be appropriate for some patients with mild to moderate infections, but it may not be sufficient for a patient with severe pneumonia caused by MRSA.\n\n③ 200: This is an appropriate AUC value for a patient with hospital-acquired pneumonia caused by MRSA and a vancomycin MIC of 1 mg/L.\n\n④ 300: This AUC value is higher than necessary and may increase the risk of adverse effects.\n\n⑤ 400: This AUC value is excessively high and may lead to toxic effects.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 12,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ 21 g</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 13,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Sodium chloride → Potassium chloride → Calcium gluconate → Magnesium sulfate → Potassium dihydrogen phosphate</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 14,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② The cumulative dose is checked to prevent cardiac toxicity.\n\nPlease note that I'm an AI, and my answer is based on my training data. I try my best to provide accurate and helpful responses, but I'm not perfect and can make mistakes. It's essential to double-check and verify the information I provide, especially in high-stakes situations like a licensing exam.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 15,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Vision</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 16,
        "common_question": true,
        "input": "",
        "answer": 4,
        "response": " ④ Metoclopramide.\n\nMetoclopramide is known to have a potential to exacerbate Parkinson's disease motor symptoms, as it can antagonize dopamine receptors and increase the risk of dyskinesias in patients with Parkinson's disease. As a pharmacist, it would be appropriate to review the patient's medication regimen and consider alternatives that may not have this potential side effect.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 17,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Probable</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 18,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Lactulose</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 19,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Albendazole</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 20,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Tolfenamic acid</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 21,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Replace every 3 days</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 22,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Diltiazem</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 23,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ulipristal</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 24,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ④</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 25,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Press the button while slowly and deeply inhaling.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 26,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ③ Almagate</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-2",
        "question_number": 27,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ① Samsoeum (參蘇飮)\n\nSamsoeum is a traditional Korean herbal preparation that is commonly used to treat gastrointestinal issues such as diarrhea and dysentery. It is a mild and safe formula that can help to restore the balance of the gut microbiome and alleviate symptoms of watery diarrhea.\n\nThe other options are not appropriate for this patient's symptoms:\n\n② Oryeong-san is a herbal preparation that is used to treat respiratory issues such as cough and sore throat.\n\n③ Daecheongryong-tang is a herbal preparation that is used to treat fatigue, dizziness, and other symptoms associated with qi deficiency.\n\n④ Danggwisoo-san is a herbal preparation that is used to treat symptoms of menstrual irregularities and infertility.\n\n⑤ Geopungjibodan is a herbal preparation that is used to treat symptoms of allergies and respiratory issues such as sneezing, runny nose, and itchy eyes.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 28,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 29,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Manufacturing support equipment validation</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 30,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③ Neomycin sulfate ointment</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 31,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 32,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 33,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Quality control chart</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 34,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Corrective and Preventive Action</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 35,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Microbial limit test</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 36,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Ophthalmic ointments</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 37,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Antigenicity test</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 38,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ 1.00</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 39,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ 25</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 40,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③ Thiamine hydrochloride</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 41,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Specific gravity measurement method</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 42,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② Randomization</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 43,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ 1.50</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 44,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ③ C\n\nExplanation:\n\nThe changes proposed by Pharmaceutical company K are as follows:\n\n* Lactose hydrate: Decrease from 35 mg to 33 mg (a 6% decrease)\n* Magnesium stearate: Increase from 5 mg to 7 mg (a 40% increase)\n\nAccording to the Pharmaceutical Equivalence Test Standards, a 6% decrease in the content of an excipient (Lactose hydrate) is considered a Level C change. Similarly, a 40% increase in the content of an excipient (Magnesium stearate) is also considered a Level C change.\n\nTherefore, the level of change that Pharmaceutical company K wants to make is Level C.\n\nAnswer: ③ C</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-3",
        "question_number": 45,
        "common_question": true,
        "input": "",
        "answer": 2,
        "response": " ⑤ Bioequivalence test.\n\nExplanation:\n\nThe changes made to the formulation of the uncoated tablet, specifically the reduction in lactose hydrate and the increase in magnesium stearate, may potentially affect the bioavailability of the drug. Therefore, a bioequivalence test should be conducted to ensure that the modified formulation is bioequivalent to the original formulation, meaning that it delivers the same amount of drug into the bloodstream at the same rate and extent.\n\nThe other options are not relevant to this scenario:\n\n① Comparative disintegration test: This test is used to determine whether the tablet disintegrates within a specified time frame, but it does not assess bioavailability.\n\n② Comparative dissolution test: This test is used to determine the rate and extent of drug dissolution from a dosage form, but it does not assess bioavailability.\n\n③ Comparative permeation test: This test is used to determine the rate of drug permeation through a membrane, but it does not assess bioavailability.\n\n④ Comparative solubility test: This test is used to determine the solubility of a drug in a solvent, but it does not assess bioavailability.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 46,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ① WT strategy: Utilize the company's strengths to create market opportunities</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 47,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Return on assets (ROA)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 48,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ It presents the amount of capital and liabilities at a specific point in time.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 49,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 50,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ 100 bottles</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 51,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Insured individuals receive the same coverage regardless of the amount of insurance premiums paid.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 52,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Out-of-pocket maximum system</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 53,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Shingles (herpes zoster) vaccination</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 54,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Common Technical Document (CTD)</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 55,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Korea Orphan and Essential Drug Center</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 56,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Risk-sharing agreement</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 57,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Using search limitation filters</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 58,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 59,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Comparative analysis using the lower and upper limits of therapeutic effects.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 60,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Distribution of limited medical resources among patients</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 61,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Principle of respect for autonomy.\n\nPharmacist A is respecting the patient's autonomy by giving them the option to choose between a substitute medication or going to another pharmacy. This allows the patient to make an informed decision about their treatment, which aligns with the principle of respect for autonomy.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 62,
        "common_question": true,
        "input": "",
        "answer": 5,
        "response": " ④ 1.20</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "3-4",
        "question_number": 63,
        "common_question": true,
        "input": "",
        "answer": 1,
        "response": " ① Prospective cohort study.\n\nExplanation:\n\nA prospective cohort study would increase the validity compared to the case-control study presented in the question. In a prospective cohort study, participants are followed over time, and the exposure (in this case, the use of rheumatoid arthritis drug A) is measured before the outcome (cardiovascular adverse events) occurs. This design allows for the establishment of a temporal relationship between the exposure and the outcome, which is important in determining causality. Additionally, a prospective cohort study would allow researchers to control for potential confounding variables and collect data on the exposure and outcome simultaneously, reducing bias and increasing the accuracy of the results.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 64,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ Manufacturing of COVID-19–influenza diagnostic reagents</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 65,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② If designating a pharmacist to manage the pharmacy, approval must be obtained from the Mayor of Gangnam District.\n\nAccording to the \"Pharmaceutical Affairs Act,\" the management of a pharmacy in Gangnam-gu, Seoul, must comply with the following requirements:\n\n* The original pharmacy establishment registration certificate must be displayed in a visible place inside the pharmacy.\n* Necessary safety measures must be devised in case of side effects related to the use of pharmaceuticals.\n* If intending to close the pharmacy for 3 months, it must be reported to the Mayor of Gangnam District within 7 days from the date of closure.\n* If intending to change the location of the pharmacy, an application for change registration must be submitted at least 3 days before the intended date of change.\n\nTherefore, the correct answer is ② If designating a pharmacist to manage the pharmacy, approval must be obtained from the Mayor of Gangnam District, as this is not a requirement for the management of a pharmacy in Gangnam-gu, Seoul, according to the \"Pharmaceutical Affairs Act.\"</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 66,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 67,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ④ Pharmacists working in the dispensary of medical institutions must not prepare medications for patients who have been issued prescriptions.\n\nThis statement is incorrect because pharmacists working in the dispensary of medical institutions are responsible for preparing medications for patients based on prescriptions issued by physicians. They are trained to accurately dispense medications, ensure proper dosing, and provide patients with instructions on how to take their medications. Therefore, statement ④ is incorrect.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 68,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③ Name of the preparer.\n\nAccording to the Pharmaceutical Affairs Act, the following information is required to be written on the container or packaging of a medication prepared by a pharmacist for the purpose of sale:\n\n* Quantity prepared (①)\n* Date of preparation (②)\n* Dosage and administration as written on the prescription (④)\n* Name and location of the pharmacy where it was prepared (⑤)\n\nThe name of the preparer (③) is not required to be written on the container or packaging of a medication prepared by a pharmacist for the purpose of sale.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 69,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ A pharmacy owner can sell pharmaceuticals to animal hospital owners established under the \"Veterinarians Act\".</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 70,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ④ Selling prescription drugs to a veterinarian working at a research institution.\n\nAccording to the Pharmaceutical Affairs Act, prescription drugs can only be dispensed and sold to patients through a licensed pharmacy, and only by or under the supervision of a licensed pharmacist. Selling prescription drugs to a veterinarian working at a research institution would not meet these requirements, as the veterinarian is not a patient and the research institution is not a licensed pharmacy. Therefore, this option is not allowed under the Pharmaceutical Affairs Act.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 71,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ① Development plan</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 72,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ③ Patent scope confirmation trial</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 73,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ⑤ Live virus vaccine injection for preventing Japanese encephalitis.\n\nAccording to the Pharmaceutical Affairs Act, live virus vaccines are considered to be prescription-only medications, and their sale without a veterinarian's prescription is prohibited. Therefore, option ⑤ is the correct answer.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 74,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ⑤ Advertising in medical journals about the name and efficacy of prescription drugs, published simultaneously with the application for product approval.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 75,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ④ When the pharmacist allows unqualified individuals to dispense or sell medications.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 76,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ① Narcotics manager</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 77,
        "common_question": false,
        "input": "",
        "answer": 1,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 78,
        "common_question": false,
        "input": "",
        "answer": 5,
        "response": " ② After dispensing narcotics based on a prescription, the prescription must be preserved for 5 years.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 79,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ③ Nutrition improvement</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 80,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② General hospitals established and operated by private schools are included in public healthcare institutions.\n\nThe correct answer is ②. While private schools may operate hospitals, they are not considered public healthcare institutions. Public healthcare institutions are typically owned and operated by the government or by non-profit organizations.</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 81,
        "common_question": false,
        "input": "",
        "answer": 2,
        "response": " ② National Health Insurance Service</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 82,
        "common_question": false,
        "input": "",
        "answer": 4,
        "response": " ③</s>"
    },
    {
        "year": 2024,
        "session": 4,
        "subject_id": "4-1",
        "question_number": 83,
        "common_question": false,
        "input": "",
        "answer": 3,
        "response": " ② Licensing pharmaceutical wholesalers</s>"
    }
]